0001428336-21-000041.txt : 20211209 0001428336-21-000041.hdr.sgml : 20211209 20211209160423 ACCESSION NUMBER: 0001428336-21-000041 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20211031 FILED AS OF DATE: 20211209 DATE AS OF CHANGE: 20211209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 211481969 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-20211031.htm 10-Q hqy-20211031
00014283361/312022Q3FALSE00014283362021-02-012021-10-3100014283362021-11-30xbrli:shares00014283362021-10-31iso4217:USD00014283362021-01-31iso4217:USDxbrli:shares0001428336us-gaap:ServiceMember2021-08-012021-10-310001428336us-gaap:ServiceMember2020-08-012020-10-310001428336us-gaap:ServiceMember2021-02-012021-10-310001428336us-gaap:ServiceMember2020-02-012020-10-310001428336us-gaap:FinancialServiceOtherMember2021-08-012021-10-310001428336us-gaap:FinancialServiceOtherMember2020-08-012020-10-310001428336us-gaap:FinancialServiceOtherMember2021-02-012021-10-310001428336us-gaap:FinancialServiceOtherMember2020-02-012020-10-310001428336us-gaap:CreditAndDebitCardMember2021-08-012021-10-310001428336us-gaap:CreditAndDebitCardMember2020-08-012020-10-310001428336us-gaap:CreditAndDebitCardMember2021-02-012021-10-310001428336us-gaap:CreditAndDebitCardMember2020-02-012020-10-3100014283362021-08-012021-10-3100014283362020-08-012020-10-3100014283362020-02-012020-10-3100014283362021-07-3100014283362020-07-3100014283362020-01-310001428336us-gaap:CommonStockMember2021-07-310001428336us-gaap:CommonStockMember2020-07-310001428336us-gaap:CommonStockMember2021-01-310001428336us-gaap:CommonStockMember2020-01-310001428336us-gaap:CommonStockMember2020-02-012020-10-310001428336us-gaap:CommonStockMember2021-10-310001428336us-gaap:CommonStockMember2020-10-310001428336us-gaap:AdditionalPaidInCapitalMember2021-07-310001428336us-gaap:AdditionalPaidInCapitalMember2020-07-310001428336us-gaap:AdditionalPaidInCapitalMember2021-01-310001428336us-gaap:AdditionalPaidInCapitalMember2020-01-310001428336us-gaap:AdditionalPaidInCapitalMember2021-08-012021-10-310001428336us-gaap:AdditionalPaidInCapitalMember2020-08-012020-10-310001428336us-gaap:AdditionalPaidInCapitalMember2021-02-012021-10-310001428336us-gaap:AdditionalPaidInCapitalMember2020-02-012020-10-310001428336us-gaap:AdditionalPaidInCapitalMember2021-10-310001428336us-gaap:AdditionalPaidInCapitalMember2020-10-310001428336us-gaap:RetainedEarningsMember2021-07-310001428336us-gaap:RetainedEarningsMember2020-07-310001428336us-gaap:RetainedEarningsMember2021-01-310001428336us-gaap:RetainedEarningsMember2020-01-310001428336us-gaap:RetainedEarningsMember2021-08-012021-10-310001428336us-gaap:RetainedEarningsMember2020-08-012020-10-310001428336us-gaap:RetainedEarningsMember2021-02-012021-10-310001428336us-gaap:RetainedEarningsMember2020-02-012020-10-310001428336us-gaap:RetainedEarningsMember2021-10-310001428336us-gaap:RetainedEarningsMember2020-10-3100014283362020-10-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2021-02-012021-10-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2020-02-012020-10-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-02-012021-10-310001428336hqy:AcquiredHSAIntangibleAssetsMember2020-02-012020-10-310001428336hqy:FollowOnEquityOfferingMember2021-02-012021-04-300001428336hqy:FollowOnEquityOfferingMember2021-04-300001428336hqy:LuumAcquisitionMember2021-03-082021-03-080001428336hqy:LuumAcquisitionMember2021-03-08xbrli:pure0001428336hqy:FifthThirdBankHSAPortfolioAcquisitionMember2021-09-012021-09-290001428336hqy:LuumAcquisitionMember2021-08-012021-10-310001428336hqy:LuumAcquisitionMember2021-02-012021-10-310001428336hqy:LuumAcquisitionMember2021-10-310001428336hqy:LuumAcquisitionMember2021-03-082021-10-310001428336hqy:LuumAcquisitionMemberus-gaap:CustomerRelationshipsMember2021-03-082021-03-080001428336us-gaap:DevelopedTechnologyRightsMemberhqy:LuumAcquisitionMember2021-03-082021-03-080001428336hqy:LuumAcquisitionMemberus-gaap:TrademarksAndTradeNamesMember2021-03-082021-03-080001428336us-gaap:LeaseholdImprovementsMember2021-10-310001428336us-gaap:LeaseholdImprovementsMember2021-01-310001428336us-gaap:FurnitureAndFixturesMember2021-10-310001428336us-gaap:FurnitureAndFixturesMember2021-01-310001428336us-gaap:ComputerEquipmentMember2021-10-310001428336us-gaap:ComputerEquipmentMember2021-01-3100014283362021-11-012021-10-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-10-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-10-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-01-310001428336us-gaap:CustomerRelationshipsMember2021-10-310001428336us-gaap:CustomerRelationshipsMember2021-01-310001428336us-gaap:DevelopedTechnologyRightsMember2021-10-310001428336us-gaap:DevelopedTechnologyRightsMember2021-01-310001428336us-gaap:TradeNamesMember2021-10-310001428336us-gaap:TradeNamesMember2021-01-310001428336hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember2021-09-29hqy:member0001428336hqy:A4500SeniorNotesDue2029Member2021-10-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-10-310001428336hqy:CreditAgreementMember2021-10-310001428336hqy:WageWorksInc.Member2021-04-300001428336hqy:UnionMesaMemberhqy:WageWorksInc.Memberus-gaap:SubsequentEventMember2021-11-240001428336hqy:WageWorksInc.Member2021-10-310001428336hqy:WageWorksInsurersMember2021-10-3100014283362018-09-062018-09-06hqy:lawsuit00014283362018-06-222018-06-220001428336hqy:A4500SeniorNotesDue2029Member2021-01-310001428336hqy:TermLoanFacilityMember2021-01-310001428336hqy:PriorCreditAgreementMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:PriorCreditAgreementMemberhqy:TermLoanFacilityMember2021-01-310001428336us-gaap:RevolvingCreditFacilityMember2021-10-310001428336us-gaap:RevolvingCreditFacilityMember2021-01-310001428336us-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-080001428336us-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-310001428336us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:SecuredDebtMemberhqy:TermLoanFacilityMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:SecuredDebtMemberhqy:TermLoanFacilityMember2021-10-080001428336hqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-10-080001428336hqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LetterOfCreditMember2021-10-080001428336hqy:CreditAgreementMember2021-10-080001428336srt:MinimumMemberhqy:CreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMember2021-10-082021-10-080001428336srt:MinimumMemberhqy:CreditAgreementMemberus-gaap:BaseRateMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:BaseRateMembersrt:MaximumMember2021-10-082021-10-080001428336srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-02-012021-10-310001428336us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2021-02-012021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:DebtInstrumentAmortizationPeriodOneMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:DebtInstrumentAmortizationPeriodTwoAndThreePeriodMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:DebtInstrumentAmortizationPeriodFourMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:DebtInstrumentAmortizationPeriodFiveMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:TermLoanFacilityMember2021-10-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberhqy:TermLoanFacilityMember2021-02-012021-10-310001428336hqy:PriorCreditAgreementMemberus-gaap:SecuredDebtMemberhqy:TermLoanFacilityMember2019-08-302019-08-300001428336hqy:PriorCreditAgreementMemberus-gaap:SecuredDebtMemberhqy:TermLoanFacilityMember2019-08-300001428336us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhqy:PriorCreditAgreementMember2019-08-302019-08-300001428336us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhqy:PriorCreditAgreementMember2019-08-300001428336srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhqy:PriorCreditAgreementMember2019-08-302019-08-300001428336us-gaap:LondonInterbankOfferedRateLIBORMemberhqy:PriorCreditAgreementMembersrt:MaximumMember2019-08-302019-08-300001428336srt:MinimumMemberus-gaap:BaseRateMemberhqy:PriorCreditAgreementMember2019-08-302019-08-300001428336us-gaap:BaseRateMemberhqy:PriorCreditAgreementMembersrt:MaximumMember2019-08-302019-08-300001428336srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhqy:PriorCreditAgreementMember2019-08-302019-08-300001428336us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhqy:PriorCreditAgreementMembersrt:MaximumMember2019-08-302019-08-300001428336hqy:PriorCreditAgreementMemberhqy:DebtCovenantPeriodOneMember2019-08-300001428336hqy:PriorCreditAgreementMemberhqy:DebtCovenantPeriodTwoMember2019-08-300001428336hqy:PriorCreditAgreementMember2019-08-302019-08-300001428336hqy:PriorCreditAgreementMember2019-08-300001428336us-gaap:CostOfSalesMember2021-08-012021-10-310001428336us-gaap:CostOfSalesMember2020-08-012020-10-310001428336us-gaap:CostOfSalesMember2021-02-012021-10-310001428336us-gaap:CostOfSalesMember2020-02-012020-10-310001428336hqy:SalesandMarketingMember2021-08-012021-10-310001428336hqy:SalesandMarketingMember2020-08-012020-10-310001428336hqy:SalesandMarketingMember2021-02-012021-10-310001428336hqy:SalesandMarketingMember2020-02-012020-10-310001428336hqy:TechnologyandDevelopmentMember2021-08-012021-10-310001428336hqy:TechnologyandDevelopmentMember2020-08-012020-10-310001428336hqy:TechnologyandDevelopmentMember2021-02-012021-10-310001428336hqy:TechnologyandDevelopmentMember2020-02-012020-10-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2021-08-012021-10-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2020-08-012020-10-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2021-02-012021-10-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2020-02-012020-10-310001428336us-gaap:OtherExpenseMember2021-08-012021-10-310001428336us-gaap:OtherExpenseMember2020-08-012020-10-310001428336us-gaap:OtherExpenseMember2021-02-012021-10-310001428336us-gaap:OtherExpenseMember2020-02-012020-10-310001428336hqy:IncentivePlanMember2021-10-3100014283362021-02-012021-04-300001428336us-gaap:RestrictedStockUnitsRSUMember2021-01-310001428336us-gaap:RestrictedStockMember2021-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-02-012021-10-310001428336us-gaap:RestrictedStockMember2021-02-012021-10-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-10-310001428336us-gaap:RestrictedStockMember2021-10-310001428336hqy:PerformanceRestrictedStockUnitsMember2021-02-012021-04-300001428336hqy:PerformanceRestrictedStockUnitsMember2021-04-300001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2021-02-012021-10-310001428336hqy:PerformanceRestrictedStockUnitsMembersrt:MaximumMember2021-02-012021-10-310001428336us-gaap:FairValueInputsLevel2Memberhqy:A4500SeniorNotesDue2029Member2021-10-310001428336us-gaap:FairValueInputsLevel3Member2021-10-310001428336hqy:ContingentConsiderationMember2021-01-310001428336hqy:ContingentConsiderationMember2021-02-012021-10-310001428336hqy:ContingentConsiderationMember2021-10-310001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-04-012021-04-300001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-04-300001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-09-012021-09-300001428336hqy:HealthSavingsAdministratorsLLCMemberus-gaap:SubsequentEventMember2021-12-062021-12-060001428336hqy:HealthSavingsAdministratorsLLCMemberus-gaap:SubsequentEventMember2021-12-06



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
HEALTHEQUITY, INC.
(Exact name of registrant as specified in its charter)
Delaware52-2383166
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 30, 2021, there were 83,601,381 shares of the registrant's common stock outstanding.



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
Page
Part I. FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
Item 1.
Item 1A.
Item 6.


-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)October 31, 2021January 31, 2021
(unaudited)
Assets
Current assets
Cash and cash equivalents$649,129 $328,803 
Accounts receivable, net of allowance for doubtful accounts of $6,063 and $4,239 as of October 31, 2021 and January 31, 2021, respectively
84,083 72,767 
Other current assets30,919 58,607 
Total current assets764,131 460,177 
Property and equipment, net24,930 29,106 
Operating lease right-of-use assets81,150 89,508 
Intangible assets, net820,946 767,003 
Goodwill1,363,549 1,327,193 
Other assets44,908 37,420 
Total assets$3,099,614 $2,710,407 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$5,244 $1,614 
Accrued compensation32,695 50,670 
Accrued liabilities49,879 75,880 
Current portion of long-term debt6,563 62,500 
Operating lease liabilities12,693 14,037 
Total current liabilities107,074 204,701 
Long-term liabilities
Long-term debt, net923,501 924,217 
Operating lease liabilities, non-current67,836 74,224 
Other long-term liabilities18,953 8,808 
Deferred tax liability110,400 119,729 
Total long-term liabilities1,120,690 1,126,978 
Total liabilities1,227,764 1,331,679 
Commitments and contingencies (see Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively
  
Common stock, $0.0001 par value, 900,000 shares authorized, 83,586 and 77,168 shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively
8 8 
Additional paid-in capital1,662,965 1,158,372 
Accumulated earnings208,877 220,348 
Total stockholders’ equity1,871,850 1,378,728 
Total liabilities and stockholders’ equity$3,099,614 $2,710,407 
See accompanying notes to condensed consolidated financial statements.

-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (loss) (unaudited)
Three months ended October 31,Nine months ended October 31,
(in thousands, except per share data)2021202020212020
Revenue
Service revenue$102,733 $104,562 $314,449 $319,638 
Custodial revenue49,006 48,544 144,760 142,352 
Interchange revenue28,215 26,245 94,050 83,411 
Total revenue179,954 179,351 553,259 545,401 
Cost of revenue
Service costs66,217 65,936 204,183 202,195 
Custodial costs5,734 4,762 15,567 14,805 
Interchange costs4,683 4,095 15,102 13,985 
Total cost of revenue76,634 74,793 234,852 230,985 
Gross profit103,320 104,558 318,407 314,416 
Operating expenses
Sales and marketing12,726 12,880 42,288 36,502 
Technology and development38,070 30,758 111,437 92,490 
General and administrative20,004 22,099 63,503 61,590 
Amortization of acquired intangible assets19,642 19,126 59,745 56,905 
Merger integration13,244 8,193 38,422 31,328 
Total operating expenses103,686 93,056 315,395 278,815 
Income (loss) from operations(366)11,502 3,012 35,601 
Other expense
Interest expense(11,881)(6,952)(25,824)(28,110)
Other income (expense), net3,122 (421)(164)(2,009)
Total other expense(8,759)(7,373)(25,988)(30,119)
Income (loss) before income taxes(9,125)4,129 (22,976)5,482 
Income tax provision (benefit)(4,087)2,340 (11,505)2,015 
Net income (loss) and comprehensive income (loss)$(5,038)$1,789 $(11,471)$3,467 
Net income (loss) per share:
Basic$(0.06)$0.02 $(0.14)$0.05 
Diluted$(0.06)$0.02 $(0.14)$0.05 
Weighted-average number of shares used in computing net income (loss) per share:
Basic83,551 76,701 82,939 73,358 
Diluted83,551 77,845 82,939 74,665 
See accompanying notes to condensed consolidated financial statements.
-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Total stockholders' equity, beginning balance$1,862,666 $1,340,336 $1,378,728 $1,030,295 
Common stock:
Beginning balance8 8 8 7 
Issuance of common stock upon exercise of stock options, and for restricted stock— — — — 
Other issuance of common stock— — — 1 
Ending balance8 8 8 8 
Additional paid-in capital:
Beginning balance1,648,743 1,127,136 1,158,372 818,774 
Issuance of common stock upon exercise of stock options, and for restricted stock938 1,651 6,253 4,402 
Other issuance of common stock— 2 456,640 286,779 
Stock-based compensation13,284 11,479 41,700 30,313 
Ending balance1,662,965 1,140,268 1,662,965 1,140,268 
Accumulated earnings
Beginning balance213,915 213,192 220,348 211,514 
Net income (loss)(5,038)1,789 (11,471)3,467 
Ending balance208,877 214,981 208,877 214,981 
Total stockholders' equity, ending balance$1,871,850 $1,355,257 $1,871,850 $1,355,257 
See accompanying notes to condensed consolidated financial statements.

-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
Nine months ended October 31,
(in thousands)20212020
Cash flows from operating activities:
Net income (loss)$(11,471)$3,467 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization98,364 85,485 
Stock-based compensation41,700 30,313 
Amortization of debt discount and issuance costs3,616 3,818 
Loss on extinguishment of debt4,044  
Change in fair value of contingent consideration(2,147) 
Other non-cash items(750)1,727 
Deferred taxes(8,765)(973)
Changes in operating assets and liabilities:
Accounts receivable, net(10,090)8,063 
Other assets19,888 3,309 
Operating lease right-of-use assets8,944 8,344 
Accrued compensation(18,098)(15,251)
Accounts payable, accrued liabilities, and other current liabilities(34,023)(7,936)
Operating lease liabilities, non-current(6,808)(8,361)
Other long-term liabilities6,034 8,712 
Net cash provided by operating activities90,438 120,717 
Cash flows from investing activities:
Acquisitions, net of cash acquired(49,533) 
Purchases of software and capitalized software development costs(49,033)(37,242)
Purchases of property and equipment(7,284)(11,388)
Acquisition of intangible member assets(64,463)(28,100)
Proceeds from sale of equity securities2,367  
Net cash used in investing activities(167,946)(76,730)
Cash flows from financing activities:
Principal payments on long-term debt(1,003,125)(223,438)
Proceeds from issuance of long-term debt950,000  
Payment of debt issuance costs(11,846) 
Proceeds from follow-on equity offering, net of payments for offering costs456,642 286,779 
Settlement of client-held funds obligation, net(1,565)(4,189)
Proceeds from exercise of common stock options7,728 4,491 
Net cash provided by financing activities397,834 63,643 
Increase in cash and cash equivalents320,326 107,630 
Beginning cash and cash equivalents328,803 191,726 
Ending cash and cash equivalents$649,129 $299,356 
See accompanying notes to condensed consolidated financial statements.
-6-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
Nine months ended October 31,
(in thousands)20212020
Supplemental cash flow data:
Interest expense paid in cash$13,685 $22,849 
Income tax payments (refunds), net(5,926)1,053 
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation3,708 1,346 
Purchases of property and equipment included in accounts payable or accrued liabilities479 167 
Purchases of intangible member assets included in accounts payable or accrued liabilities2,281 289 
Contingent consideration recognized at acquisition8,147  
Exercise of common stock options receivable1 89 
Decrease in goodwill due to measurement period adjustments, net19 5,838 
See accompanying notes to condensed consolidated financial statements.
-7-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements
Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of October 31, 2021 and for the three and nine months ended October 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Follow-on equity offering
In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and used an additional $60.8 million to acquire the Fifth Third Bank HSA portfolio. The Company used the remaining net proceeds from the offering, and other cash on hand, for the acquisition of Further on November 1, 2021. For a description of the Further acquisition, refer to Note 11—Subsequent events.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
-8-

Table of Contents


Note 2. Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended October 31,Nine months ended October 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(5,038)$1,789 $(11,471)$3,467 
Denominator (basic):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Denominator (diluted):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Weighted-average dilutive effect of stock options and restricted stock units 1,144  1,307 
Diluted weighted-average common shares outstanding83,551 77,845 82,939 74,665 
Net income (loss) per share:
Basic $(0.06)$0.02 $(0.14)$0.05 
Diluted$(0.06)$0.02 $(0.14)$0.05 
For the three months ended October 31, 2021 and 2020, 1.6 million and 1.0 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the nine months ended October 31, 2021 and 2020, approximately 1.9 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
Note 3. Business combination
Acquisition of Luum
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which were contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). During the three and nine months ended October 31, 2021, the Company recognized income of $3.2 million and $2.1 million, respectively, resulting from changes in the fair value of the contingent consideration. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, which is presented within accrued liabilities on the Company's condensed consolidated balance sheet as of October 31, 2021.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
-9-

Table of Contents


The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $ $58,306 
The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.

The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.
Note 4. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Leasehold improvements$20,718 $22,271 
Furniture and fixtures9,068 9,230 
Computer equipment34,099 28,592 
Property and equipment, gross63,885 60,093 
Accumulated depreciation(38,955)(30,987)
Property and equipment, net$24,930 $29,106 
Depreciation expense for the three months ended October 31, 2021 and 2020 was $3.5 million and $4.0 million, respectively, and $10.9 million and $12.0 million for the nine months ended October 31, 2021 and 2020, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of
-10-

October 31, 2021 and January 31, 2021, the balance of deferred revenue was $10.1 million and $4.1 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 40% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and nine months ended October 31, 2021, approximately $0.3 million and $1.4 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.
Leases
The components of operating lease costs were as follows:
Three months ended October 31,Nine months ended October 31,
(in thousands)
2021202020212020
Operating lease expense$3,512 $3,777 $11,322 $12,297 
Sublease income(455)(450)(1,355)(1,349)
Net operating lease expense$3,057 $3,327 $9,967 $10,948 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Interest income$478 $174 $1,419 $850 
Gain on equity securities  1,677  
Acquisition gains (costs), net2,687 (13)(4,917)(79)
Other income (expense), net(43)(582)1,657 (2,780)
Total other income (expense), net$3,122 $(421)$(164)$(2,009)
Interest expense
Based on the application of Accounting Standards Codification ("ASC") 470-50, Debt - Modifications and Extinguishments, the Company recorded a $4.0 million loss on extinguishment of debt during the three months ended October 31, 2021, which is included within interest expense in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended October 31, 2021.
Supplemental cash flow information
Supplemental cash flow information related to the Company's operating leases was as follows:
Nine months ended October 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,928 $9,739 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$586 $17,480 





-11-

Table of Contents
Note 5. Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$177,693 $127,005 
Acquired HSA portfolios191,885 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,104,084 962,752 
Accumulated amortization(283,138)(195,749)
Amortizable intangible assets, net$820,946 $767,003 
Amortization expense for the three months ended October 31, 2021 and 2020 was $30.0 million and $25.3 million, respectively, and $87.5 million and $73.5 million for the nine months ended October 31, 2021 and 2020, respectively.
Fifth Third Bank HSA portfolio acquisition. In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition the custody of Fifth Third’s HSA portfolio to HealthEquity. On September 29, 2021, the transaction was closed, in which the Company paid a $60.8 million purchase price for a transfer of approximately 160,000 HSAs and $491.0 million of HSA Assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred.
Goodwill
During the nine months ended October 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the nine months ended October 31, 2021.
Note 6. Commitments and contingencies
Commitments
The following table summarizes the payments due by fiscal year for our outstanding contractual obligations as of October 31, 2021:
Payments due by fiscal year
(in thousands)20222023202420252026ThereafterTotal
4.50% Senior Notes due 2029 (1)
$ $ $ $ $ $600,000 $600,000 
Term Loan Facility (1) 8,750 17,500 17,500 26,250 280,000 350,000 
Interest on long-term debt obligations (2)8,577 33,951 33,708 33,467 32,965 103,739 246,407 
Operating lease obligations (3)3,416 12,689 10,442 10,836 11,080 52,563 101,026 
Further acquisition (4)500,000      500,000 
Contingent acquisition consideration6,000      6,000 
Other contractual obligations (5)7,143 21,368 9,559 622 16  38,708 
Total$525,136 $76,758 $71,209 $62,425 $70,311 $1,036,302 $1,842,141 
(1)As of October 31, 2021, our outstanding combined principal of $950.0 million is presented net of debt discount and issuance costs on our condensed consolidated balance sheets. The debt discount and issuance costs are not included in the table above.
(2)With respect to the Term Loan Facility, estimated interest payments assume the stated interest rate applicable as of October 31, 2021 of 1.88% per annum.
(3)We lease office space and data storage facilities, and we have other non-cancelable operating leases expiring at various dates through 2031. These amounts exclude contractual sublease income of $2.7 million, which is expected to be received through March 2023.
(4)For a description of the Further acquisition, refer to Note 11—Subsequent events.
(5)Other contractual obligations consist of processing services agreements, telephony services, and other contractual commitments.
-12-

Table of Contents

Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit.
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the nine months ended October 31, 2021, WageWorks contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021. This matter is now closed.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. On October 28, 2021, the court of appeal dismissed the appeal pursuant to the release in the class action settlement discussed above. The District Court action is currently stayed.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a
-13-

Table of Contents

material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
Note 7. Income taxes
The Company follows ASC 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and nine months ended October 31, 2021, the Company recorded an income tax benefit of $4.1 million and $11.5 million, respectively. This resulted in an effective income tax benefit rate of 44.8% and 50.1% for the three and nine months ended October 31, 2021, respectively, compared with an effective income tax expense rate of 56.7% and 36.8% for the three and nine months ended October 31, 2020, respectively. For the three and nine months ended October 31, 2021, discrete tax items had an effective tax rate benefit of 7.7% and 20.5%, respectively, compared with an effective tax rate expense of 6.0% and an effective tax rate benefit of 9.6% for the three and nine months ended October 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
As of October 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $11.2 million and $10.2 million, respectively. If recognized, $10.3 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of October 31, 2021.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.
Note 8. Indebtedness
Long-term debt consisted of the following:
(in thousands)October 31, 2021January 31, 2021
4.50% Senior Notes due 2029
$600,000 $ 
Term Loan Facility350,000  
Prior Term Loan Facility 1,003,125 
Principal amount950,000 1,003,125 
Less: unamortized discount and issuance costs (1)19,936 16,408 
Total debt, net930,064 986,717 
Less: current portion of long-term debt6,56362,500
Long-term debt, net$923,501 $924,217 
(1)In addition to the $19.9 million and $16.4 million of unamortized discount and issuance costs related to long-term debt as of October 31, 2021 and January 31, 2021, respectively, $4.6 million and $5.0 million of unamortized issuance costs related to our Revolving Credit Facility (as defined below) and Prior Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of October 31, 2021 and January 31, 2021, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The net proceeds from the issuance of the Notes together with borrowings under the Credit Agreement (as defined below) and cash on hand, were used to repay the outstanding borrowings under the Prior Credit Agreement (as defined below).
The Notes are guaranteed by each of the Company’s existing direct and indirect, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes will be payable on April 1 and October 1 of each year, beginning on April 1, 2022. The effective interest rate on the Notes is 4.72%.
-14-

Table of Contents
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a new credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350.0 million, the proceeds of which were used to refinance the Company’s existing senior secured credit facility as described below (the “Refinancing”), to pay fees and expenses incurred in connection with the Refinancing and the establishment of the Credit Facilities (as defined below) and for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments; and
(ii)     a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of October 31, 2021, the stated interest rate was 1.88% and the effective interest rate was 2.63%. The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the Term Loan Facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the
-15-

Table of Contents
end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.”
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022, and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022. The Company was in compliance with all covenants under the Credit Agreement as of October 31, 2021, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
Prior Credit Agreement
On August 30, 2019, the Company entered into a credit agreement (the "Prior Credit Agreement”) that provided for:
(i)       a five-year senior secured term loan A facility (the “Prior Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and
(ii)      a five-year senior secured revolving credit facility (the “Prior Revolving Credit Facility” and, together with the Prior Term Loan Facility, the “Prior Credit Facilities”), in an aggregate principal amount of up to $350.0 million. No amounts were drawn under the Prior Revolving Credit Facility.
Borrowings under the Prior Credit Facilities bore interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement. The Company was also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Prior Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement.
The Prior Credit Agreement contained customary affirmative and negative covenants, including covenants that limited, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Prior Credit Agreement contained financial performance covenants, which required the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Prior Credit Agreement during the period ended October 31, 2021.
The obligations of HealthEquity under the Prior Credit Agreement were required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and were secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.
-16-

Table of Contents
On October 8, 2021, in connection with the entry into the Credit Agreement, the Company repaid all outstanding obligations under the Prior Credit Agreement and terminated all commitments thereunder.
Note 9. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Cost of revenue$3,076 $2,209 $8,547 $5,737 
Sales and marketing829 2,035 5,677 4,810 
Technology and development3,458 2,641 10,164 8,051 
General and administrative5,921 4,594 17,312 11,715 
Other expense (1)  342  
Total stock-based compensation expense$13,284 $11,479 $42,042 $30,313 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of October 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.0$87,164 
Exercised(280)
$1.25 - 44.53
$22.36 
Outstanding as of October 31, 20211,394 
$1.25 - 82.39
$33.29 4.2$47,032 
Vested and expected to vest as of October 31, 20211,394 $33.29 4.2$47,032 
Exercisable as of October 31, 20211,303 $30.76 4.0$46,863 
Restricted stock units and restricted stock awards
A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,381 71.61   
Vested(418)58.09 (116)61.77 
Forfeited(255)62.99 (75)61.77 
Outstanding as of October 31, 20212,540 $66.62 2 $61.72 
-17-

Performance restricted stock units. During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
Note 10. Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of October 31, 2021, the fair value of the Notes was $605.2 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.
The Prior Term Loan Facility was considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Prior Term Loan Facility repriced frequently due to variable interest rate terms and entailed no significant changes in credit risk. As a result, the fair value of the Prior Term Loan Facility approximated carrying value.
The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation required subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement was based on inputs unobservable in the market and thus represented a level 3 measurement. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, and accordingly, the liability was transferred out of Level 3 as it was no longer measured at fair value. For further information, see Note 3—Business combination.
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying amount
Balance as of January 31, 2021$ 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)(2,147)
Balance as of October 31, 2021$6,000 
-18-

Note 11. Subsequent events
In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an amended agreement to acquire Further (other than VEBA, as described below) for $455 million, which closed on November 1, 2021, and (2) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto, subject to satisfaction of certain customary closing conditions, for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021. On December 3, 2021, the parties agreed to terminate the agreement to acquire the Further VEBA business. The initial accounting for the acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.
On December 6, 2021, HealthEquity entered into a definitive agreement with Health Savings Administrators, L.L.C. (“HealthSavings”) to transition the custody of HealthSavings’ HSA portfolio to HealthEquity. The definitive agreement provides a $60 million purchase price for approximately $1.3 billion of HSA assets held in approximately 87,000 HSAs. Given that a significant portion of the HSA assets are currently invested, HealthSavings and HealthEquity are working closely to coordinate an in-kind transfer of most of the invested assets. The transition of HealthSavings’ HSAs to the HealthEquity platform is expected to be completed in the first quarter of fiscal 2023.
-19-

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning our ability to integrate the acquisition of Further, the impact of the ongoing COVID-19 pandemic on the Company, the anticipated synergies and other benefits of the acquisitions of WageWorks and Further, health savings accounts and other tax-advantaged consumer-directed benefits, tax and other regulatory changes, market opportunity, our future financial and operating results, our investment and acquisition strategy, our sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, this Quarterly Report on Form 10-Q, and our other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving and spending decisions. We use our innovative technology to manage consumers' tax-advantaged health savings accounts ("HSAs") and other consumer-directed benefits ("CDBs") offered by employers, including flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), and to administer Consolidated Omnibus Budget Reconciliation Act (“COBRA”), commuter and other benefits. As part of our services, we and our subsidiaries provide consumers with healthcare bill evaluation and payment processing services, personalized benefit information including information on treatment options and comparative pricing, access to remote and telemedicine benefits, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of October 31, 2021, we administered 6.2 million HSAs, with balances totaling $16.4 billion, which we call HSA Assets. Also, as of October 31, 2021, we administered 7.1 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs that we administer as Total Accounts, of which we had 13.3 million as of October 31, 2021.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through a sales force that calls on Clients directly, relationships with benefits brokers and advisors, and integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners.
We have increased our share of the growing HSA market from 4% in calendar year 2010 to 17% as of October 31, 2021, measured by HSA Assets. According to Devenir, we are the largest HSA provider by accounts and second largest by assets as of June 2021. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our proprietary technology, product breadth, ecosystem connectivity, and service-
-20-

driven culture. Our proprietary technology allows us to help consumers optimize the value of their HSAs and other CDBs and gain confidence and skills in managing their healthcare costs as part of their financial security.
Our ability to assist consumers is enhanced by our capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers. These strengths reflect our “DEEP Purple” culture of remarkable service to customers and teammates, achieved by driving excellence, ethics, and process into everything we do.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by Clients on a recurring per-account per-month basis. We earn custodial revenue mainly from HSA Assets held at our members’ direction in federally insured cash deposits, insurance contracts or mutual funds, and from investment of Client-held funds. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and on our virtual payment system. See “Key components of our results of operations” for additional information on our sources of revenue, including the adverse impacts caused by the ongoing COVID-19 pandemic.
WageWorks Acquisition
On August 30, 2019, we completed the acquisition of WageWorks, Inc. (the "WageWorks Acquisition") and paid approximately $2.0 billion in cash to WageWorks stockholders, financed through net borrowings of approximately $1.22 billion under our prior term loan facility and approximately $816.9 million of cash on hand. As a result of the WageWorks Acquisition, WageWorks Inc. became a wholly owned subsidiary of HealthEquity, Inc.
The key strategy of the WageWorks Acquisition was to enable us to increase the number of our employer sales opportunities, the conversion of these opportunities to Clients, and the value of Clients in generating members, HSA Assets and complementary CDBs. WageWorks’ historic strength of selling to employers directly and through health benefits brokers and advisors complemented our distribution through Network Partners. With WageWorks’ CDB capabilities, we provide employers with a single partner for both HSAs and other CDBs, which is preferred by the vast majority of employers according to research conducted for us by Aite Group. For Clients that partner with us in this way, we believe we can produce more value by encouraging both CDB participants to contribute to HSAs and HSA-only members to take advantage of tax savings available through other CDBs. Accordingly, we believe that there are significant opportunities to expand the scope of services that we provide to our Clients.
We are continuing our multi-year integration effort that we expect will produce long-term cost savings and revenue synergies. We have identified opportunities of approximately $80 million in annualized ongoing net synergies to be achieved by the end of fiscal year 2022, of which approximately $75 million were achieved as of October 31, 2021. Furthermore, we anticipate generating additional revenue synergies over the longer-term as our combined distribution channels and existing client base take advantage of the broader service offerings and as we continue to drive member engagement. We estimate non-recurring costs to achieve these synergies of approximately $110 million resulting from investment in technology we use to provide our services, and to run our back-office systems, and from integration of technology, as well as rationalization of cost of operations. Merger integration expenses attributable to the WageWorks Acquisition are expected to be completed by the end of fiscal year 2022, with the exception of ongoing lease expense related to certain WageWorks offices that have been permanently closed, less any related sublease income. As of October 31, 2021, we had incurred a total of $104 million of non-recurring merger integration costs related to the WageWorks Acquisition.
Luum Acquisition
In March 2021, we bolstered our commuter offering by acquiring 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition") for an aggregate purchase price consisting of $50.2 million in cash and up to $20.0 million in contingent payments payable during the two-year period following the closing of the Luum Acquisition. On October 31, 2021, we entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability. Luum provides employers with a suite of commute tools as well as real-time commute data, to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
Fifth Third Bank HSA portfolio acquisition
In April 2021, we entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition the custody of Fifth Third’s HSA portfolio to HealthEquity. On September 29, 2021, the transaction was closed, in which we paid a $60.8 million purchase price for a transfer of approximately 160,000 HSAs and
-21-

$491.0 million of HSA Assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred.
Further Acquisition
In April 2021, we entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an amended agreement to acquire Further (other than VEBA, as described below) for $455 million, which closed on November 1, 2021, and (2) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto, subject to satisfaction of certain customary closing conditions, for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021. On December 3, 2021, the parties agreed to terminate the agreement to acquire the Further VEBA business.
HealthSavings HSA portfolio acquisition
On December 6, 2021, we entered into a definitive agreement with Health Savings Administrators, L.L.C. (“HealthSavings”) to transition the custody of HealthSavings’ HSA portfolio to HealthEquity. The definitive agreement provides a $60 million purchase price for approximately $1.3 billion of HSA assets held in approximately 87,000 HSAs. Given that a significant portion of the HSA assets are currently invested, HealthSavings and HealthEquity are working closely to coordinate an in-kind transfer of most of the invested assets. The transition of HealthSavings’ HSAs to the HealthEquity platform is expected to be completed in the first quarter of fiscal 2023.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See also "Results of operations - Revenue" for information relating to the ongoing COVID-19 pandemic and also the section entitled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, this Quarterly Report on Form 10-Q, and our other reports filed with the SEC.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average premium for employer-sponsored health insurance has risen by 22% since 2016 and 47% since 2011, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.
Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients, and Network Partners consist primarily of services enabled, mandated, or advantaged by provisions of U.S. tax law and regulations. Changes in tax policy are speculative, and may affect our business in ways that are difficult to predict.
Our client base
Our business model is based on a B2B2C distribution strategy, whereby we work with Network Partners and Clients to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe that there are significant opportunities to expand the scope of services that we provide to our current Clients.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators, and retirement plan record keepers.

-22-

Product breadth
We are the largest custodian and administrator of HSAs (by number of accounts), as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With our CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
Our proprietary technology
We believe that innovations incorporated in our technology, which enable us to better assist consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits, differentiate us from our competitors and drive our growth. We built on these innovations by combining our HSA offering with WageWorks' complementary CDB offerings, giving us a full suite of CDB products, and adding to our solutions set and leadership position within the HSA sector. We intend to continue to invest in our technology development to enhance our capabilities and infrastructure, while maintaining a focus on data security and the privacy of our customers' data. For example, we are making significant investments in the architecture and infrastructure of the technology that we use to provide our services to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more, and build wealth for retirement.
Our “DEEP Purple” service culture
The successful healthcare consumer needs education and guidance delivered by people as well as by technology. We believe that our "DEEP Purple" culture, which we define as driving excellence, ethics, and process while providing remarkable service, is a significant factor in our ability to attract and retain customers and to address nimbly, opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster DEEP Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development, and advancement opportunities.
Interest rates
As a non-bank custodian, we contract with federally insured banks and credit unions, which we collectively call our Depository Partners, and also with insurance company partners, to hold custodial cash assets on behalf of our members. We earn a material portion of our total revenue from interest paid to us by these partners. Custodial cash assets held by our insurance company partners are held in group annuity contracts and similar arrangements. The lengths of our agreements with Depository Partners typically range from three to five years and may have fixed or variable interest rate terms. The terms of new and renewing agreements with our Depository Partners may be impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members. We believe that diversification of Depository Partners and insurance company partners, varied contract terms and other factors reduce our exposure to short-term fluctuations in prevailing interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
Although interest rates have improved somewhat, we expect our custodial revenue to continue to be adversely affected by the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic, the lack of demand from Depository Partners for deposits, and other market conditions that have caused the interest rates offered by our Depository Partners to decline significantly.
Interest on our five-year senior secured term loan A facility (the “Term Loan Facility”) changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe benefits administration services are not a core business. Some of our direct competitors (including healthcare service companies such as United Health Group's Optum, Webster Bank, and well-known retail investment companies, such as Fidelity Investments) are in a position to
-23-

devote more resources to the development, sale, and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
As a result of the COVID-19 pandemic, we have seen an adverse impact on sales opportunities, with some opportunities delayed and most now being held virtually. We have seen a significant decline in the use of commuter benefits due to many of our members working from home during the outbreak or other impacts from the outbreak, which has negatively impacted both our interchange revenue and service revenue, and this "work from home" trend may continue after the pandemic. We have also seen a decline in interchange revenue across all other products. The extent to which the COVID-19 pandemic will negatively impact our business remains highly uncertain and cannot be accurately predicted.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our services, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Various states also have laws and regulations that impose additional restrictions on our collection, storage, and use of personally identifiable information. Privacy regulation in particular has become a priority issue in many states, including California, which in 2018 enacted the California Consumer Privacy Act broadly regulating California residents’ personal information and providing California residents with various rights to access and control their data, and the new California Privacy Rights Act. We have also seen an increase in regulatory changes related to our services due to government responses to the COVID-19 pandemic and may continue to see additional regulatory changes. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
On March 21, 2021, the American Rescue Plan Act of 2021 (“ARPA”) was signed into law. ARPA temporarily increased the dependent care flexible spending account contribution limit for the 2021 plan year. It also provided a temporary 100% subsidy of COBRA premium payments for eligible individuals who lost coverage due to an involuntary termination or a reduction of hours for up to 6 months.
Our acquisition strategy
We have a successful history of acquiring HSA portfolios and businesses that strengthen our service offerings. We seek to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquired HSA portfolios. We intend to continue to pursue acquisitions of complementary assets and businesses that we believe will strengthen our service offering, and our success depends in part on our ability to successfully integrate acquired businesses and HSA portfolios with our business in an efficient and effective manner.
-24-

Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)October 31, 2021October 31, 2020% ChangeJanuary 31, 2021
HSAs6,241 5,460 14 %5,782 
New HSAs from sales - Quarter-to-date151 104 45 %370 
New HSAs from sales - Year-to-date446 317 41 %687 
New HSAs from acquisitions - Year-to-date160 — n/a— 
HSAs with investments431 302 43 %333 
CDBs7,085 7,060 %7,028 
Total Accounts13,326 12,520 %12,810 
Average Total Accounts - Quarter-to-date13,247 12,084 10 %12,659 
Average Total Accounts - Year-to-date13,158 12,429 %12,604 
The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by approximately 0.8 million, or 14%, from October 31, 2020 to October 31, 2021, due to further penetration into existing Network Partners, the addition of new Network Partners, and HSA portfolio acquisitions. The number of our CDBs increased slightly from October 31, 2020 to October 31, 2021, driven by an increase in COBRA and HRA accounts, largely offset by a decrease in FSA accounts and also commuter benefit accounts that are currently suspended due to the COVID-19 pandemic and fewer workers being required to commute to an office. The suspended commuter accounts continue to be administered on our platform and can be reinstated at any time. We have excluded the suspended commuter accounts from our account totals because they are currently not generating revenue for the Company.
HSA Assets
The following table sets forth HSA Assets as of and for the periods indicated:
(in millions, except percentages)October 31, 2021October 31, 2020% ChangeJanuary 31, 2021
HSA cash with yield (1)$10,410 $8,759 19 %$9,875 
HSA cash without yield (2)59 258 (77)%244 
Total HSA cash10,469 9,017 16 %10,119 
HSA investments with yield (1)5,900 3,255 81 %4,078 
HSA investments without yield (2)59 168 (65)%138 
Total HSA investments5,959 3,423 74 %4,216 
Total HSA Assets16,428 12,440 32 %14,335 
Average daily HSA cash with yield - Year-to-date9,925 8,445 18 %8,599 
Average daily HSA cash with yield - Quarter-to-date$10,099 $8,672 16 %$9,060 
(1)HSA Assets that generate custodial revenue.
(2)HSA Assets that do not generate custodial revenue.
HSA Assets, which are our HSA members' assets for which we are the custodian or administrator, or from which we generate custodial revenue, consist of the following components: (i) HSA cash, which includes cash deposits with our Depository Partners or other custodians and cash placed in group annuity contracts with our insurance company partners, and (ii) HSA investments in mutual funds through our custodial investment fund partners. We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022. Measuring HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
-25-

Total HSA cash increased by $1.5 billion, or 16%, from October 31, 2020 to October 31, 2021, due primarily to HSA contributions, new HSAs, and acquisitions of HSA portfolios, partially offset by transfers to HSA investments.
HSA investments increased by $2.5 billion, or 74%, from October 31, 2020 to October 31, 2021, due primarily to transfers from HSA cash and appreciation of invested balances.
Total HSA Assets increased by $4.0 billion, or 32%, from October 31, 2020 to October 31, 2021, due primarily to HSA contributions, new HSAs, acquisitions of HSA portfolios, and appreciation of invested balances.
Client-held funds
(in millions, except percentages)October 31, 2021October 31, 2020% ChangeJanuary 31, 2021
Client-held funds (1)$811 $798 %$986 
Average daily Client-held funds - Year-to-date (1)849 847 — %847 
Average daily Client-held funds - Quarter-to-date (1)796 819 (3)%848 
(1) Client-held funds that generate custodial revenue.
Client-held funds are interest-earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of CDBs. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. Client-held funds fluctuate depending on the timing of funding and spending of CDB balances.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to Adjusted EBITDA for the periods indicated:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Net income (loss)$(5,038)$1,789 $(11,471)$3,467 
Interest income(478)(174)(1,419)(850)
Interest expense11,881 6,952 25,824 28,110 
Income tax provision (benefit)(4,087)2,340 (11,505)2,015 
Depreciation and amortization13,904 10,253 38,619 28,580 
Amortization of acquired intangible assets19,642 19,126 59,745 56,905 
Stock-based compensation expense13,284 11,479 41,700 30,313 
Merger integration expenses13,244 8,193 38,422 31,328 
Acquisition costs (gains) (1)(2,687)13 4,917 79 
Gain on equity securities— — (1,677)— 
Other (2)1,422 1,168 2,421 4,202 
Adjusted EBITDA$61,087 $61,139 $185,576 $184,149 
(1)For the nine months ended October 31, 2021, acquisition costs included $0.3 million of stock-based compensation expense.
(2)For the three months ended October 31, 2021, other consisted of amortization of incremental costs to obtain a contract of $0.8 million and other expenses, net, of $0.6 million. For the three months ended October 31, 2020, other consisted of amortization of incremental costs to obtain a contract of $0.6 million and other expenses, net, of $0.6 million. For the nine months ended October 31, 2021, other consisted of amortization of incremental costs to obtain a contract of $3.5 million, partially offset by other income, net, of $1.0 million. For the nine months ended October 31, 2020, other consisted of amortization of incremental costs to obtain a contract of $1.4 million and other expenses, net, of $2.8 million.
-26-

The following table further sets forth our Adjusted EBITDA as a percentage of revenue:
Three months ended October 31,Nine months ended October 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Adjusted EBITDA$61,087$61,139$(52)— %$185,576$184,149$1,427 %
As a percentage of revenue34 %34 %34 %34 %
Our Adjusted EBITDA was $61.1 million for each of the three month periods ended October 31, 2021 and 2020.
Our Adjusted EBITDA increased by $1.4 million, or 1%, from $184.1 million for the nine months ended October 31, 2020 to $185.6 million for the nine months ended October 31, 2021, which reflects a similar increase in total revenue from the nine months ended October 31, 2020 to the nine months ended October 31, 2021.
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners and Clients, our fees are generally based on a fixed tiered structure for the duration of the relevant service agreement and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered to our members and Clients.
Custodial revenue.    We earn custodial revenue primarily from HSA Assets deposited with our Depository Partners and with our insurance company partners, recordkeeping fees we earn in respect of mutual funds in which our members invest, and Client-held funds deposited with our Depository Partners. We deposit HSA cash with our Depository Partners pursuant to contracts that (i) typically have terms ranging from three to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant Depository Partner, and (iii) have minimum and maximum required deposit balances. HSA cash placed with our insurance company partners is placed in group annuity contracts or similar arrangements. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on HSA Assets and Client-held funds that is based on the interest rates offered to us by these Depository Partners and insurance company partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA Assets in mutual funds through our custodial investment partner. We earn a recordkeeping fee, calculated as a percentage of custodial investments. We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our physical payment cards or virtual platforms to make a purchase. This revenue is collected each time a member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Cost of revenue includes costs related to servicing accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members. Other components of cost of revenue include interest retained by members on HSA cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards, and costs of marketing materials that we produce for our Network Partners.
Custodial costs.    Custodial costs are comprised of interest retained by our HSA members, in respect of HSA cash with yield, and fees we pay to banking consultants whom we use to help secure agreements with our Depository
-27-

Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our Network Partners, Clients, and members, the mix of our sources of revenue, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software development and delivery, information technology, data management, product, and security. Technology and development expenses also include software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, corporate development, compliance, and people departments. They also include depreciation, amortization, stock-based compensation, and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 7-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, legal expenses, and facilities and technology expenses directly related to integration activities to merge operations as a result of acquisitions.
Interest expense
Interest expense consists of accrued interest expense and amortization of deferred financing costs associated with our long-term debt. Interest on our Term Loan Facility changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Other income (expense), net
Other income (expense), net, consists of acquisition costs, interest income earned on corporate cash and other miscellaneous income and expense.
Income tax provision (benefit)
We are subject to federal and state income taxes in the United States based on a January 31 fiscal year end. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. Valuation allowances are established when necessary to reduce net deferred tax assets to the
-28-

amount expected to be realized. As of October 31, 2021, we have recorded an overall net deferred tax liability on our condensed consolidated balance sheet.
Comparison of the three and nine months ended October 31, 2021 and 2020
Revenue
The following table sets forth our revenue for the periods indicated:
Three months ended October 31,Nine months ended October 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Service revenue$102,733 $104,562 $(1,829)(2)%$314,449 $319,638 $(5,189)(2)%
Custodial revenue49,006 48,544 462 %144,760 142,352 2,408 %
Interchange revenue28,215 26,245 1,970 %94,050 83,411 10,639 13 %
Total revenue$179,954 $179,351 $603 %$553,259 $545,401 $7,858 %
Service revenue. The $1.8 million, or 2%, decrease in service revenue from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to a decrease in CDB accounts due to the COVID-19 pandemic and efforts to simplify our CDB administrative engagements on our go-forward platform, partially offset by new revenue from the Luum Acquisition.
The $5.2 million, or 2%, decrease in service revenue from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to a decrease in CDB accounts due to the COVID-19 pandemic and efforts to simplify our CDB administrative engagements on our go-forward platform, partially offset by new revenue from the Luum Acquisition and an increase in revenue related to COBRA benefits administration.
Custodial revenue. The $0.5 million, or 1%, increase in custodial revenue from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to the $1.4 billion, or 16%, increase in the year-over-year average daily balance of HSA cash with yield. The increase was partially offset by a decrease in average annualized yield from 2.08% for the three months ended October 31, 2020 to 1.72% for the three months ended October 31, 2021, which was due in part to the interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic, and by increased transfers from HSA cash to HSA investments.
The $2.4 million, or 2%, increase in custodial revenue from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to the $1.5 billion, or 18%, increase in the year-over-year average daily balance of HSA cash with yield. The increase was partially offset by a decrease in average annualized yield from 2.10% for the nine months ended October 31, 2020 to 1.76% for the nine months ended October 31, 2021, which was due in part to the interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic, and by increased transfers from HSA cash to HSA investments.
We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022. This cash is being placed with our Depository Partners at prevailing interest rates, which we expect will generate additional custodial revenue.
Interchange revenue. The $2.0 million, or 8%, increase in interchange revenue from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to increased spend per account and an increase in accounts.
The $10.6 million, or 13%, increase in interchange revenue from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to increased spend per account and an increase in accounts.
Total revenue. Total revenue increased $0.6 million, or less than one percent, from the three months ended October 31, 2020 to the three months ended October 31, 2021 due to the increases in custodial and interchange revenues, largely offset by the decrease in service revenue.
Total revenue increased $7.9 million, or 1%, from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 due to the increases in custodial and interchange revenues, partially offset by the decrease in service revenue.
Impact of COVID-19. Our business has been adversely affected by the COVID-19 pandemic, and we expect that it will continue to be adversely affected by the COVID-19 pandemic, including as a result of the associated interest
-29-

rate cuts by the Federal Reserve and other market conditions that have caused interest rates to decline significantly, which reduces the yield on funds placed with our Depository Partners and insurance company partners in this environment. Sales opportunities have also been impacted, with some opportunities delayed and most now being held virtually. Our financial results related to certain of our products have also been adversely affected, such as commuter benefits, due to many of our members working from home during the outbreak and other impacts from the outbreak, and the "work from home" trend may continue after the pandemic. In particular, the recent increased spread of COVID-19 and the associated decisions by employers to delay return-to-office plans for their employees will further delay the recovery of use of these commuter benefits. During the initial stages of the COVID-19 pandemic, we saw a negative impact on our members' spend on healthcare, which negatively impacted both our interchange revenue and service revenue, and the current increase in COVID-19 cases has negatively impacted our interchange revenue and service revenue. In addition, we are required to support our Clients' open enrollment activities virtually. We may be unable to meet our service level commitments to our Clients as a result of disruptions to our work force and disruptions to third-party contracts that we rely on to provide our services. The extent to which the COVID-19 pandemic will continue to negatively impact our business remains highly uncertain and as a result may have a material adverse impact on our business and financial results.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
Three months ended October 31,Nine months ended October 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Service costs$66,217 $65,936 $281 — %$204,183 $202,195 $1,988 %
Custodial costs5,734 4,762 972 20 %15,567 14,805 762 %
Interchange costs4,683 4,095 588 14 %15,102 13,985 1,117 %
Total cost of revenue$76,634 $74,793 $1,841 %$234,852 $230,985 $3,867 %
Service costs. The $0.3 million, or less than one percent, increase in service costs from the three months ended October 31, 2020 to the three months ended October 31, 2021 reflects a similar increase in total revenue from the three months ended October 31, 2020 to the three months ended October 31, 2021.
The $2.0 million, or 1%, increase in service costs from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 reflects a similar increase in total revenue from the three months ended October 31, 2020 to the three months ended October 31, 2021.
Custodial costs. The $1.0 million, or 20%, increase in custodial costs from the three months ended October 31, 2020 to the three months ended October 31, 2021 was due to an increase in the average daily balance of HSA cash with yield, which increased from $8.7 billion for the three months ended October 31, 2020 to $10.1 billion for the three months ended October 31, 2021 and an associated increase in interest retained by HSA members, partially offset by a lower average annualized rate of interest retained by HSA members on HSA cash with yield, which decreased from 0.18% for the three months ended October 31, 2020 to 0.17% for the three months ended October 31, 2021.
The $0.8 million, or 5%, increase in custodial costs from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was due to an increase in the average daily balance of HSA cash with yield, which increased from $8.4 billion for the nine months ended October 31, 2020 to $9.9 billion for the nine months ended October 31, 2021 and an associated increase in interest retained by HSA members, partially offset by a lower average annualized rate of interest retained by HSA members on HSA cash with yield, which decreased from 0.20% for the nine months ended October 31, 2020 to 0.17% for the nine months ended October 31, 2021.
Interchange costs. The $0.6 million, or 14%, increase in interchange costs from the three months ended October 31, 2020 to the three months ended October 31, 2021 was due to increased spend per account and an increase in accounts.
The $1.1 million, or 8%, increase in interchange costs from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was due to increased spend per account and an increase in accounts.
Total cost of revenue. As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation, account management functions, realized synergies, and the impact of the COVID-19 pandemic. We expect our cost
-30-

of revenue to increase as a percentage of our total revenue, primarily due to the Further acquisition and stock-based compensation.
Operating expenses
The following table sets forth our operating expenses for the periods indicated:
Three months ended October 31,Nine months ended October 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Sales and marketing$12,726 $12,880 $(154)(1)%$42,288 $36,502 $5,786 16 %
Technology and development38,070 30,758 7,312 24 %111,437 92,490 18,947 20 %
General and administrative20,004 22,099 (2,095)(9)%63,503 61,590 1,913 %
Amortization of acquired intangible assets19,642 19,126 516 %59,745 56,905 2,840 %
Merger integration13,244 8,193 5,051 62 %38,422 31,328 7,094 23 %
Total operating expenses$103,686 $93,056 $10,630 11 %$315,395 $278,815 $36,580 13 %
Sales and marketing. Sales and marketing expense decreased by $0.2 million, or 1%, from the three months ended October 31, 2020 to the three months ended October 31, 2021.
The $5.8 million, or 16%, increase in sales and marketing expense from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to an increase in marketing expenses from increased staffing and marketing collateral and increases in team member and partner commissions.
We expect our sales and marketing expenses to increase for the foreseeable future as we focus on our cross-selling program and marketing campaigns. On an annual basis, we expect our sales and marketing expenses to continue to increase as a percentage of our total revenue. However, our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses. We expect our sales and marketing expenses to increase as a percentage of our total revenue, primarily due to the Further acquisition and stock-based compensation.
Technology and development. The $7.3 million, or 24%, increase in technology and development expense from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to increases in amortization, stock-based compensation, and personnel-related expenses.
The $18.9 million, or 20%, increase in technology and development expense from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to increases in amortization, stock-based compensation, and personnel-related expenses.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development and security of our proprietary technology. On an annual basis, we expect our technology and development expenses to continue to increase as a percentage of our total revenue pursuant to our growth initiatives. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses. We expect our technology and development expenses to increase as a percentage of our total revenue, primarily due to the Further acquisition and stock-based compensation.
General and administrative. The $2.1 million, or 9%, decrease in general and administrative expense from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to temporary decreases in personnel-related expenses and professional fees.
The $1.9 million, or 3%, increase in general and administrative expense from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to increases in credit losses on trade receivables and stock-based compensation, partially offset by decreases in personnel-related expenses and professional fees.
We expect our general and administrative expenses to continue to increase for the foreseeable future due to the additional demands on our legal, compliance, accounting, and insurance functions that we incur as we continue to grow our business. On an annual basis, we expect our general and administrative expenses to increase as a percentage of our total revenue over the near term pursuant to our growth initiatives. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our
-31-

total revenue and the timing and extent of our general and administrative expenses. We expect our technology and development expenses to increase as a percentage of our total revenue, primarily due to the Further acquisition and stock-based compensation.
Amortization of acquired intangible assets. The $0.5 million, or 3%, increase in amortization of acquired intangible assets from the three months ended October 31, 2020 to the three months ended October 31, 2021 was primarily due to the inclusion of amortization related to identified intangible assets acquired through the Luum Acquisition. The remainder of the increase was due to amortization of the Fifth Third Bank HSA portfolio and other acquired HSA portfolios.
The $2.8 million, or 5%, increase in amortization of acquired intangible assets from the nine months ended October 31, 2020 to the nine months ended October 31, 2021 was primarily due to the inclusion of amortization related to identified intangible assets acquired through the Luum Acquisition commencing March 8, 2021. The remainder of the increase was due to amortization of acquired HSA portfolios.
Merger integration. The $13.2 million and $38.4 million in merger integration expense for the three and nine months ended October 31, 2021, respectively, was primarily due to personnel and related expenses, including expenses incurred in conjunction with the migration of accounts, severance, professional fees, technology-related, and facilities expenses directly related to the WageWorks Acquisition and additional integration expenses incurred related to the acquisition of Further. We expect integration expenses totaling approximately $110 million and $55 million in the aggregate for the WageWorks and Further acquisitions, respectively. Merger integration expenses attributable to the WageWorks Acquisition are expected to be completed by the end of fiscal year 2022, with the exception of ongoing lease expense related to certain WageWorks offices that have been permanently closed, less any related sublease income. As of October 31, 2021, we had incurred a total of approximately $117 million of non-recurring merger integration costs related to the WageWorks Acquisition and the Further acquisition.
Interest expense
The $11.9 million and $25.8 million in interest expense for the three and nine months ended October 31, 2021, respectively, consisted primarily of interest accrued on our long-term debt and amortization of debt discount and issuance costs, as well as a $4.0 million loss on extinguishment of debt recorded during the three months ended October 31, 2021 as a result of the refinancing of our prior credit facility. We expect interest expense to increase, primarily as a result of the interest expense we will incur on the $600.0 million aggregate principal amount of the Notes issued during the quarter.
Other income (expense), net
The $3.5 million change in other income (expense), net, from expense of $0.4 million during the three months ended October 31, 2020 to income of $3.1 million during the three months ended October 31, 2021 was due to a $3.2 million gain resulting from a change in the fair value of contingent acquisition consideration from the Luum Acquisition and a $0.3 million increase in net other income.
The $1.8 million decrease in other expense, net, from $2.0 million during the nine months ended October 31, 2020 to $0.2 million during the nine months ended October 31, 2021 was due to a $1.7 million gain on the sale of equity securities, a $0.6 million increase in interest income, and a $4.4 million increase in net other income, partially offset by a $4.9 million increase in net acquisition costs, which includes a $2.1 million gain resulting from a change in the fair value of contingent acquisition consideration from the Luum Acquisition.
Income tax benefit
Income tax benefit for the three and nine months ended October 31, 2021 was $4.1 million and $11.5 million, respectively, compared to income tax expense of $2.3 million and $2.0 million for the three and nine months ended October 31, 2020, respectively. The $6.4 million and $13.5 million increase in the income tax benefit for the three and nine months ended October 31, 2021 compared to the three and nine months ended October 31, 2020 was primarily due to a decrease in pre-tax book income and an increase in excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. Revenue results are seasonally impacted due to ancillary service fees, timing of HSA contributions, and timing of card spend. Cost of revenue is seasonally impacted as a significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate
-32-

to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter, with the majority of expenses incurred in our fourth fiscal quarter.
Liquidity and capital resources
Cash and cash equivalents overview
Our principal sources of liquidity are our current cash and cash equivalents balances, collections from our service, custodial, and interchange revenue activities, and availability under our Revolving Credit Facility (as defined below). We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, payments under our Term Loan Facility, and capital expenditures.
As of October 31, 2021 and January 31, 2021, cash and cash equivalents were $649.1 million and $328.8 million, respectively. Cash and cash equivalents as of October 31, 2021 included $456.6 million of net proceeds we received from our follow-on public offering in the first quarter of fiscal year 2022 from the sale of 5,750,000 shares of our common stock, partially offset by $50.2 million used for the Luum Acquisition, and an additional $60.8 million used to acquire the Fifth Third Bank HSA portfolio. Subsequent to October 31, 2021, the Company used the remaining net proceeds from the offering, and other cash on hand, for the acquisition of Further.
Capital resources
We maintain a “shelf” registration statement on Form S-3 on file with the SEC. A shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters, capital expenditures, and repayment of indebtedness, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
In the first quarter of fiscal year 2022, we closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. We received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million.
On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029. In addition, on October 8, 2021, the Company entered into a Credit Agreement (the “Credit Agreement”) which includes a five-year senior secured term loan A facility, in an aggregate principal amount of $350.0 million, and a five-year senior secured revolving credit facility (the “Revolving Credit Facility”), in an aggregate principal amount of up to $1.0 billion, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. The net proceeds from the issuance of the Notes together with borrowings under the Credit Agreement and $31.8 million of cash on hand, were used to repay the outstanding borrowings under the prior credit agreement, dated August 20, 2019. For a description of the terms of the Credit Agreement, refer to Note 8—Indebtedness. As of October 31, 2021, there were no amounts outstanding under the Revolving Credit Facility. We were in compliance with all covenants under the Credit Agreement as of October 31, 2021, and for the period then ended.
Use of cash
We used $50.2 million of the net proceeds from the follow-on public offering for the Luum Acquisition and used an additional $60.8 million to acquire the Fifth Third Bank HSA portfolio. Subsequent to October 31, 2021, the Company used the remaining net proceeds from the offering, and other cash on hand, for the acquisition of Further.
Capital expenditures for the nine months ended October 31, 2021 and 2020 were $56.3 million and $48.6 million, respectively. We expect to continue our current level of increased capital expenditures for the remainder of the fiscal year ending January 31, 2022 as we continue to devote a significant amount of our capital expenditures to improving the architecture and functionality of our proprietary systems. Costs to improve the architecture of our proprietary systems include computer hardware, personnel and related costs for software engineering and outsourced software engineering services.
-33-

We believe our existing cash, cash equivalents, and Revolving Credit Facility will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
The following table shows our cash flows from operating activities, investing activities, and financing activities for the stated periods:
Nine months ended October 31,
(in thousands)20212020
Net cash provided by operating activities$90,438 $120,717 
Net cash used in investing activities(167,946)(76,730)
Net cash provided by financing activities397,834 63,643 
Increase in cash and cash equivalents320,326 107,630 
Beginning cash and cash equivalents328,803 191,726 
Ending cash and cash equivalents$649,129 $299,356 
Cash flows from operating activities. Net cash provided by operating activities during the nine months ended October 31, 2021 resulted from net loss of $11.5 million, plus depreciation and amortization expense of $98.4 million, stock-based compensation expense of $41.7 million, amortization of debt discount and issuance costs of $3.6 million, and a loss on extinguishment of debt of $4.0 million, partially offset by a decrease in the fair value of contingent consideration of $2.1 million and other non-cash items and working capital changes totaling $43.7 million.
Net cash provided by operating activities during the nine months ended October 31, 2020 resulted from net income of $3.5 million, plus depreciation and amortization expense of $85.5 million, stock-based compensation expense of $30.3 million, and amortization of debt discount and issuance costs of $3.8 million, partially offset by other non-cash items and working capital changes totaling $2.4 million.
Cash flows from investing activities. Cash used in investing activities for the nine months ended October 31, 2021 resulted from the Luum Acquisition for $49.5 million, net of cash acquired, $49.0 million in software and capitalized software development, $7.3 million in purchases of property and equipment, and $64.5 million in acquisitions of intangible member assets, partially offset by $2.4 million of proceeds from the sale of equity securities associated with a long-term capital investment.
Net cash used in investing activities for the nine months ended October 31, 2020 resulted from $37.2 million in software and capitalized software development, $11.4 million in purchases of property and equipment, and $28.1 million in acquisitions of intangible member assets.
Cash flows from financing activities. Net cash provided by financing activities during the nine months ended October 31, 2021 resulted from $938.2 million of net proceeds from the issuance of long-term debt, $456.6 million of net proceeds from our follow-on public offering of 5,750,000 shares of common stock, and the exercise of stock options of $7.7 million. These items were partially offset by $1.0 billion of principal payments on our long-term debt and $1.6 million used in the settlement of Client-held funds obligations.

Net cash provided by financing activities during the nine months ended October 31, 2020 resulted primarily from $286.8 million of net proceeds from our follow-on public offering of 5,290,000 shares of common stock and the exercise of stock options of $4.5 million, partially offset by $223.4 million of principal payments on our long-term debt and $4.2 million used in the settlement of Client-held funds obligations.
Contractual obligations
See Note 6—Commitments and contingencies for information about our contractual obligations.
-34-

Off-balance sheet arrangements
As of October 31, 2021, other than outstanding letters of credit issued under our Revolving Credit Facility, we did not have any off-balance sheet arrangements. The majority of the standby letters of credit expire within one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our Revolving Credit Facility, and are not reflected on our condensed consolidated balance sheets.
Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021. There have been no significant or material changes in our critical accounting policies during the nine months ended October 31, 2021, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recent accounting pronouncements
See Note 1—Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Qualitative and quantitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the nine months ended October 31, 2021 and 2020, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of October 31, 2021 were $649.1 million, the vast majority of which was not covered by federal depository insurance. We have not experienced any material losses in such accounts and believe we are not exposed to any significant credit risk with respect to our cash and cash equivalents. Our accounts receivable balance as of October 31, 2021 was $84.1 million. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable; however, the extent to which the ongoing COVID-19 pandemic will negatively impact our credit risk remains highly uncertain and cannot be accurately predicted. We continue to monitor our credit risk and place our cash and cash equivalents with reputable financial institutions.
-35-

Interest rate risk
HSA Assets and Client-held funds. HSA Assets consist of custodial HSA funds we hold in custody on behalf of our members. As of October 31, 2021, we held in custody HSA Assets of approximately $16.4 billion. As a non-bank custodian, we contract with our Depository Partners and insurance company partners to hold custodial cash assets on behalf of our members, and we earn a significant portion of our total revenue from interest paid to us by these partners. Custodial cash assets held by our insurance company partners are held in group annuity contracts and similar arrangements. The lengths of our agreements with Depository Partners typically range from three to five years and have either fixed or variable interest rates. As HSA Assets increase and existing contracts with Depository Partners expire, we seek to enter into new contracts with Depository Partners, the terms of which are impacted by the then-prevailing interest rate environment. The diversification of HSA Assets placed among our Depository Partners and insurance company partners, and varied contract terms, substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we can realize. Conversely, a sustained increase in prevailing interest rates can increase our yield. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, if our yield increases, we expect the spread to also increase between the interest offered to us by our Depository Partners and insurance company partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control, such as the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic.
Client-held funds are interest earning deposits from which we generate custodial revenue. As of October 31, 2021, we held Client-held funds of approximately $811.0 million. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the yield available to us and thus the amount of the custodial revenue we can realize from Client-held funds. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of October 31, 2021, we had unrestricted cash and cash equivalents of $649.1 million. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Long-term debt. As of October 31, 2021, we had $350.0 million outstanding under our Term Loan Facility and no amounts drawn under our Revolving Credit Facility. Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments. The interest rate on our term loan credit facility and Revolving Credit Facility is variable and was 1.88% at October 31, 2021. Accordingly, we may incur additional expense if interest rates increase in future periods. For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities at October 31, 2021 would result in approximately $3.5 million of additional interest expense over the next 12 months. The interest rate on our Notes is fixed at 4.50%.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the Company’s disclosure controls and procedures as of October 31, 2021, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the
-36-

information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, the CEO and CFO have concluded that as of October 31, 2021, the Company’s disclosure controls and procedures were not effective because of the material weaknesses in internal control over financial reporting described below.
Notwithstanding the ineffective disclosure controls and procedures as a result of the identified material weaknesses described below, management has concluded that the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q present fairly, in all material respects, the Company’s financial position, results of operations and cash flows in accordance with generally accepted accounting principles in the United States of America.
In accordance with interpretive guidance issued by SEC staff, companies are allowed to exclude acquired businesses from the assessment of internal control over financial reporting during the first year after completion of an acquisition and from the assessment of disclosure controls and procedures to the extent subsumed in such internal control over financial reporting. In accordance with this guidance, as the Company acquired Luum on March 8, 2021, management's evaluation and conclusion as to the effectiveness of the Company's disclosure controls and procedures as of October 31, 2021 excluded the portion of disclosure controls and procedures that are subsumed by internal control over financial reporting of Luum. Luum’s assets and revenues represented approximately 1%, excluding the effects of purchase accounting, of the Company's consolidated total assets and consolidated total revenues as of and for the fiscal quarter ended October 31, 2021.
Material Weaknesses in Internal Control over Financial Reporting
Management identified certain deficiencies in WageWorks' internal control over financial reporting that aggregated to material weaknesses in the following components of the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO Framework”):
Risk Assessment – The WageWorks subsidiary did not sufficiently identify and analyze risks arising from changes in the business environment, including risks arising in connection with the integration of acquisitions and financial system implementations.
Information and Communication – The WageWorks subsidiary did not establish cross-functional procedures and policies relating to effective information and communication necessary to support the functioning of internal control over financial reporting.
Monitoring – The WageWorks subsidiary did not implement effective monitoring controls that were responsive to changes in the business or the timely remediation of identified control deficiencies.
The COSO Framework component material weaknesses described above contributed to deficiencies at the control activity level that aggregated to the material weaknesses described below:
A. Accounting Close and Financial Reporting
The WageWorks subsidiary had inadequate process level and monitoring controls in the area of accounting close and financial reporting specifically, but not exclusively, around the review of account reconciliations, completeness and accuracy of data material to financial reporting, accounting estimates and related cut-off, the establishment, review, and implementation of accounting policies, and the review of the accuracy and completeness of certain manual and complex data feeds into journal entries and reconciliations of high-volume standard transactions.
B. Contract to Cash Process
The Company did not have effective controls around the contract-to-cash life cycle of service fees, including ineffective process level controls around billing set-up during customer implementation, managing change to existing customer billing terms and conditions, timely termination of customers, implementing complex and/or non-standard billing arrangements that require manual intervention or manual controls for billing to customers, processing timely adjustments, lack of robust, established and documented policies to assess collectability and reserve for revenue, bad debts and accounts receivable, availability of customer contracts, and reviews of non-standard contracts.

-37-

C. Information Technology General Controls
The Company did not have effective controls related to information technology general controls (ITGCs) in the areas of logical access and change-management over certain information technology systems that supported its financial reporting processes. The Company's business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.
These material weaknesses resulted in material misstatements of WageWorks' historical financial statements, which preceded the acquisition, and could result in a misstatement of our account balances or disclosures that would result in a material misstatement to the annual or interim condensed consolidated financial statements that would not be prevented or detected.
Ongoing Integration and Remediation Efforts
Management has assessed the impact of the acquisition of WageWorks on the Company’s internal control over financial reporting and continues to assess changes driven by the integration of WageWorks with the existing operations at the consolidated Company. As part of this assessment, management has continued to evaluate the Company’s internal control environment to ensure that it has appropriate controls in place to mitigate the risks of a material misstatement to its consolidated financial statements associated with the WageWorks subsidiary and the Company as a whole.
In response to the COSO Framework component material weaknesses in the WageWorks subsidiary’s internal control over financial reporting, management has taken the following actions:
performed its recurring risk assessment and scoping of key systems and business processes, including a risk assessment at the financial statement assertion level to ensure that the level of precision of relevant controls is adequate to address the identified risks;
dedicated certain senior finance, accounting, operational, and IT leadership team members to work on remediation efforts and appointed third-party internal controls advisors to assist with such efforts;
implemented a periodic assessment to monitor business changes impacting accounting processes and controls;
incorporated certain WageWorks processes into the Company’s existing entity-level controls;
established periodic reporting of the remediation plan progress to the Audit and Risk Committee of the Company's board of directors;
formalized documentation underlying processes and controls to promote knowledge and information transfer across functions and upon personnel changes; and
continued to monitor the operating effectiveness of the existing entity-level controls.
Although we have implemented the remediation plans detailed above, certain of these controls have not yet operated in the current fiscal year for us to evaluate if the material weakness has been remediated.
In response to the material weakness “A. Accounting Close and Financial Reporting,” management has taken the following actions:
incorporated certain WageWorks processes into the Company’s process-level controls, including, but not limited to, those that address the monitoring of the accounting close cycle and enhanced the evaluation of accounting policies;
redesigned certain processes and controls in conjunction with the enterprise resource planning “ERP” system migration described below;
formalized the assessment of the relevancy of information and data used in key controls, including a plan to design or augment controls to incorporate the review of the accuracy and completeness of such items; and
continued to monitor the operating effectiveness of the process-level and redesigned controls.
Although we have implemented the remediation plan detailed above, these controls have not been in place and operating for a sufficient period of time for us to evaluate if the material weakness has been remediated.
In response to the material weakness “B. Contract to Cash Process,” management has taken the following actions:
continued to execute its plan to consolidate service platforms related to the contract-to-cash cycle, which will reduce a significant number of manual business process controls;
enhanced the design of existing controls including information and data used in controls, where applicable, and began implementing additional controls to further strengthen the control environment; and
implemented a process to assess the design and monitor the operating effectiveness of the redesigned controls.
-38-

In response to the material weakness “C. Information Technology General Controls,” management has taken the following actions:
continued to execute its plan to consolidate service platforms, which will reduce the number of ITGCs in the areas of logical access and change management;
enhanced the design of existing controls, where applicable, and implemented additional controls to further strengthen the control environment; and
implemented a process to assess and enhance the design and monitor the operating effectiveness of controls related to logical access and change management for relevant applications and systems.
As we continue to evaluate operating effectiveness and monitor improvements to our internal control over financial reporting, we may take additional measures to address control deficiencies or modify the remediation plans described above.
As part of our integration efforts, we have migrated all of our material operations to a single ERP system for the consolidated Company that will enhance our business and financial processes and standardize our information systems. We have re-assessed risks in response to the ERP system migration and the associated changes to underlying processes. We have redesigned certain controls in response to the current risks and continue to monitor the operating effectiveness of the redesigned controls.
Changes in Internal Control Over Financial Reporting
Other than continuing to make progress on the ongoing integration and remediation efforts described above, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended October 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
-39-


Part II—Other Information
Item 1. Legal Proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Except as described in Note 6—Commitments and contingencies, as of the date of this Quarterly Report on Form 10-Q, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 6—Commitments and contingencies of the notes to condensed consolidated financial statements.
Item 1A. Risk factors
The risks described in “Risk factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021 could materially and adversely affect our business, financial condition and results of operations. Except as described below, there have been no material changes in such risks. These risk factors do not identify all risks that we face, and our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations.
The integration of the Further business may not be successful.

The success of the Further acquisition will depend in part on our ability to realize the anticipated business opportunities from combining the operations of Further with our business in an efficient and effective manner. The Further business is being carved out from the operations of its parent company. As such, the successful integration of the Further business with the Company is dependent on our ability to successfully carve out the Further business from its parent. While we have entered into a transition services agreement in order to effectively carve-out the Further business from its parent, no assurance can be given that the carve-out will be successful. In addition, the integration process could take longer than anticipated and could result in the loss of key employees, the disruption of the Company's ongoing business and the Further business, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with team members, Clients, Network Partners, or other third parties, or our ability to achieve the anticipated benefits of the acquisition, and could harm our financial performance. If we are unable to successfully or timely integrate the operations of Further with our business, we may incur unanticipated liabilities and be unable to realize the revenue growth, synergies and other anticipated benefits resulting from the acquisition of Further, and our business, results of operations and financial condition could be materially and adversely affected.

We rely on our management team and team members, and our business could be harmed if we are unable to retain qualified personnel.

Our success depends, in part, on the skills, working relationships and continued services of our executive leadership team and other key personnel. While we have entered into offer letters or employment agreements with certain of our executive officers, all of our team members are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason, and without notice, subject, in certain cases, to severance payment rights. In order to retain valuable team members, in addition to salary and cash incentives, we provide equity-based awards that vest over time or based on performance. The value to team members of these awards will be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract offers from other organizations. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. Volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.

Our success also depends on our ability to attract, retain, and motivate additional skilled management personnel and other team members. For example, competition for qualified personnel in our field and geographic markets is intense due to the limited number of individuals who possess the skills and experience required by our industry, particularly in the technology-related fields. In addition, we have experienced team member turnover as a result of both the WageWorks Acquisition and the ongoing "great resignation" occurring throughout the American economy, and we expect to continue to experience team member turnover in the future. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New team members may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. For
-40-

example, it has become more difficult for us to hire entry-level team members in our member service and client service teams. If our retention efforts are not successful or our team member turnover rate continues to increase in the future, our business, results of operations and financial condition could be materially and adversely affected.

In September 2021, the President of the United States signed an executive order, and related guidance was published that, together, require certain COVID-19 precautions for federal contractors, including mandatory COVID-19 vaccines for employees of federal contractors (subject to medical and religious exemptions) (the “Vaccine Mandate”). We are classified as a federal contractor due to a number of our agreements and believe we will be subject to the Vaccine Mandate. In order to comply with the Vaccine Mandate and based on current guidance provided by the federal government, HealthEquity is requiring all of its team members to show proof of vaccination or qualify for an applicable exemption by January 2022, although the timing of implementation of the executive order may be affected by additional guidance issued, including any extensions of time granted to comply. HealthEquity’s compliance with the Vaccine Mandate could result in increased team member attrition and costs associated with preventing team member attrition, and a material increase in team member attrition or increase in retention costs could have a material and adverse impact on our business, results of operations and financial condition.

Replacing our third-party vendors would be difficult and disruptive to our business.

We have entered into contracts with third-party vendors to provide critical services relating to our business, including the redesign of our technology platforms, fraud management and other customer verification services, transaction processing and settlement, telephony services, call centers and card production. In addition, WageWorks uses third-party vendors for its COBRA transaction processing and also uses one of our competitors for card processing and other services. In the event that these service providers fail to maintain adequate levels of support, do not provide high quality service, increase the fees they charge us, discontinue their lines of business, terminate our contractual arrangements or cease or reduce operations, we may suffer additional costs and be required to pursue new third-party relationships, which could harm our reputation, materially disrupt our operations and our ability to provide our products and services, and could divert management’s time and resources. A transition to a new vendor could take a significant amount of time and resources and, if we are unable to complete a transition to a new provider on a timely basis, or at all, we could be forced to temporarily or permanently discontinue certain services, such as our payment card services, which could disrupt services to our customers and adversely affect our business, financial condition, and results of operations. We may also be unable to establish comparable new third-party relationships on as favorable terms or at all, which could materially and adversely affect our business, financial condition, and results of operations.

The Vaccine Mandate requires that certain of our third-party vendors also require employees to be vaccinated. While we continue to evaluate the impact of the Vaccine Mandate on our third-party vendors, compliance with the Vaccine Mandate could result in certain key third-party vendors terminating their arrangements with us or in increased employee turnover at our third-party vendors, delays in performance by our third-party vendors, or increased costs for us. Such impacts could have a material and adverse impact on our business, results of operations and financial condition.

Our substantial debt could limit our ability to fund operations, expose us to interest rate volatility, limit our ability to raise additional capital and have a material adverse effect on our ability to fulfill our obligations under the Notes and on our business and prospects generally.

We are party to a $1.35 billion credit agreement (the "Credit Agreement"), which consists of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $350 million and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $1 billion. We have also issued $600 million of 4.50% unsecured Senior Notes due 2029. Under the Credit Agreement, we have the right to request additional commitments for new term loans and increases to then-existing term loans and revolving credit commitments in an amount up to the sum of (i) $300 million, plus (ii) an unlimited additional amount so long as the pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) does not exceed 3.85 to 1.00 (assuming any such new or increased revolving commitments are fully borrowed). We also have the right to incur additional debt from time to time, subject to the restrictions contained in the Credit Agreement and the Indenture. The substantial debt we have outstanding, combined with our other financial obligations and contractual commitments, has important consequences, including the following:

our level of debt may make it more difficult for us to satisfy our obligations with respect to our debt, including the Notes, and any failure to comply with the obligations under any of our debt instruments, including restrictive covenants, could result in an event of default under the Indenture and the agreements governing such other debt;
-41-

we will be required to use a substantial portion of our cash flow from operations to pay principal and interest on our debt, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, strategic acquisitions, investments and alliances and other general corporate requirements;
our interest expense could increase if interest rates increase because any outstanding borrowings under our Credit Facilities will be based on variable interest rates;
the interest rate on our Revolving Credit Facility will depend on the level of our specified financial ratios, and therefore could increase if such specified financial ratios increase;
such substantial debt could leave us vulnerable to general economic downturns and adverse competitive and industry conditions and could place us at a competitive disadvantage compared to those of our competitors that are less leveraged;
our debt service obligations could limit our flexibility to plan for, or react to, changes in our business and the industry in which we operate;
our level of debt may restrict us from raising additional financing on satisfactory terms to fund working capital, capital expenditures, strategic acquisitions, investments and joint ventures and other general corporate requirements;
our level of debt may prevent us from raising the funds necessary to repurchase all of the Notes tendered to us upon the occurrence of a change of control, which would constitute an event of default under the Indenture; and
a potential failure to comply with the financial and other restrictive covenants in any of our debt instruments, which, among other things, require us to maintain specified financial ratios, could, if not cured or waived, have a material adverse effect on our ability to fulfill our obligations under the Notes and on our business and prospects generally.

The Indenture and the Credit Agreement contain covenants that impose significant operational and financial restrictions on us, and the failure to comply with these covenants would result in an event of default under these instruments.

The Indenture and the Credit Agreement impose on us operating and other restrictions. These restrictions affect, and in many respects limit or prohibit, among other things, our ability to:

incur additional debt and issue certain capital stock;
create liens;
make investments or acquisitions;
enter into transactions with affiliates;
sell assets;
guarantee debt;
declare or pay dividends or other distributions to shareholders;
repurchase equity interests;
redeem debt that is subordinated in right of payment to certain debt instruments;
enter into agreements that restrict dividends or other payments from subsidiaries; and
consolidate, merge or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis.

The terms of the Revolving Credit Facility in the Credit Agreement also require us to achieve and maintain compliance with specified financial ratios. The restrictions contained in the Credit Agreement:

limit our ability to plan for or react to market conditions or meet capital needs or otherwise restrict our activities or business plans; and
adversely affect our ability to finance our operations, strategic acquisitions, investments or alliances or other capital needs or to engage in other business activities that would be in our interest.

A breach of any of these restrictive covenants or our inability to comply with the required financial ratios would result in a default under some or all of the debt agreements. During the occurrence and continuance of a default, lenders under our Credit Facilities may elect to declare all outstanding borrowings, together with accrued interest and other fees, to be immediately due and payable, which would result in an event of default under the Indenture. The lenders will also have the right in these circumstances to terminate any commitments they have to provide further borrowings. Additionally, our Credit Agreement contains a cross-default provision, which generally causes a default or event of default under the Credit Agreement upon a qualifying default or event of default under any other debt instrument (including under the Indenture) and the Indenture contains a cross-acceleration provision. If we are
-42-

unable to repay outstanding borrowings when due, the lenders under our Credit Facilities will also have the right to proceed against the collateral granted to them to secure the debt. If lenders under the Credit Facilities accelerate the debt thereunder, then the obligations under the Notes would be accelerated. We cannot provide assurance that, if the indebtedness under our Credit Facilities or the Notes were to be accelerated, our assets would be sufficient to repay in full that indebtedness and our other indebtedness. If not cured or waived, such acceleration could have a material adverse effect on our business and our prospects.
-43-

Item 6. Exhibits
Incorporate by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
2.1†8-K001-365682.1September 8, 2021
2.2†8-K001-365682.2September 8, 2021
2.3†8-K001-365682.1November 1, 2021
4.18-K001-365684.1October 12, 2021
10.1†8-K001-3656810.1October 12, 2021
31.1+
31.2+
32.1*#
32.2*#
101.INSXBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy schema linkbase document
101.CALInline XBRL Taxonomy calculation linkbase document
101.DEFInline XBRL Taxonomy definition linkbase document
101.LABInline XBRL Taxonomy labels linkbase document
101.PREInline XBRL Taxonomy presentation linkbase document
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2021, formatted in Inline XBRL.
-44-

+Filed herewith.
*Furnished herewith.
#These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. HealthEquity hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.
 

-45-

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEALTHEQUITY, INC.
Date: December 9, 2021By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:Executive Vice President and Chief Financial Officer

-46-
EX-31.1 2 exhibit311-ceo302xfy22q3.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: December 9, 2021
 
By:/s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 exhibit312-cfo302xfy22q3.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Tyson Murdock, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 9, 2021
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


EX-32.1 4 exhibit321-ceo906xfy22q3.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended October 31, 2021 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: December 9, 2021
 
By: /s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-32.2 5 exhibit322-cfo906xfy22q3.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Tyson Murdock, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended October 31, 2021 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 9, 2021
 
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 


EX-101.SCH 6 hqy-20211031.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Summary of business and significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Business combination link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Business combination (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business combination (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2119105 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2123106 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2129108 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2330306 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Indebtedness (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2334307 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Stock-based compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - Stock-based compensation (Stock option activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2139110 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 2340308 - Disclosure - Fair value (Tables) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Fair value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink 2143111 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 2444424 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hqy-20211031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hqy-20211031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hqy-20211031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Letter of Credit Letter of Credit [Member] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Trade names & trademarks Trademarks and Trade Names [Member] Merger integration Business Combination, Integration Related Costs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Contingent Acquisition Consideration [Abstract] Contingent Acquisition Consideration [Abstract] Contingent Acquisition Consideration Other income (expense), net Other Nonoperating Income (Expense), Miscellaneous Other Nonoperating Income (Expense), Miscellaneous Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Accrued compensation Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Acquisition gains (costs), net Business Combination, Acquisition Related Costs Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two 2024 Contractual Obligation, to be Paid, Year Two Forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Filer Category Entity Filer Category Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Other offering expenses payable Stock Issuance Costs Payable Stock Issuance Costs Payable Beginning balance, maximum (in usd per share) Ending balance, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Fifth Third Bank HSA portfolio Acquisition Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member] Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member] Other assets Other Assets, Noncurrent 2022 Contractual Obligation, to be Paid, Remainder of Fiscal Year Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Debt covenant, period one Debt Covenant Period One [Member] Debt Covenant Period One Shares available for grant under incentive plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Redemption price, percentage Debt Instrument, Redemption Price, Percentage Other Income (Expense), Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] 2024 Long-Term Debt, Maturity, Year Two Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Second and third years after the Effective Date Debt Instrument, Amortization Period Two and Three Period [Member] Debt Instrument, Amortization Period Two and Three Period Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Decrease in goodwill due to measurement period adjustments, net Goodwill, adjustments Goodwill, Purchase Accounting Adjustments 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type [Domain] Subsequent Event Type [Domain] Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense Amortization of Intangible Assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue recognition Contract with Customer, Liability, Revenue Recognized Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Total Asset Acquisition, Consideration,To Be Paid Asset Acquisition, Consideration,To Be Paid Business Combination and Asset Acquisition [Abstract] Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Business Acquisition [Axis] Business Acquisition [Axis] Exercised, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Award Type [Domain] Award Type [Domain] Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] 2025 Long-Term Debt, Maturity, Year Three Vested and expected to vest, weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Beginning balance, minimum (in usd per share) Ending balance, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Performance units awards (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively Preferred Stock, Value, Issued Fair value Finite-lived Intangible Assets Acquired New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Acquired trade names Trade Names [Member] Accumulated earnings Retained Earnings [Member] First year after the Effective Date Debt Instrument, Amortization Period One [Member] Debt Instrument, Amortization Period One Debt Instrument [Axis] Debt Instrument [Axis] Operating lease not yet commenced term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Long-term liabilities Liabilities, Noncurrent [Abstract] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Prior to October 1, 2024 Debt Instrument, Redemption, Period Four [Member] Percentage of capital stock Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Secured Debt Secured Debt [Member] Accounts receivable, net Increase (Decrease) in Accounts Receivable Total consideration paid, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Purchases of property and equipment included in accounts payable or accrued liabilities Capital Expenditures Incurred but Not yet Paid Operating lease right-of-use assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Interest income Investment Income, Nonoperating Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Entity Interactive Data Current Entity Interactive Data Current 2026 Interest On Long-Term Debt, To Be Paid, Year Four Interest On Long-Term Debt, To Be Paid, Year Four Basic (in usd per share) Earnings Per Share, Basic Operating lease expense Operating Lease, Expense 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Sublease income Sublease Income Balance as of January 31, 2021 Balance as of October 31, 2021 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type 2023 Long-Term Debt, Maturity, Year One Total consideration paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Exercised, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating cash flows from operating leases Operating Lease, Payments Other non-cash items Other Noncash Income (Expense) Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit) Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 2026 Contractual Obligation, to be Paid, Year Four Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Contingent consideration recognized at acquisition Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Principal amount Long-term Debt, Gross October 1, 2025 Debt Instrument, Redemption, Period Two [Member] Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Plan Name [Axis] Plan Name [Axis] Total debt, net Long-term Debt Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Customary Base Rate Base Rate [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Service revenue Service [Member] Fifth year after the Effective Date Debt Instrument, Amortization Period Five [Member] Debt Instrument, Amortization Period Five [Member] Additional paid-in capital Additional Paid in Capital Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate 2022 Contingent Acquisition Consideration, To Be Paid, Remainder Of Fiscal Year Contingent Acquisition Consideration, To Be Paid, Remainder Of Fiscal Year Net income (loss) per share Earnings Per Share [Text Block] Operating expenses Operating Expenses [Abstract] Gain on equity securities Equity Securities, FV-NI, Gain (Loss) Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Minimum Minimum [Member] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross profit Gross Profit Long-term line of credit Long-term Line of Credit 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Debt issuance costs, net Debt Issuance Costs, Net Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Gross unrecognized tax benefits Unrecognized Tax Benefits 2024 Asset Acquisition, Consideration,To Be Paid, Year Two Asset Acquisition, Consideration,To Be Paid, Year Two Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Trading Symbol Trading Symbol Ownership interest (as a percent) Business Acquisition, Percentage of Voting Interests Acquired HealthSavings Administrators, LLC HealthSavings Administrators, LLC [Member] HealthSavings Administrators, LLC Current liabilities Liabilities, Current [Abstract] 2026 Long-Term Debt, Maturity, Year Four 2023 Asset Acquisition, Consideration,To Be Paid, Year One Asset Acquisition, Consideration,To Be Paid, Year One General and administrative General and Administrative Expense Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Indebtedness Debt Disclosure [Text Block] Exercisable, weighted-average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Line of Credit Line of Credit [Member] Stock-based compensation Share-based Payment Arrangement [Text Block] Senior Notes Senior Notes [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Outstanding stock options, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Total Contractual Obligation Underwriting discounts and commissions Payments of Stock Issuance Costs Cost of revenue Cost of Revenue [Abstract] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Letters of credit outstanding Letters of Credit Outstanding, Amount Common stock, $0.0001 par value, 900,000 shares authorized, 83,586 and 77,168 shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively Common Stock, Value, Issued Total other expense Nonoperating Income (Expense) Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Goodwill acquired Goodwill, Acquired During Period Basis of presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (see Note 6) Commitments and Contingencies Long-term Debt, Fiscal Year Maturity [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Business combination Business Combination Disclosure [Text Block] Restricted Stock Awards Restricted Stock [Member] 2023 Interest On Long-Term Debt, To Be Paid, Year One Interest On Long-Term Debt, To Be Paid, Year One Payment of debt issuance costs Payments of Debt Issuance Costs Document Period End Date Document Period End Date Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Goodwill [Line Items] Goodwill [Line Items] Entity Registrant Name Entity Registrant Name Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] Net proceeds from follow on offering Sale of Stock, Consideration Received on Transaction 2024 Interest On Long-Term Debt, To Be Paid, Year Two Interest On Long-Term Debt, To Be Paid, Year Two Payments to acquire VEBA assets Payments to Acquire Productive Assets Accrued liabilities Accrued Liabilities, Current Revenue Revenue from Contract with Customer, Excluding Assessed Tax Fourth year after the Effective Date Debt Instrument, Amortization Period Four [Member] Debt Instrument, Amortization Period Four [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Common stock: Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Other expense Other Nonoperating Income (Expense) [Abstract] Income (loss) from operations Operating Income (Loss) Custodial revenue Financial Service, Other [Member] Thereafter Interest On Long-Term Debt, To Be Paid, After Year Four Interest On Long-Term Debt, To Be Paid, After Year Four Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities Operating Lease, Liability, Current Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Additional paid-in capital: Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Accounts payable, accrued liabilities, and other current liabilities Increase (Decrease) in Accrued Liabilities Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Summary of Restricted Stock Unit Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Asset Acquisition, Consideration [Abstract] Asset Acquisition, Consideration [Abstract] Asset Acquisition, Consideration Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Fair value of the notes Long-term Debt, Fair Value 2022 Asset Acquisition, Consideration,To Be Paid, Remainder Of Fiscal Year Asset Acquisition, Consideration,To Be Paid, Remainder Of Fiscal Year Percentage of principal amount redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed 2022 Other Commitment, to be Paid, Remainder of Fiscal Year Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Legal Entity [Axis] Legal Entity [Axis] Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent 2025 Asset Acquisition, Consideration,To Be Paid, Year Three Asset Acquisition, Consideration,To Be Paid, Year Three Common stock, issued (in shares) Common Stock, Shares, Issued Maximum leverage ratio Debt Instrument, Covenant, Net Leverage Ratio Debt Instrument, Covenant, Net Leverage Ratio Further Health Savings Account Portfolio Acquisition Further Health Savings Account Portfolio Acquisition [Member] Further Health Savings Account Portfolio Acquisition Preferred stock, issued (in shares) Preferred Stock, Shares Issued Exercisable, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt WageWorks Insurers WageWorks Insurers [Member] WageWorks Insurers [Member] Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Software and software development costs Software and Software Development Costs [Member] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Other long-term liabilities Increase (Decrease) in Other Deferred Liability Principal amount Debt Instrument, Face Amount Interest expense Interest Expense Accrued compensation Increase (Decrease) in Employee Related Liabilities Purchase price for HSA portfolio Payments For Asset Acquisition Payments For Asset Acquisition Effective interest rate percentage Debt Instrument, Interest Rate, Effective Percentage Debt covenant, period two Debt Covenant Period Two [Member] Debt Covenant Period Two Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period City Area Code City Area Code Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period Thereafter Contractual Obligation, to be Paid, After Year Four Contractual Obligation, to be Paid, After Year Four Accumulated earnings Retained Earnings (Accumulated Deficit) Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Number of HSA members transferred in portfolio acquisition Number Of HSA Members Transferred Number Of HSA Members Transferred Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Preliminary Allocation of Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Business Acquisition [Line Items] Business Acquisition [Line Items] Incentive Plan Incentive Plan [Member] Incentive Plan [Member] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Schedule of Change in the Fair Value of the Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax provision (benefit) Income tax benefit Income Tax Expense (Benefit) Other Commitment, Fiscal Year Maturity [Abstract] Other Commitment, Fiscal Year Maturity [Abstract] Accounts receivable, net of allowance for doubtful accounts of $6,063 and $4,239 as of October 31, 2021 and January 31, 2021, respectively Accounts Receivable, after Allowance for Credit Loss, Current Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Thereafter Other Commitment To Be Paid, After Year Four Other Commitment To Be Paid, After Year Four Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Entity File Number Entity File Number Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Fair value Fair Value Measurement, Policy [Policy Text Block] Current portion of long-term debt Less: current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Thereafter Asset Acquisition, Consideration,To Be Paid, After Year Four Asset Acquisition, Consideration,To Be Paid, After Year Four October 1, 2026 and thereafter Debt Instrument, Redemption, Period Three [Member] Sales and marketing Selling and Marketing Expense 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Statement [Line Items] Statement [Line Items] Weighted- average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Contingent consideration recognized at acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Total Other Commitment Maximum amount of contingent consideration payable Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Counterparty Name [Domain] Counterparty Name [Domain] 2024 Other Commitment, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Prior to October 1, 2024, 40% of Principal Debt Instrument, Redemption, Period Five [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] 2023 Contractual Obligation, to be Paid, Year One Entity Address, State or Province Entity Address, State or Province Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity [Domain] Entity [Domain] Estimated life (in years) Finite-Lived Intangible Asset, Useful Life Other expense Other Expense [Member] Total Interest On Long-Term Debt, To Be Paid Interest On Long-Term Debt, To Be Paid Interchange revenue Credit and Debit Card [Member] Schedule of Earnings (Loss) Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Summary of Share Based Compensation Recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Value of HSA assets transferred in portfolio acquisition Asset Acquisition, Assets Acquired And Liabilities, Assets Asset Acquisition, Assets Acquired And Liabilities, Assets Proceeds from follow-on equity offering, net of payments for offering costs Proceeds from Issuance of Common Stock Total assets Assets Deferred taxes Deferred Income Taxes and Tax Credits Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Vested and expected to vest, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Contingent Consideration Contingent Consideration [Member] Contingent Consideration Technology and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Stated interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Contingent consideration liability Business Combination, Contingent Consideration, Liability Total long-term liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities 2025 Contractual Obligation, to be Paid, Year Three Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Lease Cost Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Subsequent Event [Line Items] Subsequent Event [Line Items] Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in usd per share) Earnings Per Share, Diluted Maximum borrowing capacity of future commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Offering price per share (in usd per share) Sale of Stock, Price Per Share Schedule of payments due by fiscal year for our outstanding contractual obligations Contractual Obligation, Fiscal Year Maturity [Table Text Block] 2025 Interest On Long-Term Debt, To Be Paid, Year Three Interest On Long-Term Debt, To Be Paid, Year Three Income tax payments (refunds), net Income Taxes Paid, Net Subsequent events Subsequent Events [Text Block] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Deferred tax liability Deferred Income Tax Liabilities, Net Total Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced 2026 Other Commitment, to be Paid, Year Four Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Fair value Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization 2023 Other Commitment, to be Paid, Year One Technology and development Technology and Development [Member] Technology and Development [Member] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding 2026 Asset Acquisition, Consideration,To Be Paid, Year Four Asset Acquisition, Consideration,To Be Paid, Year Four Thereafter Long-Term Debt Maturities, Repayments Of Principal After Year Four Long-Term Debt Maturities, Repayments Of Principal After Year Four Cost of revenue Cost of Goods and Services Sold Revenues [Abstract] Revenues [Abstract] Fifth Third Bank HSA Portfolio Acquisition Fifth Third Bank HSA Portfolio Acquisition [Member] Fifth Third Bank HSA Portfolio Acquisition Computer software intangible asset Computer Software, Intangible Asset [Member] Acquisition of intangible member assets Payments to Acquire Intangible Assets 2026 Contingent Acquisition Consideration, To Be Paid, Year Four Contingent Acquisition Consideration, To Be Paid, Year Four Debt instrument, amortization of loans, percentage of principal amount Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Net operating lease expense Lease, Cost Property and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Facility term Debt Instrument, Term Customer relationships Acquired customer relationships Customer Relationships [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Contingent consideration, performance period Business Combination, Contingent Consideration, Performance Period Business Combination, Contingent Consideration, Performance Period Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Range of exercise prices Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Other long-term liabilities Other Liabilities, Noncurrent Union Mesa Union Mesa [Member] Union Mesa Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Principal payments on long-term debt Repayments of Long-term Debt Earnings Per Share [Abstract] Earnings Per Share [Abstract] Acquired HSA portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Interest On Long-Term Debt, Fiscal Year Maturity [Abstract] Interest On Long-Term Debt, Fiscal Year Maturity [Abstract] Interest On Long-Term Debt, Fiscal Year Maturity Property and equipment, gross Property, Plant and Equipment, Gross Total Contingent Acquisition Consideration, To Be Paid Contingent Acquisition Consideration, To Be Paid Document Quarterly Report Document Quarterly Report Other assets Increase (Decrease) in Other Operating Assets Remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Debt instrument, number of days to reinvest proceeds from sales of assets Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Grant date fair value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Settle of claims Loss Contingency Accrual Payment to acquire remainder of further business Asset Acquisition, Consideration Transferred Opening balance (in usd per share) Ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Long-term debt, net Long-term Debt, Excluding Current Maturities Asset Acquisition [Domain] Asset Acquisition [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Other issuance of common stock Stock Issued During Period, Value, Other Total stock-based compensation expense Share-based Payment Arrangement, Expense Exercisable, weighted-average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Net income (loss) per share: Net income (loss) per share: Earnings Per Share, Basic and Diluted [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Effective tax rate Effective Income Tax Rate Reconciliation, Percent Prior Credit Agreement Prior Credit Agreement [Member] Prior Credit Agreement Counterparty Name [Axis] Counterparty Name [Axis] Vested and expected to vest, aggregate intrinsic value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value WageWorks, Inc WageWorks Inc. [Member] WageWorks Inc. [Member] 4.50% Senior Notes due 2029 4.500% Senior Notes due 2029 [Member] 4.500% Senior Notes due 2029 Beginning cash and cash equivalents Ending cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, shares (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Current assets Assets, Current [Abstract] October 1, 2024 Debt Instrument, Redemption, Period One [Member] Amortizable intangible assets, gross Finite-Lived Intangible Assets, Gross Thereafter Contingent Acquisition Consideration, To Be Paid, After Year Four Contingent Acquisition Consideration, To Be Paid, After Year Four Entity Central Index Key Entity Central Index Key Schedule of Acquired Identified Intangible Assets Schedule of Finite-lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Acquisition threshold for maximum total net leverage ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Luum Acquisition Luum Acquisition [Member] Luum Acquisition [Member] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Minimum interest coverage ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Income taxes Income Tax Disclosure [Text Block] 2022 Interest On Long-Term Debt, To Be Paid, Remainder Of Fiscal Year Interest On Long-Term Debt, To Be Paid, Remainder Of Fiscal Year Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Follow on equity offering Follow On Equity Offering [Member] Follow On Equity Offering [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Variable rate borrowing spread Debt Instrument, Basis Spread on Variable Rate Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value General and administrative General and Administrative Expense [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] Total current liabilities Liabilities, Current Purchase price for acquisition Payments to Acquire Businesses, Gross Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Weighted-average number of shares used in computing net income (loss) per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Entity Address, Postal Zip Code Entity Address, Postal Zip Code Proceeds from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Less: unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security 2023 Contingent Acquisition Consideration, To Be Paid, Year One Contingent Acquisition Consideration, To Be Paid, Year One Statement [Table] Statement [Table] Other current assets Other Assets, Current 2025 Other Commitment, to be Paid, Year Three Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Number of derivative lawsuits Loss Contingency Number Of Lawsuits Loss Contingency Number Of Lawsuits Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation Noncash or Part Noncash Acquisition, Intangible Assets Acquired Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Purchases of software and capitalized software development costs Payments for Software Subsequent Event Subsequent Event [Member] Cover page. Cover [Abstract] 2025 Contingent Acquisition Consideration, To Be Paid, Year Three Contingent Acquisition Consideration, To Be Paid, Year Three Amortizable intangible assets, net Finite-Lived Intangible Assets, Net Goodwill Goodwill Goodwill Deferred tax liability, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Cost of revenue Cost of Sales [Member] Settlement of client-held funds obligation, net Payments To Settle Client Held Funds Payments To Settle Client Held Funds Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] 2024 Contingent Acquisition Consideration, To Be Paid, Year Two Contingent Acquisition Consideration, To Be Paid, Year Two Subsequent Event Type [Axis] Subsequent Event Type [Axis] Developed technology Acquired developed technology Developed Technology Rights [Member] Computer equipment Computer Equipment [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Sublease income to be received Sublease Income, To Be Received Sublease Income, To Be Received EX-101.PRE 10 hqy-20211031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 hqy-20211031_htm.xml IDEA: XBRL DOCUMENT 0001428336 2021-02-01 2021-10-31 0001428336 2021-11-30 0001428336 2021-10-31 0001428336 2021-01-31 0001428336 us-gaap:ServiceMember 2021-08-01 2021-10-31 0001428336 us-gaap:ServiceMember 2020-08-01 2020-10-31 0001428336 us-gaap:ServiceMember 2021-02-01 2021-10-31 0001428336 us-gaap:ServiceMember 2020-02-01 2020-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2021-08-01 2021-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2020-08-01 2020-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2021-02-01 2021-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2020-02-01 2020-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2021-08-01 2021-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2020-08-01 2020-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2021-02-01 2021-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2020-02-01 2020-10-31 0001428336 2021-08-01 2021-10-31 0001428336 2020-08-01 2020-10-31 0001428336 2020-02-01 2020-10-31 0001428336 2021-07-31 0001428336 2020-07-31 0001428336 2020-01-31 0001428336 us-gaap:CommonStockMember 2021-07-31 0001428336 us-gaap:CommonStockMember 2020-07-31 0001428336 us-gaap:CommonStockMember 2021-01-31 0001428336 us-gaap:CommonStockMember 2020-01-31 0001428336 us-gaap:CommonStockMember 2020-02-01 2020-10-31 0001428336 us-gaap:CommonStockMember 2021-10-31 0001428336 us-gaap:CommonStockMember 2020-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2021-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2020-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001428336 us-gaap:RetainedEarningsMember 2021-07-31 0001428336 us-gaap:RetainedEarningsMember 2020-07-31 0001428336 us-gaap:RetainedEarningsMember 2021-01-31 0001428336 us-gaap:RetainedEarningsMember 2020-01-31 0001428336 us-gaap:RetainedEarningsMember 2021-08-01 2021-10-31 0001428336 us-gaap:RetainedEarningsMember 2020-08-01 2020-10-31 0001428336 us-gaap:RetainedEarningsMember 2021-02-01 2021-10-31 0001428336 us-gaap:RetainedEarningsMember 2020-02-01 2020-10-31 0001428336 us-gaap:RetainedEarningsMember 2021-10-31 0001428336 us-gaap:RetainedEarningsMember 2020-10-31 0001428336 2020-10-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-02-01 2021-10-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-02-01 2020-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-02-01 2021-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2020-02-01 2020-10-31 0001428336 hqy:FollowOnEquityOfferingMember 2021-02-01 2021-04-30 0001428336 hqy:FollowOnEquityOfferingMember 2021-04-30 0001428336 hqy:LuumAcquisitionMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember 2021-03-08 0001428336 hqy:FifthThirdBankHSAPortfolioAcquisitionMember 2021-09-01 2021-09-29 0001428336 hqy:LuumAcquisitionMember 2021-08-01 2021-10-31 0001428336 hqy:LuumAcquisitionMember 2021-02-01 2021-10-31 0001428336 hqy:LuumAcquisitionMember 2021-10-31 0001428336 hqy:LuumAcquisitionMember 2021-03-08 2021-10-31 0001428336 hqy:LuumAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember us-gaap:DevelopedTechnologyRightsMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember us-gaap:TrademarksAndTradeNamesMember 2021-03-08 2021-03-08 0001428336 us-gaap:LeaseholdImprovementsMember 2021-10-31 0001428336 us-gaap:LeaseholdImprovementsMember 2021-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2021-10-31 0001428336 us-gaap:FurnitureAndFixturesMember 2021-01-31 0001428336 us-gaap:ComputerEquipmentMember 2021-10-31 0001428336 us-gaap:ComputerEquipmentMember 2021-01-31 0001428336 2021-11-01 2021-10-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-10-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2021-10-31 0001428336 us-gaap:CustomerRelationshipsMember 2021-01-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2021-10-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2021-01-31 0001428336 us-gaap:TradeNamesMember 2021-10-31 0001428336 us-gaap:TradeNamesMember 2021-01-31 0001428336 hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember 2021-09-29 0001428336 hqy:A4500SeniorNotesDue2029Member 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember 2021-10-31 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-10-31 0001428336 hqy:CreditAgreementMember 2021-10-31 0001428336 hqy:WageWorksInc.Member 2021-04-30 0001428336 hqy:UnionMesaMember us-gaap:SubsequentEventMember hqy:WageWorksInc.Member 2021-11-24 0001428336 hqy:WageWorksInc.Member 2021-10-31 0001428336 hqy:WageWorksInsurersMember 2021-10-31 0001428336 2018-09-06 2018-09-06 0001428336 2018-06-22 2018-06-22 0001428336 hqy:A4500SeniorNotesDue2029Member 2021-01-31 0001428336 hqy:TermLoanFacilityMember 2021-01-31 0001428336 hqy:TermLoanFacilityMember hqy:PriorCreditAgreementMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:PriorCreditAgreementMember 2021-01-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2021-10-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2021-01-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2021-10-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodFourMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodFiveMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-10-08 2021-10-08 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-10-08 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LetterOfCreditMember 2021-10-08 0001428336 hqy:CreditAgreementMember 2021-10-08 0001428336 srt:MinimumMember hqy:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-10-08 2021-10-08 0001428336 srt:MaximumMember hqy:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-10-08 2021-10-08 0001428336 srt:MinimumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2021-10-08 2021-10-08 0001428336 srt:MaximumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2021-10-08 2021-10-08 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-02-01 2021-10-31 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-02-01 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodOneMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodFourMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodFiveMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-02-01 2021-10-31 0001428336 hqy:TermLoanFacilityMember hqy:PriorCreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 2019-08-30 0001428336 hqy:TermLoanFacilityMember hqy:PriorCreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 srt:MinimumMember hqy:PriorCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember hqy:PriorCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember hqy:PriorCreditAgreementMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember hqy:PriorCreditAgreementMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 hqy:PriorCreditAgreementMember hqy:DebtCovenantPeriodOneMember 2019-08-30 0001428336 hqy:PriorCreditAgreementMember hqy:DebtCovenantPeriodTwoMember 2019-08-30 0001428336 hqy:PriorCreditAgreementMember 2019-08-30 2019-08-30 0001428336 hqy:PriorCreditAgreementMember 2019-08-30 0001428336 us-gaap:CostOfSalesMember 2021-08-01 2021-10-31 0001428336 us-gaap:CostOfSalesMember 2020-08-01 2020-10-31 0001428336 us-gaap:CostOfSalesMember 2021-02-01 2021-10-31 0001428336 us-gaap:CostOfSalesMember 2020-02-01 2020-10-31 0001428336 hqy:SalesandMarketingMember 2021-08-01 2021-10-31 0001428336 hqy:SalesandMarketingMember 2020-08-01 2020-10-31 0001428336 hqy:SalesandMarketingMember 2021-02-01 2021-10-31 0001428336 hqy:SalesandMarketingMember 2020-02-01 2020-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2021-08-01 2021-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2020-08-01 2020-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2021-02-01 2021-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2020-02-01 2020-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2021-08-01 2021-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2020-08-01 2020-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2021-02-01 2021-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2020-10-31 0001428336 us-gaap:OtherExpenseMember 2021-08-01 2021-10-31 0001428336 us-gaap:OtherExpenseMember 2020-08-01 2020-10-31 0001428336 us-gaap:OtherExpenseMember 2021-02-01 2021-10-31 0001428336 us-gaap:OtherExpenseMember 2020-02-01 2020-10-31 0001428336 hqy:IncentivePlanMember 2021-10-31 0001428336 2021-02-01 2021-04-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0001428336 us-gaap:RestrictedStockMember 2021-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-02-01 2021-10-31 0001428336 us-gaap:RestrictedStockMember 2021-02-01 2021-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-10-31 0001428336 us-gaap:RestrictedStockMember 2021-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-04-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2021-04-30 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-10-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-10-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:FairValueInputsLevel2Member 2021-10-31 0001428336 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001428336 hqy:ContingentConsiderationMember 2021-01-31 0001428336 hqy:ContingentConsiderationMember 2021-02-01 2021-10-31 0001428336 hqy:ContingentConsiderationMember 2021-10-31 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-04-01 2021-04-30 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-04-30 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-09-01 2021-09-30 0001428336 hqy:HealthSavingsAdministratorsLLCMember us-gaap:SubsequentEventMember 2021-12-06 2021-12-06 0001428336 hqy:HealthSavingsAdministratorsLLCMember us-gaap:SubsequentEventMember 2021-12-06 shares iso4217:USD iso4217:USD shares pure hqy:member hqy:lawsuit 0001428336 --01-31 2022 Q3 false 10-Q true 2021-10-31 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 83601381 649129000 328803000 6063000 4239000 84083000 72767000 30919000 58607000 764131000 460177000 24930000 29106000 81150000 89508000 820946000 767003000 1363549000 1327193000 44908000 37420000 3099614000 2710407000 5244000 1614000 32695000 50670000 49879000 75880000 6563000 62500000 12693000 14037000 107074000 204701000 923501000 924217000 67836000 74224000 18953000 8808000 110400000 119729000 1120690000 1126978000 1227764000 1331679000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 83586000 83586000 77168000 77168000 8000 8000 1662965000 1158372000 208877000 220348000 1871850000 1378728000 3099614000 2710407000 102733000 104562000 314449000 319638000 49006000 48544000 144760000 142352000 28215000 26245000 94050000 83411000 179954000 179351000 553259000 545401000 66217000 65936000 204183000 202195000 5734000 4762000 15567000 14805000 4683000 4095000 15102000 13985000 76634000 74793000 234852000 230985000 103320000 104558000 318407000 314416000 12726000 12880000 42288000 36502000 38070000 30758000 111437000 92490000 20004000 22099000 63503000 61590000 19642000 19126000 59745000 56905000 13244000 8193000 38422000 31328000 103686000 93056000 315395000 278815000 -366000 11502000 3012000 35601000 11881000 6952000 25824000 28110000 3122000 -421000 -164000 -2009000 -8759000 -7373000 -25988000 -30119000 -9125000 4129000 -22976000 5482000 -4087000 2340000 -11505000 2015000 -5038000 -5038000 1789000 1789000 -11471000 -11471000 3467000 3467000 -0.06 0.02 -0.14 0.05 -0.06 0.02 -0.14 0.05 83551000 76701000 82939000 73358000 83551000 77845000 82939000 74665000 1862666000 1340336000 1378728000 1030295000 8000 8000 8000 7000 1000 8000 8000 8000 8000 1648743000 1127136000 1158372000 818774000 938000 1651000 6253000 4402000 2000 456640000 286779000 13284000 11479000 41700000 30313000 1662965000 1140268000 1662965000 1140268000 213915000 213192000 220348000 211514000 -5038000 1789000 -11471000 3467000 208877000 214981000 208877000 214981000 1871850000 1355257000 1871850000 1355257000 -11471000 3467000 98364000 85485000 41700000 30313000 3616000 3818000 -4044000 0 -2147000 0 750000 -1727000 -8765000 -973000 10090000 -8063000 -19888000 -3309000 -8944000 -8344000 -18098000 -15251000 -34023000 -7936000 -6808000 -8361000 6034000 8712000 90438000 120717000 49533000 0 49033000 37242000 7284000 11388000 64463000 28100000 2367000 0 -167946000 -76730000 1003125000 223438000 950000000 0 11846000 0 456642000 286779000 1565000 4189000 7728000 4491000 397834000 63643000 320326000 107630000 328803000 191726000 649129000 299356000 13685000 22849000 -5926000 1053000 3708000 1346000 479000 167000 2281000 289000 8147000 0 1000 89000 19000 5838000 Summary of business and significant accounting policies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of October 31, 2021 and for the three and nine months ended October 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on equity offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and used an additional $60.8 million to acquire the Fifth Third Bank HSA portfolio. The Company used the remaining net proceeds from the offering, and other cash on hand, for the acquisition of Further on November 1, 2021. For a description of the Further acquisition, refer to Note 11—Subsequent events.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements as of October 31, 2021 and for the three and nine months ended October 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. 5750000 80.30 456600000 4600000 500000 50200000 1 60800000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Net income (loss) per share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,845 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,665 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended October 31, 2021 and 2020, 1.6 million and 1.0 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended October 31, 2021 and 2020, approximately 1.9 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,845 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,939 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,665 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -5038000 1789000 -11471000 3467000 83551000 76701000 82939000 73358000 83551000 76701000 82939000 73358000 0 1144000 0 1307000 83551000 77845000 82939000 74665000 -0.06 0.02 -0.14 0.05 -0.06 0.02 -0.14 0.05 1600000 1000000 1900000 600000 Business combination<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Luum</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which were contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). During the three and nine months ended October 31, 2021, the Company recognized income of $3.2 million and $2.1 million, respectively, resulting from changes in the fair value of the contingent consideration. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, which is presented within accrued liabilities on the Company's condensed consolidated balance sheet as of October 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's current allocation of the consideration paid:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Updated Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names &amp; trademarks (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.</span></div> 1 50200000 20000000 P2Y 8100000 3200000 2100000 6000000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's current allocation of the consideration paid:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Updated Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 626000 626000 1469000 1469000 23900000 23900000 36374000 -19000 36355000 100000 100000 597000 597000 3566000 -19000 3547000 58306000 0 58306000 36400000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names &amp; trademarks (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(283,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820,946 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12400000 P7Y 10900000 P5Y 600000 P3Y 23900000 P6Y Supplemental financial statement information<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following as of October 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,885 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,093 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,930 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,106 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended October 31, 2021 and 2020 was $3.5 million and $4.0 million, respectively, and $10.9 million and $12.0 million for the nine months ended October 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 31, 2021 and January 31, 2021, the balance of deferred revenue was $10.1 million and $4.1 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 40% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and nine months ended October 31, 2021, approximately $0.3 million and $1.4 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,057 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,327 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,967 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition gains (costs), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,009)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the application of Accounting Standards Codification ("ASC") 470-50, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Modifications and Extinguishments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a $4.0 million loss on extinguishment of debt during the three months ended October 31, 2021, which is included within interest expense in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended October 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,480 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following as of October 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,885 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,093 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,930 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,106 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 20718000 22271000 9068000 9230000 34099000 28592000 63885000 60093000 38955000 30987000 24930000 29106000 3500000 4000000 10900000 12000000 10100000 4100000 0.40 P12M 300000 1400000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,057 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,327 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,967 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,480 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3512000 3777000 11322000 12297000 455000 450000 1355000 1349000 3057000 3327000 9967000 10948000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition gains (costs), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,009)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 478000 174000 1419000 850000 0 0 1677000 0 -2687000 13000 4917000 79000 -43000 -582000 1657000 -2780000 3122000 -421000 -164000 -2009000 -4000000 10928000 9739000 586000 17480000 Intangible assets and goodwill<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(283,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820,946 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended October 31, 2021 and 2020 was $30.0 million and $25.3 million, respectively, and $87.5 million and $73.5 million for the nine months ended October 31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fifth Third Bank HSA portfolio acquisition. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition the custody of Fifth Third’s HSA portfolio to HealthEquity. On September 29, 2021, the transaction was closed, in which the Company paid a $60.8 million purchase price for a transfer of approximately 160,000 HSAs and $491.0 million of HSA Assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended October 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the nine months ended October 31, 2021.</span></div> 177693000 127005000 191885000 125141000 613781000 601381000 107825000 96925000 12900000 12300000 1104084000 962752000 283138000 195749000 820946000 767003000 30000000 25300000 87500000 73500000 60800000 160000000000 491000000 36400000 Commitments and contingencies<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the payments due by fiscal year for our outstanding contractual obligations as of October 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Senior Notes due 2029 (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on long-term debt obligations (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease obligations (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Further acquisition (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent acquisition consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other contractual obligations (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525,136 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,758 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,209 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,425 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,311 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,302 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,842,141 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">As of October 31, 2021, our outstanding combined principal of $950.0 million is presented net of debt discount and issuance costs on our condensed consolidated balance sheets. The debt discount and issuance costs are not included in the table above.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">With respect to the Term Loan Facility, estimated interest payments assume the stated interest rate applicable as of October 31, 2021 of 1.88% per annum.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">We lease office space and data storage facilities, and we have other non-cancelable operating leases expiring at various dates through 2031. These amounts exclude contractual sublease income of $2.7 million, which is expected to be received through March 2023.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">For a description of the Further acquisition, refer to Note 11—Subsequent events.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">Other contractual obligations consist of processing services agreements, telephony services, and other contractual commitments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, WageWorks exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the nine months ended October 31, 2021, WageWorks contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021. This matter is now closed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. On October 28, 2021, the court of appeal dismissed the appeal pursuant to the release in the class action settlement discussed above. The District Court action is currently stayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a </span></div>material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods. <div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the payments due by fiscal year for our outstanding contractual obligations as of October 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Senior Notes due 2029 (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on long-term debt obligations (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease obligations (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Further acquisition (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent acquisition consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other contractual obligations (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525,136 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,758 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,209 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,425 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,311 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,302 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,842,141 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">As of October 31, 2021, our outstanding combined principal of $950.0 million is presented net of debt discount and issuance costs on our condensed consolidated balance sheets. The debt discount and issuance costs are not included in the table above.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">With respect to the Term Loan Facility, estimated interest payments assume the stated interest rate applicable as of October 31, 2021 of 1.88% per annum.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">We lease office space and data storage facilities, and we have other non-cancelable operating leases expiring at various dates through 2031. These amounts exclude contractual sublease income of $2.7 million, which is expected to be received through March 2023.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.74pt">For a description of the Further acquisition, refer to Note 11—Subsequent events.</span></div>(5)Other contractual obligations consist of processing services agreements, telephony services, and other contractual commitments. 0.0450 0 0 0 0 0 600000000 600000000 0 8750000 17500000 17500000 26250000 280000000 350000000 8577000 33951000 33708000 33467000 32965000 103739000 246407000 3416000 12689000 10442000 10836000 11080000 52563000 101026000 500000000 0 0 0 0 0 500000000 6000000 0 0 0 0 0 6000000 7143000 21368000 9559000 622000 16000 0 38708000 525136000 76758000 71209000 62425000 70311000 1036302000 1842141000 950000000 0.0188 2700000 63100000 P11Y 2800000 30000000 5000000 25000000 2 2 Income taxes<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 740-270, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes - Interim Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and nine months ended October 31, 2021, the Company recorded an income tax benefit of $4.1 million and $11.5 million, respectively. This resulted in an effective income tax benefit rate of 44.8% and 50.1% for the three and nine months ended October 31, 2021, respectively, compared with an effective income tax expense rate of 56.7% and 36.8% for the three and nine months ended October 31, 2020, respectively. For the three and nine months ended October 31, 2021, discrete tax items had an effective tax rate benefit of 7.7% and 20.5%, respectively, compared with an effective tax rate expense of 6.0% and an effective tax rate benefit of 9.6% for the three and nine months ended October 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $11.2 million and $10.2 million, respectively. If recognized, $10.3 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of October 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.</span></div> -4100000 -11500000 -0.448 -0.501 0.567 0.368 -0.077 -0.205 0.060 -0.096 11200000 10200000 10300000 Indebtedness<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Senior Notes due 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior Term Loan Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized discount and issuance costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930,064 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,717 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,563</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923,501 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">924,217 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In addition to the $19.9 million and $16.4 million of unamortized discount and issuance costs related to long-term debt as of October 31, 2021 and January 31, 2021, respectively, $4.6 million and $5.0 million of unamortized issuance costs related to our Revolving Credit Facility (as defined below) and Prior Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of October 31, 2021 and January 31, 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.50% Senior Notes due 2029</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from the issuance of the Notes together with borrowings under the Credit Agreement (as defined below) and cash on hand, were used to repay the outstanding borrowings under the Prior Credit Agreement (as defined below).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are guaranteed by each of the Company’s existing direct and indirect, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes will be payable on April 1 and October 1 of each year, beginning on April 1, 2022. The effective interest rate on the Notes is 4.72%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company entered into a new credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350.0 million, the proceeds of which were used to refinance the Company’s existing senior secured credit facility as described below (the “Refinancing”), to pay fees and expenses incurred in connection with the Refinancing and the establishment of the Credit Facilities (as defined below) and for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)     a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of October 31, 2021, the stated interest rate was 1.88% and the effective interest rate was 2.63%. The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans made under the Term Loan Facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.”</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022, and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022. The Company was in compliance with all covenants under the Credit Agreement as of October 31, 2021, and for the period then ended.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2019, the Company entered into a credit agreement (the "Prior Credit Agreement”) that provided for:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)       a five-year senior secured term loan A facility (the “Prior Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)      a five-year senior secured revolving credit facility (the “Prior Revolving Credit Facility” and, together with the Prior Term Loan Facility, the “Prior Credit Facilities”), in an aggregate principal amount of up to $350.0 million. No amounts were drawn under the Prior Revolving Credit Facility. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Prior Credit Facilities bore interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement. The Company was also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Prior Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Credit Agreement contained customary affirmative and negative covenants, including covenants that limited, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Prior Credit Agreement contained financial performance covenants, which required the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Prior Credit Agreement during the period ended October 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of HealthEquity under the Prior Credit Agreement were required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and were secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.</span></div>On October 8, 2021, in connection with the entry into the Credit Agreement, the Company repaid all outstanding obligations under the Prior Credit Agreement and terminated all commitments thereunder. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Senior Notes due 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior Term Loan Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized discount and issuance costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930,064 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,717 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,563</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923,501 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">924,217 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)In addition to the $19.9 million and $16.4 million of unamortized discount and issuance costs related to long-term debt as of October 31, 2021 and January 31, 2021, respectively, $4.6 million and $5.0 million of unamortized issuance costs related to our Revolving Credit Facility (as defined below) and Prior Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of October 31, 2021 and January 31, 2021, respectively. 0.0450 600000000 0 350000000 0 0 1003125000 950000000 1003125000 19936000 16408000 930064000 986717000 6563000 62500000 923501000 924217000 19900000 16400000 4600000 5000000 0.0450 600000000 0.0450 0.0472 1.02250 1.01125 1.00000 1 0.40 1.04500 P5Y 350000000 P5Y 1000000000 25000000 300000000 3.85 0.0125 0.0225 0.0025 0.0125 0.0188 0.0263 0.0020 0.0040 0.025 0.050 0.075 0.100 1 P450D P450D P180D P450D 5.00 3.00 P5Y 1250000000 P5Y 350000000 0 0.0125 0.0225 0.0025 0.0125 0.0020 0.0040 4.50 5.00 100000000 3.00 Stock-based compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,284 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,479 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,042 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,313 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Equity-based awards exchanged for cash in connection with the Luum Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock award plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Plan. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of October 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of October 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.76 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,863 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted stock units and restricted stock awards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and RSA activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs and PRSAs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,540 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.62 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.72 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance restricted stock units.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.</span> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended October 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,284 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,479 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,042 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,313 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Equity-based awards exchanged for cash in connection with the Luum Acquisition.</span></div> 3076000 2209000 8547000 5737000 829000 2035000 5677000 4810000 3458000 2641000 10164000 8051000 5921000 4594000 17312000 11715000 0 0 342000 0 13284000 11479000 42042000 30313000 2600000 0.03 7500000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of October 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.76 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,863 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1674000 1.25 82.39 31.46 P5Y 87164000 280000 1.25 44.53 22.36 1394000 1.25 82.39 33.29 P4Y2M12D 47032000 1394000 33.29 P4Y2M12D 47032000 1303000 30.76 P4Y 46863000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and RSA activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs and PRSAs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,540 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.62 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.72 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1832000 60.41 193000 61.77 1381000 71.61 0 0 418000 58.09 116000 61.77 255000 62.99 75000 61.77 2540000 66.62 2000 61.72 249750 22400000 0 2 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of October 31, 2021, the fair value of the Notes was $605.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Term Loan Facility was considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Prior Term Loan Facility repriced frequently due to variable interest rate terms and entailed no significant changes in credit risk. As a result, the fair value of the Prior Term Loan Facility approximated carrying value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation required subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement was based on inputs unobservable in the market and thus represented a level 3 measurement. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, and accordingly, the liability was transferred out of Level 3 as it was no longer measured at fair value. For further information, see Note 3—Business combination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the period presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of January 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of October 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div> 605200000 6000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the period presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of January 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of October 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 8147000 -2147000 6000000 Subsequent events<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an amended agreement to acquire Further (other than VEBA, as described below) for $455 million, which closed on November 1, 2021, and (2) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto, subject to satisfaction of certain customary closing conditions, for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021. On December 3, 2021, the parties agreed to terminate the agreement to acquire the Further VEBA business. The initial accounting for the acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2021, HealthEquity entered into a definitive agreement with Health Savings Administrators, L.L.C. (“HealthSavings”) to transition the custody of HealthSavings’ HSA portfolio to HealthEquity. The definitive agreement provides a $60 million purchase price for approximately $1.3 billion of HSA assets held in approximately 87,000 HSAs. Given that a significant portion of the HSA assets are currently invested, HealthSavings and HealthEquity are working closely to coordinate an in-kind transfer of most of the invested assets. The transition of HealthSavings’ HSAs to the HealthEquity platform is expected to be completed in the first quarter of fiscal 2023.</span></div> 500000000 580000000000 1900000000 455000000 45000000 60000000 1300000000 87000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
9 Months Ended
Oct. 31, 2021
Nov. 30, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Oct. 31, 2021  
Document Transition Report false  
Entity File Number 001-36568  
Entity Registrant Name HEALTHEQUITY, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-2383166  
Entity Address, Address Line One 15 West Scenic Pointe Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Draper,  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84020  
City Area Code 801  
Local Phone Number 727-1000  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol HQY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   83,601,381
Entity Central Index Key 0001428336  
Current Fiscal Year End Date --01-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Oct. 31, 2021
Jan. 31, 2021
Current assets    
Cash and cash equivalents $ 649,129 $ 328,803
Accounts receivable, net of allowance for doubtful accounts of $6,063 and $4,239 as of October 31, 2021 and January 31, 2021, respectively 84,083 72,767
Other current assets 30,919 58,607
Total current assets 764,131 460,177
Property and equipment, net 24,930 29,106
Operating lease right-of-use assets 81,150 89,508
Intangible assets, net 820,946 767,003
Goodwill 1,363,549 1,327,193
Other assets 44,908 37,420
Total assets 3,099,614 2,710,407
Current liabilities    
Accounts payable 5,244 1,614
Accrued compensation 32,695 50,670
Accrued liabilities 49,879 75,880
Current portion of long-term debt 6,563 62,500
Operating lease liabilities 12,693 14,037
Total current liabilities 107,074 204,701
Long-term liabilities    
Long-term debt, net 923,501 924,217
Operating lease liabilities, non-current 67,836 74,224
Other long-term liabilities 18,953 8,808
Deferred tax liability 110,400 119,729
Total long-term liabilities 1,120,690 1,126,978
Total liabilities 1,227,764 1,331,679
Commitments and contingencies (see Note 6)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 83,586 and 77,168 shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively 8 8
Additional paid-in capital 1,662,965 1,158,372
Accumulated earnings 208,877 220,348
Total stockholders’ equity 1,871,850 1,378,728
Total liabilities and stockholders’ equity $ 3,099,614 $ 2,710,407
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Oct. 31, 2021
Jan. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 6,063 $ 4,239
Preferred stock, par value (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 900,000,000 900,000,000
Common stock, issued (in shares) 83,586,000 77,168,000
Common stock, outstanding (in shares) 83,586,000 77,168,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Revenues [Abstract]        
Revenue $ 179,954 $ 179,351 $ 553,259 $ 545,401
Cost of revenue        
Cost of revenue 76,634 74,793 234,852 230,985
Gross profit 103,320 104,558 318,407 314,416
Operating expenses        
Sales and marketing 12,726 12,880 42,288 36,502
Technology and development 38,070 30,758 111,437 92,490
General and administrative 20,004 22,099 63,503 61,590
Amortization of acquired intangible assets 19,642 19,126 59,745 56,905
Merger integration 13,244 8,193 38,422 31,328
Total operating expenses 103,686 93,056 315,395 278,815
Income (loss) from operations (366) 11,502 3,012 35,601
Other expense        
Interest expense (11,881) (6,952) (25,824) (28,110)
Other income (expense), net 3,122 (421) (164) (2,009)
Total other expense (8,759) (7,373) (25,988) (30,119)
Income (loss) before income taxes (9,125) 4,129 (22,976) 5,482
Income tax provision (benefit) (4,087) 2,340 (11,505) 2,015
Net income (loss) (5,038) 1,789 (11,471) 3,467
Comprehensive income (loss) $ (5,038) $ 1,789 $ (11,471) $ 3,467
Net income (loss) per share:        
Basic (in usd per share) $ (0.06) $ 0.02 $ (0.14) $ 0.05
Diluted (in usd per share) $ (0.06) $ 0.02 $ (0.14) $ 0.05
Weighted-average number of shares used in computing net income (loss) per share:        
Basic (in shares) 83,551 76,701 82,939 73,358
Diluted (in shares) 83,551 77,845 82,939 74,665
Service revenue        
Revenues [Abstract]        
Revenue $ 102,733 $ 104,562 $ 314,449 $ 319,638
Cost of revenue        
Cost of revenue 66,217 65,936 204,183 202,195
Custodial revenue        
Revenues [Abstract]        
Revenue 49,006 48,544 144,760 142,352
Cost of revenue        
Cost of revenue 5,734 4,762 15,567 14,805
Interchange revenue        
Revenues [Abstract]        
Revenue 28,215 26,245 94,050 83,411
Cost of revenue        
Cost of revenue $ 4,683 $ 4,095 $ 15,102 $ 13,985
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
$ in Thousands
Total
Common stock:
Additional paid-in capital:
Accumulated earnings
Beginning balance at Jan. 31, 2020 $ 1,030,295 $ 7 $ 818,774 $ 211,514
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     4,402  
Other issuance of common stock   1 286,779  
Stock-based compensation     30,313  
Net income (loss) 3,467     3,467
Ending balance at Oct. 31, 2020 1,355,257 8 1,140,268 214,981
Beginning balance at Jul. 31, 2020 1,340,336 8 1,127,136 213,192
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     1,651  
Other issuance of common stock     2  
Stock-based compensation     11,479  
Net income (loss) 1,789     1,789
Ending balance at Oct. 31, 2020 1,355,257 8 1,140,268 214,981
Beginning balance at Jan. 31, 2021 1,378,728 8 1,158,372 220,348
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     6,253  
Other issuance of common stock     456,640  
Stock-based compensation     41,700  
Net income (loss) (11,471)     (11,471)
Ending balance at Oct. 31, 2021 1,871,850 8 1,662,965 208,877
Beginning balance at Jul. 31, 2021 1,862,666 8 1,648,743 213,915
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     938  
Stock-based compensation     13,284  
Net income (loss) (5,038)     (5,038)
Ending balance at Oct. 31, 2021 $ 1,871,850 $ 8 $ 1,662,965 $ 208,877
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of cash flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Cash flows from operating activities:    
Net income (loss) $ (11,471) $ 3,467
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 98,364 85,485
Stock-based compensation 41,700 30,313
Amortization of debt discount and issuance costs 3,616 3,818
Loss on extinguishment of debt 4,044 0
Change in fair value of contingent consideration (2,147) 0
Other non-cash items (750) 1,727
Deferred taxes (8,765) (973)
Changes in operating assets and liabilities:    
Accounts receivable, net (10,090) 8,063
Other assets 19,888 3,309
Operating lease right-of-use assets 8,944 8,344
Accrued compensation (18,098) (15,251)
Accounts payable, accrued liabilities, and other current liabilities (34,023) (7,936)
Operating lease liabilities, non-current (6,808) (8,361)
Other long-term liabilities 6,034 8,712
Net cash provided by operating activities 90,438 120,717
Cash flows from investing activities:    
Acquisitions, net of cash acquired (49,533) 0
Purchases of software and capitalized software development costs (49,033) (37,242)
Purchases of property and equipment (7,284) (11,388)
Acquisition of intangible member assets (64,463) (28,100)
Proceeds from sale of equity securities 2,367 0
Net cash used in investing activities (167,946) (76,730)
Cash flows from financing activities:    
Principal payments on long-term debt (1,003,125) (223,438)
Proceeds from issuance of long-term debt 950,000 0
Payment of debt issuance costs (11,846) 0
Proceeds from follow-on equity offering, net of payments for offering costs 456,642 286,779
Settlement of client-held funds obligation, net (1,565) (4,189)
Proceeds from exercise of common stock options 7,728 4,491
Net cash provided by financing activities 397,834 63,643
Increase in cash and cash equivalents 320,326 107,630
Beginning cash and cash equivalents 328,803 191,726
Ending cash and cash equivalents 649,129 299,356
Supplemental cash flow data:    
Interest expense paid in cash 13,685 22,849
Income tax payments (refunds), net (5,926) 1,053
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable or accrued liabilities 479 167
Contingent consideration recognized at acquisition 8,147 0
Exercise of common stock options receivable 1 89
Decrease in goodwill due to measurement period adjustments, net 19 5,838
Computer software intangible asset    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation 3,708 1,346
Acquired HSA portfolios    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation $ 2,281 $ 289
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies
9 Months Ended
Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of October 31, 2021 and for the three and nine months ended October 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Follow-on equity offering
In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and used an additional $60.8 million to acquire the Fifth Third Bank HSA portfolio. The Company used the remaining net proceeds from the offering, and other cash on hand, for the acquisition of Further on November 1, 2021. For a description of the Further acquisition, refer to Note 11—Subsequent events.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share
9 Months Ended
Oct. 31, 2021
Earnings Per Share [Abstract]  
Net income (loss) per share Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended October 31,Nine months ended October 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(5,038)$1,789 $(11,471)$3,467 
Denominator (basic):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Denominator (diluted):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Weighted-average dilutive effect of stock options and restricted stock units— 1,144 — 1,307 
Diluted weighted-average common shares outstanding83,551 77,845 82,939 74,665 
Net income (loss) per share:
Basic $(0.06)$0.02 $(0.14)$0.05 
Diluted$(0.06)$0.02 $(0.14)$0.05 
For the three months ended October 31, 2021 and 2020, 1.6 million and 1.0 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the nine months ended October 31, 2021 and 2020, approximately 1.9 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination
9 Months Ended
Oct. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Business combination Business combination
Acquisition of Luum
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which were contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). During the three and nine months ended October 31, 2021, the Company recognized income of $3.2 million and $2.1 million, respectively, resulting from changes in the fair value of the contingent consideration. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, which is presented within accrued liabilities on the Company's condensed consolidated balance sheet as of October 31, 2021.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $— $58,306 
The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.

The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information
9 Months Ended
Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Leasehold improvements$20,718 $22,271 
Furniture and fixtures9,068 9,230 
Computer equipment34,099 28,592 
Property and equipment, gross63,885 60,093 
Accumulated depreciation(38,955)(30,987)
Property and equipment, net$24,930 $29,106 
Depreciation expense for the three months ended October 31, 2021 and 2020 was $3.5 million and $4.0 million, respectively, and $10.9 million and $12.0 million for the nine months ended October 31, 2021 and 2020, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of
October 31, 2021 and January 31, 2021, the balance of deferred revenue was $10.1 million and $4.1 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 40% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and nine months ended October 31, 2021, approximately $0.3 million and $1.4 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.
Leases
The components of operating lease costs were as follows:
Three months ended October 31,Nine months ended October 31,
(in thousands)
2021202020212020
Operating lease expense$3,512 $3,777 $11,322 $12,297 
Sublease income(455)(450)(1,355)(1,349)
Net operating lease expense$3,057 $3,327 $9,967 $10,948 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Interest income$478 $174 $1,419 $850 
Gain on equity securities— — 1,677 — 
Acquisition gains (costs), net2,687 (13)(4,917)(79)
Other income (expense), net(43)(582)1,657 (2,780)
Total other income (expense), net$3,122 $(421)$(164)$(2,009)
Interest expense
Based on the application of Accounting Standards Codification ("ASC") 470-50, Debt - Modifications and Extinguishments, the Company recorded a $4.0 million loss on extinguishment of debt during the three months ended October 31, 2021, which is included within interest expense in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended October 31, 2021.
Supplemental cash flow information
Supplemental cash flow information related to the Company's operating leases was as follows:
Nine months ended October 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,928 $9,739 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$586 $17,480 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill
9 Months Ended
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$177,693 $127,005 
Acquired HSA portfolios191,885 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,104,084 962,752 
Accumulated amortization(283,138)(195,749)
Amortizable intangible assets, net$820,946 $767,003 
Amortization expense for the three months ended October 31, 2021 and 2020 was $30.0 million and $25.3 million, respectively, and $87.5 million and $73.5 million for the nine months ended October 31, 2021 and 2020, respectively.
Fifth Third Bank HSA portfolio acquisition. In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition the custody of Fifth Third’s HSA portfolio to HealthEquity. On September 29, 2021, the transaction was closed, in which the Company paid a $60.8 million purchase price for a transfer of approximately 160,000 HSAs and $491.0 million of HSA Assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred.
Goodwill
During the nine months ended October 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the nine months ended October 31, 2021.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies
9 Months Ended
Oct. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Commitments
The following table summarizes the payments due by fiscal year for our outstanding contractual obligations as of October 31, 2021:
Payments due by fiscal year
(in thousands)20222023202420252026ThereafterTotal
4.50% Senior Notes due 2029 (1)
$— $— $— $— $— $600,000 $600,000 
Term Loan Facility (1)— 8,750 17,500 17,500 26,250 280,000 350,000 
Interest on long-term debt obligations (2)8,577 33,951 33,708 33,467 32,965 103,739 246,407 
Operating lease obligations (3)3,416 12,689 10,442 10,836 11,080 52,563 101,026 
Further acquisition (4)500,000 — — — — — 500,000 
Contingent acquisition consideration6,000 — — — — — 6,000 
Other contractual obligations (5)7,143 21,368 9,559 622 16 — 38,708 
Total$525,136 $76,758 $71,209 $62,425 $70,311 $1,036,302 $1,842,141 
(1)As of October 31, 2021, our outstanding combined principal of $950.0 million is presented net of debt discount and issuance costs on our condensed consolidated balance sheets. The debt discount and issuance costs are not included in the table above.
(2)With respect to the Term Loan Facility, estimated interest payments assume the stated interest rate applicable as of October 31, 2021 of 1.88% per annum.
(3)We lease office space and data storage facilities, and we have other non-cancelable operating leases expiring at various dates through 2031. These amounts exclude contractual sublease income of $2.7 million, which is expected to be received through March 2023.
(4)For a description of the Further acquisition, refer to Note 11—Subsequent events.
(5)Other contractual obligations consist of processing services agreements, telephony services, and other contractual commitments.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit.
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the nine months ended October 31, 2021, WageWorks contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021. This matter is now closed.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. On October 28, 2021, the court of appeal dismissed the appeal pursuant to the release in the class action settlement discussed above. The District Court action is currently stayed.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a
material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Income taxes
9 Months Ended
Oct. 31, 2021
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company follows ASC 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and nine months ended October 31, 2021, the Company recorded an income tax benefit of $4.1 million and $11.5 million, respectively. This resulted in an effective income tax benefit rate of 44.8% and 50.1% for the three and nine months ended October 31, 2021, respectively, compared with an effective income tax expense rate of 56.7% and 36.8% for the three and nine months ended October 31, 2020, respectively. For the three and nine months ended October 31, 2021, discrete tax items had an effective tax rate benefit of 7.7% and 20.5%, respectively, compared with an effective tax rate expense of 6.0% and an effective tax rate benefit of 9.6% for the three and nine months ended October 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
As of October 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $11.2 million and $10.2 million, respectively. If recognized, $10.3 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of October 31, 2021.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness
9 Months Ended
Oct. 31, 2021
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
Long-term debt consisted of the following:
(in thousands)October 31, 2021January 31, 2021
4.50% Senior Notes due 2029
$600,000 $— 
Term Loan Facility350,000 — 
Prior Term Loan Facility— 1,003,125 
Principal amount950,000 1,003,125 
Less: unamortized discount and issuance costs (1)19,936 16,408 
Total debt, net930,064 986,717 
Less: current portion of long-term debt6,56362,500
Long-term debt, net$923,501 $924,217 
(1)In addition to the $19.9 million and $16.4 million of unamortized discount and issuance costs related to long-term debt as of October 31, 2021 and January 31, 2021, respectively, $4.6 million and $5.0 million of unamortized issuance costs related to our Revolving Credit Facility (as defined below) and Prior Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of October 31, 2021 and January 31, 2021, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The net proceeds from the issuance of the Notes together with borrowings under the Credit Agreement (as defined below) and cash on hand, were used to repay the outstanding borrowings under the Prior Credit Agreement (as defined below).
The Notes are guaranteed by each of the Company’s existing direct and indirect, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes will be payable on April 1 and October 1 of each year, beginning on April 1, 2022. The effective interest rate on the Notes is 4.72%.
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a new credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350.0 million, the proceeds of which were used to refinance the Company’s existing senior secured credit facility as described below (the “Refinancing”), to pay fees and expenses incurred in connection with the Refinancing and the establishment of the Credit Facilities (as defined below) and for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments; and
(ii)     a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of October 31, 2021, the stated interest rate was 1.88% and the effective interest rate was 2.63%. The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the Term Loan Facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the
end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.”
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022, and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00 beginning with the fiscal quarter ending January 31, 2022. The Company was in compliance with all covenants under the Credit Agreement as of October 31, 2021, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
Prior Credit Agreement
On August 30, 2019, the Company entered into a credit agreement (the "Prior Credit Agreement”) that provided for:
(i)       a five-year senior secured term loan A facility (the “Prior Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and
(ii)      a five-year senior secured revolving credit facility (the “Prior Revolving Credit Facility” and, together with the Prior Term Loan Facility, the “Prior Credit Facilities”), in an aggregate principal amount of up to $350.0 million. No amounts were drawn under the Prior Revolving Credit Facility.
Borrowings under the Prior Credit Facilities bore interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement. The Company was also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Prior Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Prior Credit Agreement.
The Prior Credit Agreement contained customary affirmative and negative covenants, including covenants that limited, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Prior Credit Agreement contained financial performance covenants, which required the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Prior Credit Agreement during the period ended October 31, 2021.
The obligations of HealthEquity under the Prior Credit Agreement were required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and were secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.
On October 8, 2021, in connection with the entry into the Credit Agreement, the Company repaid all outstanding obligations under the Prior Credit Agreement and terminated all commitments thereunder.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation
9 Months Ended
Oct. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Cost of revenue$3,076 $2,209 $8,547 $5,737 
Sales and marketing829 2,035 5,677 4,810 
Technology and development3,458 2,641 10,164 8,051 
General and administrative5,921 4,594 17,312 11,715 
Other expense (1)— — 342 — 
Total stock-based compensation expense$13,284 $11,479 $42,042 $30,313 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of October 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.0$87,164 
Exercised(280)
$1.25 - 44.53
$22.36 
Outstanding as of October 31, 20211,394 
$1.25 - 82.39
$33.29 4.2$47,032 
Vested and expected to vest as of October 31, 20211,394 $33.29 4.2$47,032 
Exercisable as of October 31, 20211,303 $30.76 4.0$46,863 
Restricted stock units and restricted stock awards
A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,381 71.61 — — 
Vested(418)58.09 (116)61.77 
Forfeited(255)62.99 (75)61.77 
Outstanding as of October 31, 20212,540 $66.62 $61.72 
Performance restricted stock units. During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value
9 Months Ended
Oct. 31, 2021
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of October 31, 2021, the fair value of the Notes was $605.2 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.
The Prior Term Loan Facility was considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Prior Term Loan Facility repriced frequently due to variable interest rate terms and entailed no significant changes in credit risk. As a result, the fair value of the Prior Term Loan Facility approximated carrying value.
The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation required subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement was based on inputs unobservable in the market and thus represented a level 3 measurement. On October 31, 2021, the Company entered into an amendment to the purchase agreement to pay $6.0 million in satisfaction of the contingent consideration liability, and accordingly, the liability was transferred out of Level 3 as it was no longer measured at fair value. For further information, see Note 3—Business combination.
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying amount
Balance as of January 31, 2021$— 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)(2,147)
Balance as of October 31, 2021$6,000 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent events
9 Months Ended
Oct. 31, 2021
Subsequent Events [Abstract]  
Subsequent events Subsequent events
In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an amended agreement to acquire Further (other than VEBA, as described below) for $455 million, which closed on November 1, 2021, and (2) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto, subject to satisfaction of certain customary closing conditions, for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021. On December 3, 2021, the parties agreed to terminate the agreement to acquire the Further VEBA business. The initial accounting for the acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.
On December 6, 2021, HealthEquity entered into a definitive agreement with Health Savings Administrators, L.L.C. (“HealthSavings”) to transition the custody of HealthSavings’ HSA portfolio to HealthEquity. The definitive agreement provides a $60 million purchase price for approximately $1.3 billion of HSA assets held in approximately 87,000 HSAs. Given that a significant portion of the HSA assets are currently invested, HealthSavings and HealthEquity are working closely to coordinate an in-kind transfer of most of the invested assets. The transition of HealthSavings’ HSAs to the HealthEquity platform is expected to be completed in the first quarter of fiscal 2023.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies (Policies)
9 Months Ended
Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation The accompanying condensed consolidated financial statements as of October 31, 2021 and for the three and nine months ended October 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share (Tables)
9 Months Ended
Oct. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings (Loss) Per Share, Basic and Diluted The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended October 31,Nine months ended October 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(5,038)$1,789 $(11,471)$3,467 
Denominator (basic):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Denominator (diluted):
Weighted-average common shares outstanding83,551 76,701 82,939 73,358 
Weighted-average dilutive effect of stock options and restricted stock units— 1,144 — 1,307 
Diluted weighted-average common shares outstanding83,551 77,845 82,939 74,665 
Net income (loss) per share:
Basic $(0.06)$0.02 $(0.14)$0.05 
Diluted$(0.06)$0.02 $(0.14)$0.05 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Tables)
9 Months Ended
Oct. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Preliminary Allocation of Consideration The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $— $58,306 
Schedule of Acquired Identified Intangible Assets
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$177,693 $127,005 
Acquired HSA portfolios191,885 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,104,084 962,752 
Accumulated amortization(283,138)(195,749)
Amortizable intangible assets, net$820,946 $767,003 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Tables)
9 Months Ended
Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and Equipment Property and equipment consisted of the following as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Leasehold improvements$20,718 $22,271 
Furniture and fixtures9,068 9,230 
Computer equipment34,099 28,592 
Property and equipment, gross63,885 60,093 
Accumulated depreciation(38,955)(30,987)
Property and equipment, net$24,930 $29,106 
Lease Cost The components of operating lease costs were as follows:
Three months ended October 31,Nine months ended October 31,
(in thousands)
2021202020212020
Operating lease expense$3,512 $3,777 $11,322 $12,297 
Sublease income(455)(450)(1,355)(1,349)
Net operating lease expense$3,057 $3,327 $9,967 $10,948 
Supplemental cash flow information related to the Company's operating leases was as follows:
Nine months ended October 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,928 $9,739 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$586 $17,480 
Other Income (Expense), Net Other income (expense), net, consisted of the following:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Interest income$478 $174 $1,419 $850 
Gain on equity securities— — 1,677 — 
Acquisition gains (costs), net2,687 (13)(4,917)(79)
Other income (expense), net(43)(582)1,657 (2,780)
Total other income (expense), net$3,122 $(421)$(164)$(2,009)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Tables)
9 Months Ended
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-lived Intangible Assets
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2021 and January 31, 2021:
(in thousands)October 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$177,693 $127,005 
Acquired HSA portfolios191,885 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,104,084 962,752 
Accumulated amortization(283,138)(195,749)
Amortizable intangible assets, net$820,946 $767,003 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies (Tables)
9 Months Ended
Oct. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of payments due by fiscal year for our outstanding contractual obligations
The following table summarizes the payments due by fiscal year for our outstanding contractual obligations as of October 31, 2021:
Payments due by fiscal year
(in thousands)20222023202420252026ThereafterTotal
4.50% Senior Notes due 2029 (1)
$— $— $— $— $— $600,000 $600,000 
Term Loan Facility (1)— 8,750 17,500 17,500 26,250 280,000 350,000 
Interest on long-term debt obligations (2)8,577 33,951 33,708 33,467 32,965 103,739 246,407 
Operating lease obligations (3)3,416 12,689 10,442 10,836 11,080 52,563 101,026 
Further acquisition (4)500,000 — — — — — 500,000 
Contingent acquisition consideration6,000 — — — — — 6,000 
Other contractual obligations (5)7,143 21,368 9,559 622 16 — 38,708 
Total$525,136 $76,758 $71,209 $62,425 $70,311 $1,036,302 $1,842,141 
(1)As of October 31, 2021, our outstanding combined principal of $950.0 million is presented net of debt discount and issuance costs on our condensed consolidated balance sheets. The debt discount and issuance costs are not included in the table above.
(2)With respect to the Term Loan Facility, estimated interest payments assume the stated interest rate applicable as of October 31, 2021 of 1.88% per annum.
(3)We lease office space and data storage facilities, and we have other non-cancelable operating leases expiring at various dates through 2031. These amounts exclude contractual sublease income of $2.7 million, which is expected to be received through March 2023.
(4)For a description of the Further acquisition, refer to Note 11—Subsequent events.
(5)Other contractual obligations consist of processing services agreements, telephony services, and other contractual commitments.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Tables)
9 Months Ended
Oct. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Long-term debt consisted of the following:
(in thousands)October 31, 2021January 31, 2021
4.50% Senior Notes due 2029
$600,000 $— 
Term Loan Facility350,000 — 
Prior Term Loan Facility— 1,003,125 
Principal amount950,000 1,003,125 
Less: unamortized discount and issuance costs (1)19,936 16,408 
Total debt, net930,064 986,717 
Less: current portion of long-term debt6,56362,500
Long-term debt, net$923,501 $924,217 
(1)In addition to the $19.9 million and $16.4 million of unamortized discount and issuance costs related to long-term debt as of October 31, 2021 and January 31, 2021, respectively, $4.6 million and $5.0 million of unamortized issuance costs related to our Revolving Credit Facility (as defined below) and Prior Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of October 31, 2021 and January 31, 2021, respectively.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Tables)
9 Months Ended
Oct. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of Share Based Compensation Recognized
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended October 31,Nine months ended October 31,
(in thousands)2021202020212020
Cost of revenue$3,076 $2,209 $8,547 $5,737 
Sales and marketing829 2,035 5,677 4,810 
Technology and development3,458 2,641 10,164 8,051 
General and administrative5,921 4,594 17,312 11,715 
Other expense (1)— — 342 — 
Total stock-based compensation expense$13,284 $11,479 $42,042 $30,313 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Summary of Stock Option Activity A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.0$87,164 
Exercised(280)
$1.25 - 44.53
$22.36 
Outstanding as of October 31, 20211,394 
$1.25 - 82.39
$33.29 4.2$47,032 
Vested and expected to vest as of October 31, 20211,394 $33.29 4.2$47,032 
Exercisable as of October 31, 20211,303 $30.76 4.0$46,863 
Summary of Restricted Stock Unit Activity A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,381 71.61 — — 
Vested(418)58.09 (116)61.77 
Forfeited(255)62.99 (75)61.77 
Outstanding as of October 31, 20212,540 $66.62 $61.72 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value (Tables)
9 Months Ended
Oct. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Change in the Fair Value of the Contingent Consideration
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying amount
Balance as of January 31, 2021$— 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)(2,147)
Balance as of October 31, 2021$6,000 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
1 Months Ended 3 Months Ended
Mar. 08, 2021
Sep. 29, 2021
Apr. 30, 2021
Fifth Third Bank HSA Portfolio Acquisition      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Purchase price for HSA portfolio   $ 60.8  
Luum Acquisition      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Purchase price for acquisition $ 50.2    
Ownership interest (as a percent) 100.00%    
Follow on equity offering      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Common stock, shares (in shares)     5,750
Offering price per share (in usd per share)     $ 80.30
Net proceeds from follow on offering     $ 456.6
Underwriting discounts and commissions     4.6
Other offering expenses payable     $ 0.5
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Numerator (basic and diluted):        
Net income (loss) $ (5,038) $ 1,789 $ (11,471) $ 3,467
Denominator (basic):        
Weighted-average common shares outstanding (in shares) 83,551 76,701 82,939 73,358
Denominator (diluted):        
Weighted-average common shares outstanding (in shares) 83,551 76,701 82,939 73,358
Weighted-average dilutive effect of stock options and restricted stock units (in shares) 0 1,144 0 1,307
Diluted weighted-average common shares outstanding (in shares) 83,551 77,845 82,939 74,665
Net income (loss) per share:        
Basic (in usd per share) $ (0.06) $ 0.02 $ (0.14) $ 0.05
Diluted (in usd per share) $ (0.06) $ 0.02 $ (0.14) $ 0.05
Antidilutive securities excluded from computation of earnings per share (in shares) 1,600 1,000 1,900 600
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 08, 2021
Oct. 31, 2021
Oct. 31, 2021
Jan. 31, 2021
Business Acquisition [Line Items]        
Goodwill   $ 1,363,549 $ 1,363,549 $ 1,327,193
Luum Acquisition        
Business Acquisition [Line Items]        
Ownership interest (as a percent) 100.00%      
Purchase price for acquisition $ 50,200      
Maximum amount of contingent consideration payable $ 20,000      
Contingent consideration, performance period 2 years      
Contingent consideration liability $ 8,100 6,000 6,000  
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)   3,200 2,100  
Goodwill $ 36,374 $ 36,355 $ 36,355  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Preliminary Allocation of Consideration) (Details) - USD ($)
$ in Thousands
8 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2021
Oct. 31, 2020
Mar. 08, 2021
Jan. 31, 2021
Business Acquisition [Line Items]          
Goodwill $ 1,363,549 $ 1,363,549     $ 1,327,193
Goodwill, adjustments   19 $ 5,838    
Luum Acquisition          
Business Acquisition [Line Items]          
Cash and cash equivalents 626 626   $ 626  
Other current assets 1,469 1,469   1,469  
Intangible assets 23,900 23,900   23,900  
Goodwill 36,355 36,355   36,374  
Goodwill, adjustments (19)        
Other assets 100 100   100  
Current liabilities (597) (597)   (597)  
Deferred tax liability (3,547) (3,547)   (3,566)  
Deferred tax liability, adjustments 19        
Total consideration paid 58,306 $ 58,306   $ 58,306  
Total consideration paid, adjustments $ 0        
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Acquired Identified Intangible Assets) (Details) - Luum Acquisition
$ in Thousands
Mar. 08, 2021
USD ($)
Business Acquisition [Line Items]  
Fair value $ 23,900
Estimated life (in years) 6 years
Customer relationships  
Business Acquisition [Line Items]  
Fair value $ 12,400
Estimated life (in years) 7 years
Developed technology  
Business Acquisition [Line Items]  
Fair value $ 10,900
Estimated life (in years) 5 years
Trade names & trademarks  
Business Acquisition [Line Items]  
Fair value $ 600
Estimated life (in years) 3 years
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Property and equipment) (Details) - USD ($)
$ in Thousands
Oct. 31, 2021
Jan. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 63,885 $ 60,093
Accumulated depreciation (38,955) (30,987)
Property and equipment, net 24,930 29,106
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 20,718 22,271
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,068 9,230
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 34,099 $ 28,592
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Jan. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Depreciation expense $ 3,500 $ 4,000 $ 10,900 $ 12,000  
Remaining performance obligation 10,100   10,100   $ 4,100
Revenue recognition 300   1,400    
Loss on extinguishment of debt $ 4,000   $ 4,044 $ 0  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-11-01          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Remaining performance obligation, percentage 40.00%   40.00%    
Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months   12 months    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Lease Cost) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Operating lease expense $ 3,512 $ 3,777 $ 11,322 $ 12,297
Sublease income (455) (450) (1,355) (1,349)
Net operating lease expense $ 3,057 $ 3,327 $ 9,967 $ 10,948
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Other income (expense), net) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Interest income $ 478 $ 174 $ 1,419 $ 850
Gain on equity securities 0 0 1,677 0
Acquisition gains (costs), net 2,687 (13) (4,917) (79)
Other income (expense), net (43) (582) 1,657 (2,780)
Total other income (expense), net $ 3,122 $ (421) $ (164) $ (2,009)
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Supplemental Cash Flow Information) (Details) - USD ($)
$ in Thousands
9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 10,928 $ 9,739
Operating lease right-of-use assets obtained in exchange for new operating lease obligations $ 586 $ 17,480
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Schedule of intangible assets) (Details) - USD ($)
$ in Thousands
Oct. 31, 2021
Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 1,104,084 $ 962,752
Accumulated amortization (283,138) (195,749)
Amortizable intangible assets, net 820,946 767,003
Software and software development costs    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 177,693 127,005
Acquired HSA portfolios    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 191,885 125,141
Acquired customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 613,781 601,381
Acquired developed technology    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 107,825 96,925
Acquired trade names    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 12,900 $ 12,300
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Narrative) (Details)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Sep. 29, 2021
USD ($)
member
Goodwill [Line Items]          
Amortization expense $ 30.0 $ 25.3 $ 87.5 $ 73.5  
Goodwill acquired     $ 36.4    
Fifth Third Bank HSA portfolio Acquisition          
Goodwill [Line Items]          
Number of HSA members transferred in portfolio acquisition | member         160,000,000,000
Value of HSA assets transferred in portfolio acquisition         $ 491.0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies - Outstanding Contractual Obligations (Details) - USD ($)
$ in Thousands
9 Months Ended
Oct. 31, 2021
Jan. 31, 2021
Long-term Debt, Fiscal Year Maturity [Abstract]    
Total debt, net $ 930,064 $ 986,717
Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]    
2022 8,577  
2023 33,951  
2024 33,708  
2025 33,467  
2026 32,965  
Thereafter 103,739  
Total 246,407  
Lessee, Operating Lease, Liability, Payment, Due [Abstract]    
2022 3,416  
2023 12,689  
2024 10,442  
2025 10,836  
2026 11,080  
Thereafter 52,563  
Total 101,026  
Contingent Acquisition Consideration [Abstract]    
2022 6,000  
2023 0  
2024 0  
2025 0  
2026 0  
Thereafter 0  
Total 6,000  
Other Commitment, Fiscal Year Maturity [Abstract]    
2022 7,143  
2023 21,368  
2024 9,559  
2025 622  
2026 16  
Thereafter 0  
Total 38,708  
Contractual Obligation, Fiscal Year Maturity [Abstract]    
2022 525,136  
2023 76,758  
2024 71,209  
2025 62,425  
2026 70,311  
Thereafter 1,036,302  
Total 1,842,141  
Principal amount 950,000 1,003,125
Sublease income to be received 2,700  
Term Loan Facility    
Contractual Obligation, Fiscal Year Maturity [Abstract]    
Principal amount   0
4.50% Senior Notes due 2029    
Long-term Debt, Fiscal Year Maturity [Abstract]    
2022 0  
2023 0  
2024 0  
2025 0  
2026 0  
Thereafter 600,000  
Total debt, net 600,000  
Contractual Obligation, Fiscal Year Maturity [Abstract]    
Principal amount $ 600,000 $ 0
Stated interest rate percentage 4.50%  
Credit Agreement    
Contractual Obligation, Fiscal Year Maturity [Abstract]    
Stated interest rate percentage 1.88%  
Credit Agreement | Term Loan Facility    
Long-term Debt, Fiscal Year Maturity [Abstract]    
2022 $ 0  
2023 8,750  
2024 17,500  
2025 17,500  
2026 26,250  
Thereafter 280,000  
Total debt, net 350,000  
Contractual Obligation, Fiscal Year Maturity [Abstract]    
Principal amount 350,000  
Further Health Savings Account Portfolio Acquisition    
Asset Acquisition, Consideration [Abstract]    
2022 500,000  
2023 0  
2024 0  
2025 0  
2026 0  
Thereafter 0  
Total $ 500,000  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies - Narrative (Details)
$ in Millions
Sep. 06, 2018
lawsuit
Jun. 22, 2018
lawsuit
Nov. 24, 2021
USD ($)
Oct. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Loss Contingencies [Line Items]          
Settle of claims       $ 30.0  
Number of derivative lawsuits | lawsuit 2 2      
WageWorks Insurers          
Loss Contingencies [Line Items]          
Settle of claims       25.0  
WageWorks, Inc          
Loss Contingencies [Line Items]          
Operating lease not yet commenced undiscounted amount         $ 63.1
Operating lease not yet commenced term of contract         11 years
Settle of claims       $ 5.0  
WageWorks, Inc | Union Mesa | Subsequent Event          
Loss Contingencies [Line Items]          
Letters of credit outstanding     $ 2.8    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Jan. 31, 2021
Income Tax Disclosure [Abstract]          
Income tax benefit $ 4,087 $ (2,340) $ 11,505 $ (2,015)  
Effective tax rate (44.80%) 56.70% (50.10%) 36.80%  
Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit) (7.70%) 6.00% (20.50%) (9.60%)  
Gross unrecognized tax benefits $ 11,200   $ 11,200   $ 10,200
Unrecognized tax benefits that would impact the effective tax rate $ 10,300   $ 10,300    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Schedule of Long-term Debt) (Details) - USD ($)
$ in Thousands
Oct. 31, 2021
Jan. 31, 2021
Debt Instrument [Line Items]    
Principal amount $ 950,000 $ 1,003,125
Less: unamortized discount and issuance costs 19,936 16,408
Total debt, net 930,064 986,717
Less: current portion of long-term debt 6,563 62,500
Long-term debt, net 923,501 924,217
4.50% Senior Notes due 2029    
Debt Instrument [Line Items]    
Principal amount 600,000 0
Total debt, net $ 600,000  
Stated interest rate percentage 4.50%  
Credit Agreement    
Debt Instrument [Line Items]    
Stated interest rate percentage 1.88%  
Term Loan Facility    
Debt Instrument [Line Items]    
Principal amount   0
Term Loan Facility | Credit Agreement    
Debt Instrument [Line Items]    
Principal amount $ 350,000  
Total debt, net 350,000  
Term Loan Facility | Prior Credit Agreement    
Debt Instrument [Line Items]    
Principal amount 0 1,003,125
Revolving Credit Facility    
Debt Instrument [Line Items]    
Debt issuance costs, net $ 4,600 $ 5,000
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Narrative) (Details)
9 Months Ended
Oct. 08, 2021
USD ($)
Aug. 30, 2019
USD ($)
Oct. 31, 2021
Line of Credit | Revolving Credit Facility | Minimum      
Debt Instrument [Line Items]      
Commitment fee percentage     0.20%
Line of Credit | Revolving Credit Facility | Maximum      
Debt Instrument [Line Items]      
Commitment fee percentage     0.40%
4.50% Senior Notes due 2029      
Debt Instrument [Line Items]      
Stated interest rate percentage     4.50%
4.50% Senior Notes due 2029 | Senior Notes      
Debt Instrument [Line Items]      
Stated interest rate percentage 4.50%    
Principal amount $ 600,000,000    
Effective interest rate percentage     4.72%
4.50% Senior Notes due 2029 | October 1, 2024 | Senior Notes      
Debt Instrument [Line Items]      
Redemption price, percentage 102.25%    
4.50% Senior Notes due 2029 | October 1, 2025 | Senior Notes      
Debt Instrument [Line Items]      
Redemption price, percentage 101.125%    
4.50% Senior Notes due 2029 | October 1, 2026 and thereafter | Senior Notes      
Debt Instrument [Line Items]      
Redemption price, percentage 100.00%    
4.50% Senior Notes due 2029 | Prior to October 1, 2024 | Senior Notes      
Debt Instrument [Line Items]      
Redemption price, percentage 100.00%    
4.50% Senior Notes due 2029 | Prior to October 1, 2024, 40% of Principal | Senior Notes      
Debt Instrument [Line Items]      
Redemption price, percentage 104.50%    
Percentage of principal amount redeemed 40.00%    
Credit Agreement      
Debt Instrument [Line Items]      
Stated interest rate percentage     1.88%
Effective interest rate percentage     2.63%
Maximum borrowing capacity of future commitments $ 300,000,000    
Maximum leverage ratio 3.85   5.00
Minimum interest coverage ratio     3.00
Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread 1.25%    
Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread 2.25%    
Credit Agreement | Customary Base Rate | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread 0.25%    
Credit Agreement | Customary Base Rate | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread 1.25%    
Credit Agreement | Secured Debt | Term Loan Facility      
Debt Instrument [Line Items]      
Facility term 5 years    
Credit facility, amount $ 350,000,000    
Credit Agreement | Line of Credit | Term Loan Facility      
Debt Instrument [Line Items]      
Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay     100.00%
Debt instrument, number of days to reinvest proceeds from sales of assets     450 days
Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period     180 days
Credit Agreement | Line of Credit | Term Loan Facility | First year after the Effective Date      
Debt Instrument [Line Items]      
Debt instrument, amortization of loans, percentage of principal amount     2.50%
Credit Agreement | Line of Credit | Term Loan Facility | Second and third years after the Effective Date      
Debt Instrument [Line Items]      
Debt instrument, amortization of loans, percentage of principal amount     5.00%
Credit Agreement | Line of Credit | Term Loan Facility | Fourth year after the Effective Date      
Debt Instrument [Line Items]      
Debt instrument, amortization of loans, percentage of principal amount     7.50%
Credit Agreement | Line of Credit | Term Loan Facility | Fifth year after the Effective Date      
Debt Instrument [Line Items]      
Debt instrument, amortization of loans, percentage of principal amount     10.00%
Credit Agreement | Line of Credit | Revolving Credit Facility      
Debt Instrument [Line Items]      
Facility term 5 years    
Credit facility, amount $ 1,000,000,000    
Credit Agreement | Letter of Credit | Revolving Credit Facility      
Debt Instrument [Line Items]      
Credit facility, amount $ 25,000,000    
Prior Credit Agreement      
Debt Instrument [Line Items]      
Acquisition threshold for maximum total net leverage ratio   $ 100,000,000  
Minimum interest coverage ratio   3.00  
Prior Credit Agreement | Debt covenant, period one      
Debt Instrument [Line Items]      
Maximum leverage ratio   4.50  
Prior Credit Agreement | Debt covenant, period two      
Debt Instrument [Line Items]      
Maximum leverage ratio   5.00  
Prior Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   1.25%  
Prior Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   2.25%  
Prior Credit Agreement | Customary Base Rate | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   0.25%  
Prior Credit Agreement | Customary Base Rate | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   1.25%  
Prior Credit Agreement | Secured Debt | Term Loan Facility      
Debt Instrument [Line Items]      
Facility term   5 years  
Credit facility, amount   $ 1,250,000,000  
Prior Credit Agreement | Line of Credit | Revolving Credit Facility      
Debt Instrument [Line Items]      
Facility term   5 years  
Credit facility, amount   $ 350,000,000  
Long-term line of credit   $ 0  
Prior Credit Agreement | Line of Credit | Revolving Credit Facility | Minimum      
Debt Instrument [Line Items]      
Commitment fee percentage   0.20%  
Prior Credit Agreement | Line of Credit | Revolving Credit Facility | Maximum      
Debt Instrument [Line Items]      
Commitment fee percentage   0.40%  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Summary of share based compensation recognized) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 13,284 $ 11,479 $ 42,042 $ 30,313
Cost of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,076 2,209 8,547 5,737
Sales and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 829 2,035 5,677 4,810
Technology and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,458 2,641 10,164 8,051
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 5,921 4,594 17,312 11,715
Other expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 0 $ 0 $ 342 $ 0
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Apr. 30, 2021
Oct. 31, 2021
Performance restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Performance units awards (in shares) 249,750  
Grant date fair value $ 22.4  
Performance restricted stock units | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting rights percentage   0.00%
Performance restricted stock units | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting rights percentage   200.00%
Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares)   2,600,000
Percentage of capital stock   3.00%
Shares available for grant under incentive plan (in shares)   7,500,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Stock option activity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Apr. 30, 2021
Oct. 31, 2021
Jan. 31, 2021
Number of options (shares)      
Outstanding, beginning balance (in shares) 1,674 1,674  
Exercised (in shares)   (280)  
Outstanding, ending balance (in shares)   1,394  
Vested and expected to vest (in shares)   1,394  
Exercisable (in shares)   1,303  
Range of exercise prices      
Beginning balance, minimum (in usd per share) $ 1.25 $ 1.25  
Beginning balance, maximum (in usd per share) 82.39 82.39  
Exercised, minimum (in usd per share)   1.25  
Exercised, maximum (in usd per share)   44.53  
Ending balance, minimum (in usd per share)   1.25  
Ending balance, maximum (in usd per share)   82.39  
Weighted- average exercise price      
Opening balance (in usd per share) $ 31.46 31.46  
Exercised (in usd per share)   22.36  
Ending balance (in usd per share)   33.29  
Vested and expected to vest, weighted average exercise price (in usd per share)   33.29  
Exercisable, weighted-average exercise price (in usd per share)   $ 30.76  
Outstanding stock options, weighted average contractual term (in years) 5 years 4 years 2 months 12 days  
Vested and expected to vest, weighted average contractual term (in years)   4 years 2 months 12 days  
Exercisable, weighted-average contractual term (in years)   4 years  
Aggregate intrinsic value   $ 47,032 $ 87,164
Vested and expected to vest, aggregate intrinsic value (in usd per share)   47,032  
Exercisable, aggregate intrinsic value   $ 46,863  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Restricted stock unity activity) (Details)
shares in Thousands
9 Months Ended
Oct. 31, 2021
$ / shares
shares
Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning balance (in shares) | shares 1,832
Granted (in shares) | shares 1,381
Vested (in shares) | shares (418)
Forfeited (in shares) | shares (255)
Outstanding, ending balance (in shares) | shares 2,540
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning balance (in usd per share) | $ / shares $ 60.41
Granted (in usd per share) | $ / shares 71.61
Vested (in usd per share) | $ / shares 58.09
Forfeited (in usd per share) | $ / shares 62.99
Outstanding, ending balance (in usd per share) | $ / shares $ 66.62
Restricted Stock Awards  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning balance (in shares) | shares 193
Granted (in shares) | shares 0
Vested (in shares) | shares (116)
Forfeited (in shares) | shares (75)
Outstanding, ending balance (in shares) | shares 2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning balance (in usd per share) | $ / shares $ 61.77
Granted (in usd per share) | $ / shares 0
Vested (in usd per share) | $ / shares 61.77
Forfeited (in usd per share) | $ / shares 61.77
Outstanding, ending balance (in usd per share) | $ / shares $ 61.72
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value - Narrative (Details)
$ in Millions
Oct. 31, 2021
USD ($)
Level 2 | 4.50% Senior Notes due 2029  
Defined Benefit Plan Disclosure [Line Items]  
Fair value of the notes $ 605.2
Level 3  
Defined Benefit Plan Disclosure [Line Items]  
Contingent consideration liability $ 6.0
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value (Details) - Contingent Consideration
$ in Thousands
9 Months Ended
Oct. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance as of January 31, 2021 $ 0
Contingent consideration recognized at acquisition 8,147
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss) (2,147)
Balance as of October 31, 2021 $ 6,000
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details)
1 Months Ended
Dec. 06, 2021
USD ($)
member
Sep. 30, 2021
USD ($)
Apr. 30, 2021
USD ($)
member
Further Health Savings Account Portfolio Acquisition      
Subsequent Event [Line Items]      
Purchase price for HSA portfolio     $ 500,000,000
Number of HSA members transferred in portfolio acquisition | member     580,000,000,000
Value of HSA assets transferred in portfolio acquisition     $ 1,900,000,000
Payment to acquire remainder of further business   $ 455,000,000  
Payments to acquire VEBA assets   $ 45,000,000  
HealthSavings Administrators, LLC | Subsequent Event      
Subsequent Event [Line Items]      
Purchase price for HSA portfolio $ 60,000,000    
Number of HSA members transferred in portfolio acquisition | member 87,000    
Value of HSA assets transferred in portfolio acquisition $ 1,300,000,000    
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 181 388 1 false 63 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/Condensedconsolidatedbalancesheets Condensed consolidated balance sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 2104102 - Disclosure - Net income (loss) per share Sheet http://healthequity.com/role/Netincomelosspershare Net income (loss) per share Notes 8 false false R9.htm 2107103 - Disclosure - Business combination Sheet http://healthequity.com/role/Businesscombination Business combination Notes 9 false false R10.htm 2112104 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/Supplementalfinancialstatementinformation Supplemental financial statement information Notes 10 false false R11.htm 2119105 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 11 false false R12.htm 2123106 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 12 false false R13.htm 2127107 - Disclosure - Income taxes Sheet http://healthequity.com/role/Incometaxes Income taxes Notes 13 false false R14.htm 2129108 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 14 false false R15.htm 2133109 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/Stockbasedcompensation Stock-based compensation Notes 15 false false R16.htm 2139110 - Disclosure - Fair value Sheet http://healthequity.com/role/Fairvalue Fair value Notes 16 false false R17.htm 2143111 - Disclosure - Subsequent events Sheet http://healthequity.com/role/Subsequentevents Subsequent events Notes 17 false false R18.htm 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 18 false false R19.htm 2305301 - Disclosure - Net income (loss) per share (Tables) Sheet http://healthequity.com/role/NetincomelosspershareTables Net income (loss) per share (Tables) Tables http://healthequity.com/role/Netincomelosspershare 19 false false R20.htm 2308302 - Disclosure - Business combination (Tables) Sheet http://healthequity.com/role/BusinesscombinationTables Business combination (Tables) Tables http://healthequity.com/role/Businesscombination 20 false false R21.htm 2313303 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/Supplementalfinancialstatementinformation 21 false false R22.htm 2320304 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/Intangibleassetsandgoodwill 22 false false R23.htm 2324305 - Disclosure - Commitments and contingencies (Tables) Sheet http://healthequity.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://healthequity.com/role/Commitmentsandcontingencies 23 false false R24.htm 2330306 - Disclosure - Indebtedness (Tables) Sheet http://healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://healthequity.com/role/Indebtedness 24 false false R25.htm 2334307 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/Stockbasedcompensation 25 false false R26.htm 2340308 - Disclosure - Fair value (Tables) Sheet http://healthequity.com/role/FairvalueTables Fair value (Tables) Tables http://healthequity.com/role/Fairvalue 26 false false R27.htm 2403401 - Disclosure - Summary of business and significant accounting policies (Details) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails Summary of business and significant accounting policies (Details) Details http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies 27 false false R28.htm 2406402 - Disclosure - Net income (loss) per share (Details) Sheet http://healthequity.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://healthequity.com/role/NetincomelosspershareTables 28 false false R29.htm 2409403 - Disclosure - Business combination (Narrative) (Details) Sheet http://healthequity.com/role/BusinesscombinationNarrativeDetails Business combination (Narrative) (Details) Details http://healthequity.com/role/BusinesscombinationTables 29 false false R30.htm 2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) Sheet http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails Business combination (Preliminary Allocation of Consideration) (Details) Details http://healthequity.com/role/BusinesscombinationTables 30 false false R31.htm 2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details) Sheet http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails Business combination (Acquired Identified Intangible Assets) (Details) Details http://healthequity.com/role/BusinesscombinationTables 31 false false R32.htm 2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails Supplemental financial statement information (Property and equipment) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 32 false false R33.htm 2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails Supplemental financial statement information (Narrative) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 33 false false R34.htm 2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails Supplemental financial statement information (Lease Cost) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 34 false false R35.htm 2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails Supplemental financial statement information (Other income (expense), net) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 35 false false R36.htm 2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 36 false false R37.htm 2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails Intangible assets and goodwill (Schedule of intangible assets) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 37 false false R38.htm 2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 38 false false R39.htm 2425413 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details) Sheet http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails Commitments and contingencies - Outstanding Contractual Obligations (Details) Details 39 false false R40.htm 2426414 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 40 false false R41.htm 2428415 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncometaxesDetails Income taxes (Details) Details http://healthequity.com/role/Incometaxes 41 false false R42.htm 2431416 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) Sheet http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails Indebtedness (Schedule of Long-term Debt) (Details) Details http://healthequity.com/role/IndebtednessTables 42 false false R43.htm 2432417 - Disclosure - Indebtedness (Narrative) (Details) Sheet http://healthequity.com/role/IndebtednessNarrativeDetails Indebtedness (Narrative) (Details) Details http://healthequity.com/role/IndebtednessTables 43 false false R44.htm 2435418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) Sheet http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails Stock-based compensation (Summary of share based compensation recognized) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 44 false false R45.htm 2436419 - Disclosure - Stock-based compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation (Narrative) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 45 false false R46.htm 2437420 - Disclosure - Stock-based compensation (Stock option activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails Stock-based compensation (Stock option activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 46 false false R47.htm 2438421 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails Stock-based compensation (Restricted stock unity activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 47 false false R48.htm 2441422 - Disclosure - Fair value - Narrative (Details) Sheet http://healthequity.com/role/FairvalueNarrativeDetails Fair value - Narrative (Details) Details 48 false false R49.htm 2442423 - Disclosure - Fair value (Details) Sheet http://healthequity.com/role/FairvalueDetails Fair value (Details) Details http://healthequity.com/role/FairvalueTables 49 false false R50.htm 2444424 - Disclosure - Subsequent Events (Details) Sheet http://healthequity.com/role/SubsequentEventsDetails Subsequent Events (Details) Details 50 false false All Reports Book All Reports hqy-20211031.htm exhibit311-ceo302xfy22q3.htm exhibit312-cfo302xfy22q3.htm exhibit321-ceo906xfy22q3.htm exhibit322-cfo906xfy22q3.htm hqy-20211031.xsd hqy-20211031_cal.xml hqy-20211031_def.xml hqy-20211031_lab.xml hqy-20211031_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20211031.htm": { "axisCustom": 2, "axisStandard": 22, "contextCount": 181, "dts": { "calculationLink": { "local": [ "hqy-20211031_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20211031_def.xml" ] }, "inline": { "local": [ "hqy-20211031.htm" ] }, "labelLink": { "local": [ "hqy-20211031_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20211031_pre.xml" ] }, "schema": { "local": [ "hqy-20211031.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 509, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 55, "keyStandard": 333, "memberCustom": 25, "memberStandard": 38, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20211031", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Supplemental financial statement information", "role": "http://healthequity.com/role/Supplementalfinancialstatementinformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119105 - Disclosure - Intangible assets and goodwill", "role": "http://healthequity.com/role/Intangibleassetsandgoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123106 - Disclosure - Commitments and contingencies", "role": "http://healthequity.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Income taxes", "role": "http://healthequity.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Indebtedness", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Stock-based compensation", "role": "http://healthequity.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - Fair value", "role": "http://healthequity.com/role/Fairvalue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - Subsequent events", "role": "http://healthequity.com/role/Subsequentevents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of business and significant accounting policies (Policies)", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Net income (loss) per share (Tables)", "role": "http://healthequity.com/role/NetincomelosspershareTables", "shortName": "Net income (loss) per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed consolidated balance sheets", "role": "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Business combination (Tables)", "role": "http://healthequity.com/role/BusinesscombinationTables", "shortName": "Business combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Supplemental financial statement information (Tables)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Intangible assets and goodwill (Tables)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Commitments and contingencies (Tables)", "role": "http://healthequity.com/role/CommitmentsandcontingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330306 - Disclosure - Indebtedness (Tables)", "role": "http://healthequity.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334307 - Disclosure - Stock-based compensation (Tables)", "role": "http://healthequity.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - Fair value (Tables)", "role": "http://healthequity.com/role/FairvalueTables", "shortName": "Fair value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "ibc48c2d59dc94c32ab4aa637359ecb49_D20210901-20210929", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:PaymentsForAssetAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Summary of business and significant accounting policies (Details)", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails", "shortName": "Summary of business and significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "ibc48c2d59dc94c32ab4aa637359ecb49_D20210901-20210929", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:PaymentsForAssetAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Net income (loss) per share (Details)", "role": "http://healthequity.com/role/NetincomelosspershareDetails", "shortName": "Net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Business combination (Narrative) (Details)", "role": "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "shortName": "Business combination (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i93be55fb81d84f0e824f45b22b9ef67e_I20210308", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed consolidated balance sheets (Parenthetical)", "role": "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details)", "role": "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "shortName": "Business combination (Preliminary Allocation of Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i93be55fb81d84f0e824f45b22b9ef67e_I20210308", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "ib6609db9623c42cd877a600f16fd690f_D20210308-20210308", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details)", "role": "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "shortName": "Business combination (Acquired Identified Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "ib6609db9623c42cd877a600f16fd690f_D20210308-20210308", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails", "shortName": "Supplemental financial statement information (Property and equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails", "shortName": "Supplemental financial statement information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails", "shortName": "Supplemental financial statement information (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails", "shortName": "Supplemental financial statement information (Other income (expense), net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails", "shortName": "Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails", "shortName": "Intangible assets and goodwill (Schedule of intangible assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details)", "role": "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "shortName": "Commitments and contingencies - Outstanding Contractual Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "lang": "en-US", "name": "hqy:InterestOnLongTermDebtToBePaidRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Commitments and contingencies - Narrative (Details)", "role": "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "shortName": "Commitments and contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Income taxes (Details)", "role": "http://healthequity.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "shortName": "Indebtedness (Schedule of Long-term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i1ec245e64d5642328ff8bcb5311fb526_I20211031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i0e5a689632364830a196be291d623124_D20210201-20211031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Indebtedness (Narrative) (Details)", "role": "http://healthequity.com/role/IndebtednessNarrativeDetails", "shortName": "Indebtedness (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i0e5a689632364830a196be291d623124_D20210201-20211031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails", "shortName": "Stock-based compensation (Summary of share based compensation recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4361f3414da2435e8eabae0c77dd4882_D20210801-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4fa7ffa584ec4f1eb3d508f223ea191d_D20210201-20210430", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Stock-based compensation (Narrative) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "shortName": "Stock-based compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i4fa7ffa584ec4f1eb3d508f223ea191d_D20210201-20210430", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "iaf51479dcfba4b5a8b2479d2c8b68d0a_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - Stock-based compensation (Stock option activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails", "shortName": "Stock-based compensation (Stock option activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i3ff4126848f849d2af492550a9c513ce_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "shortName": "Stock-based compensation (Restricted stock unity activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i3ff4126848f849d2af492550a9c513ce_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i0b9d75660d9749ffa040e01ada32e5cf_I20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Fair value - Narrative (Details)", "role": "http://healthequity.com/role/FairvalueNarrativeDetails", "shortName": "Fair value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i0b9d75660d9749ffa040e01ada32e5cf_I20211031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "idc00cac3f70f470987103920f7349b8a_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Fair value (Details)", "role": "http://healthequity.com/role/FairvalueDetails", "shortName": "Fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "idc00cac3f70f470987103920f7349b8a_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i8d983241d8d34f518bf290f38c065e9f_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i8d983241d8d34f518bf290f38c065e9f_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i85c37bf70d394d6e815775227cefa663_D20210401-20210430", "decimals": "-6", "first": true, "lang": "en-US", "name": "hqy:PaymentsForAssetAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444424 - Disclosure - Subsequent Events (Details)", "role": "http://healthequity.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i85c37bf70d394d6e815775227cefa663_D20210401-20210430", "decimals": "-6", "first": true, "lang": "en-US", "name": "hqy:PaymentsForAssetAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed consolidated statements of cash flows (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of business and significant accounting policies", "role": "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Net income (loss) per share", "role": "http://healthequity.com/role/Netincomelosspershare", "shortName": "Net income (loss) per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Business combination", "role": "http://healthequity.com/role/Businesscombination", "shortName": "Business combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20211031.htm", "contextRef": "i17164ad26ea74c3294920d1daa2baa48_D20210201-20211031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hqy_A4500SeniorNotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.500% Senior Notes due 2029", "label": "4.500% Senior Notes due 2029 [Member]", "terseLabel": "4.50% Senior Notes due 2029" } } }, "localname": "A4500SeniorNotesDue2029Member", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/FairvalueNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Acquired HSA portfolios" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities, Assets", "label": "Asset Acquisition, Assets Acquired And Liabilities, Assets", "terseLabel": "Value of HSA assets transferred in portfolio acquisition" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssets", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration", "label": "Asset Acquisition, Consideration [Abstract]", "terseLabel": "Asset Acquisition, Consideration [Abstract]" } } }, "localname": "AssetAcquisitionConsiderationAbstract", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "hqy_AssetAcquisitionConsiderationToBePaid": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid", "label": "Asset Acquisition, Consideration,To Be Paid", "totalLabel": "Total" } } }, "localname": "AssetAcquisitionConsiderationToBePaid", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, After Year Four", "label": "Asset Acquisition, Consideration,To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "AssetAcquisitionConsiderationToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, Remainder Of Fiscal Year", "label": "Asset Acquisition, Consideration,To Be Paid, Remainder Of Fiscal Year", "terseLabel": "2022" } } }, "localname": "AssetAcquisitionConsiderationToBePaidRemainderOfFiscalYear", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, Year Four", "label": "Asset Acquisition, Consideration,To Be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "AssetAcquisitionConsiderationToBePaidYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidYearOne": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, Year One", "label": "Asset Acquisition, Consideration,To Be Paid, Year One", "terseLabel": "2023" } } }, "localname": "AssetAcquisitionConsiderationToBePaidYearOne", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidYearThree": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, Year Three", "label": "Asset Acquisition, Consideration,To Be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "AssetAcquisitionConsiderationToBePaidYearThree", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionConsiderationToBePaidYearTwo": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "hqy_AssetAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration,To Be Paid, Year Two", "label": "Asset Acquisition, Consideration,To Be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "AssetAcquisitionConsiderationToBePaidYearTwo", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationContingentConsiderationPerformancePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Performance Period", "label": "Business Combination, Contingent Consideration, Performance Period", "terseLabel": "Contingent consideration, performance period" } } }, "localname": "BusinessCombinationContingentConsiderationPerformancePeriod", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes", "negatedLabel": "Deferred tax liability, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration", "label": "Contingent Acquisition Consideration [Abstract]", "terseLabel": "Contingent Acquisition Consideration [Abstract]" } } }, "localname": "ContingentAcquisitionConsiderationAbstract", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaid": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid", "label": "Contingent Acquisition Consideration, To Be Paid", "totalLabel": "Total" } } }, "localname": "ContingentAcquisitionConsiderationToBePaid", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, After Year Four", "label": "Contingent Acquisition Consideration, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, Remainder Of Fiscal Year", "label": "Contingent Acquisition Consideration, To Be Paid, Remainder Of Fiscal Year", "terseLabel": "2022" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidRemainderOfFiscalYear", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, Year Four", "label": "Contingent Acquisition Consideration, To Be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidYearOne": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, Year One", "label": "Contingent Acquisition Consideration, To Be Paid, Year One", "terseLabel": "2023" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidYearOne", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidYearThree": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, Year Three", "label": "Contingent Acquisition Consideration, To Be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidYearThree", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentAcquisitionConsiderationToBePaidYearTwo": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "hqy_ContingentAcquisitionConsiderationToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Acquisition Consideration, To Be Paid, Year Two", "label": "Contingent Acquisition Consideration, To Be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "ContingentAcquisitionConsiderationToBePaidYearTwo", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "hqy_ContractualObligationToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual Obligation, to be Paid, After Year Four", "label": "Contractual Obligation, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "ContractualObligationToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period One", "label": "Debt Covenant Period One [Member]", "verboseLabel": "Debt covenant, period one" } } }, "localname": "DebtCovenantPeriodOneMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period Two", "label": "Debt Covenant Period Two [Member]", "verboseLabel": "Debt covenant, period two" } } }, "localname": "DebtCovenantPeriodTwoMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Axis]", "terseLabel": "Debt Instrument, Amortization Period [Axis]" } } }, "localname": "DebtInstrumentAmortizationPeriodAxis", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtInstrumentAmortizationPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Domain]", "terseLabel": "Debt Instrument, Amortization Period [Domain]" } } }, "localname": "DebtInstrumentAmortizationPeriodDomain", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Five [Member]", "label": "Debt Instrument, Amortization Period Five [Member]", "verboseLabel": "Fifth year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodFiveMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Four [Member]", "label": "Debt Instrument, Amortization Period Four [Member]", "terseLabel": "Fourth year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodFourMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period One", "label": "Debt Instrument, Amortization Period One [Member]", "verboseLabel": "First year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodOneMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Two and Three Period", "label": "Debt Instrument, Amortization Period Two and Three Period [Member]", "terseLabel": "Second and third years after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "label": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "terseLabel": "Acquisition threshold for maximum total net leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_DebtInstrumentCovenantMinimumInterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "label": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantMinimumInterestCoverageRatio", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantNetLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Net Leverage Ratio", "label": "Debt Instrument, Covenant, Net Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantNetLeverageRatio", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount", "label": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount", "terseLabel": "Debt instrument, amortization of loans, percentage of principal amount" } } }, "localname": "DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales", "label": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales", "terseLabel": "Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay" } } }, "localname": "DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period", "label": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period", "terseLabel": "Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period" } } }, "localname": "DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales", "label": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales", "terseLabel": "Debt instrument, number of days to reinvest proceeds from sales of assets" } } }, "localname": "DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_ExerciseofStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise of Stock Options Receivable", "label": "Exercise of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseofStockOptionsReceivable", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_FifthThirdBankHSAPortfolioAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifth Third Bank HSA Portfolio Acquisition", "label": "Fifth Third Bank HSA Portfolio Acquisition [Member]", "terseLabel": "Fifth Third Bank HSA Portfolio Acquisition" } } }, "localname": "FifthThirdBankHSAPortfolioAcquisitionMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "hqy_FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member]", "label": "Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member]", "terseLabel": "Fifth Third Bank HSA portfolio Acquisition" } } }, "localname": "FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_FollowOnEquityOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow On Equity Offering [Member]", "label": "Follow On Equity Offering [Member]", "terseLabel": "Follow on equity offering" } } }, "localname": "FollowOnEquityOfferingMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "hqy_FurtherHealthSavingsAccountPortfolioAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Further Health Savings Account Portfolio Acquisition", "label": "Further Health Savings Account Portfolio Acquisition [Member]", "terseLabel": "Further Health Savings Account Portfolio Acquisition" } } }, "localname": "FurtherHealthSavingsAccountPortfolioAcquisitionMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_HealthSavingsAdministratorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HealthSavings Administrators, LLC", "label": "HealthSavings Administrators, LLC [Member]", "terseLabel": "HealthSavings Administrators, LLC" } } }, "localname": "HealthSavingsAdministratorsLLCMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Plan [Member]", "label": "Incentive Plan [Member]", "terseLabel": "Incentive Plan" } } }, "localname": "IncentivePlanMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, Fiscal Year Maturity", "label": "Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "InterestOnLongTermDebtFiscalYearMaturityAbstract", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "hqy_InterestOnLongTermDebtToBePaid": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid", "label": "Interest On Long-Term Debt, To Be Paid", "totalLabel": "Total" } } }, "localname": "InterestOnLongTermDebtToBePaid", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, After Year Four", "label": "Interest On Long-Term Debt, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "InterestOnLongTermDebtToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, Remainder Of Fiscal Year", "label": "Interest On Long-Term Debt, To Be Paid, Remainder Of Fiscal Year", "terseLabel": "2022" } } }, "localname": "InterestOnLongTermDebtToBePaidRemainderOfFiscalYear", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, Year Four", "label": "Interest On Long-Term Debt, To Be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "InterestOnLongTermDebtToBePaidYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidYearOne": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, Year One", "label": "Interest On Long-Term Debt, To Be Paid, Year One", "terseLabel": "2023" } } }, "localname": "InterestOnLongTermDebtToBePaidYearOne", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidYearThree": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, Year Three", "label": "Interest On Long-Term Debt, To Be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "InterestOnLongTermDebtToBePaidYearThree", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_InterestOnLongTermDebtToBePaidYearTwo": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest On Long-Term Debt, To Be Paid, Year Two", "label": "Interest On Long-Term Debt, To Be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "InterestOnLongTermDebtToBePaidYearTwo", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced", "label": "Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments", "label": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments", "terseLabel": "Maximum borrowing capacity of future commitments" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt Maturities, Repayments Of Principal After Year Four", "label": "Long-Term Debt Maturities, Repayments Of Principal After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency Number Of Lawsuits", "label": "Loss Contingency Number Of Lawsuits", "terseLabel": "Number of derivative lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hqy_LuumAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Luum Acquisition [Member]", "label": "Luum Acquisition [Member]", "terseLabel": "Luum Acquisition" } } }, "localname": "LuumAcquisitionMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "hqy_NumberOfHSAMembersTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of HSA Members Transferred", "label": "Number Of HSA Members Transferred", "terseLabel": "Number of HSA members transferred in portfolio acquisition" } } }, "localname": "NumberOfHSAMembersTransferred", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "hqy_OtherCommitmentToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Commitment To Be Paid, After Year Four", "label": "Other Commitment To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "OtherCommitmentToBePaidAfterYearFour", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_OtherNonoperatingIncomeExpenseMiscellaneous": { "auth_ref": [], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Nonoperating Income (Expense), Miscellaneous", "label": "Other Nonoperating Income (Expense), Miscellaneous", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpenseMiscellaneous", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PaymentsForAssetAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Asset Acquisition", "label": "Payments For Asset Acquisition", "terseLabel": "Purchase price for HSA portfolio" } } }, "localname": "PaymentsForAssetAcquisition", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PaymentsToSettleClientHeldFunds": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Settle Client Held Funds", "label": "Payments To Settle Client Held Funds", "negatedTerseLabel": "Settlement of client-held funds obligation, net" } } }, "localname": "PaymentsToSettleClientHeldFunds", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_PriorCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prior Credit Agreement", "label": "Prior Credit Agreement [Member]", "terseLabel": "Prior Credit Agreement" } } }, "localname": "PriorCreditAgreementMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "terseLabel": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (in usd per share)", "periodStartLabel": "Beginning balance, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (in usd per share)", "periodStartLabel": "Beginning balance, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_StockIssuanceCostsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issuance Costs Payable", "label": "Stock Issuance Costs Payable", "terseLabel": "Other offering expenses payable" } } }, "localname": "StockIssuanceCostsPayable", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_SubleaseIncomeToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sublease Income, To Be Received", "label": "Sublease Income, To Be Received", "terseLabel": "Sublease income to be received" } } }, "localname": "SubleaseIncomeToBeReceived", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_UnionMesaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Union Mesa", "label": "Union Mesa [Member]", "terseLabel": "Union Mesa" } } }, "localname": "UnionMesaMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WageWorks Inc. [Member]", "label": "WageWorks Inc. [Member]", "terseLabel": "WageWorks, Inc" } } }, "localname": "WageWorksInc.Member", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksInsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WageWorks Insurers [Member]", "label": "WageWorks Insurers [Member]", "terseLabel": "WageWorks Insurers" } } }, "localname": "WageWorksInsurersMember", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20211031", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of payments due by fiscal year for our outstanding contractual obligations" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r47", "r49", "r96", "r97", "r225", "r262", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r224", "r261", "r289", "r291", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r490", "r492", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r224", "r261", "r289", "r291", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r490", "r492", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r152", "r272", "r274", "r455", "r489", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r152", "r272", "r274", "r455", "r489", "r491" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r224", "r261", "r275", "r289", "r291", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r490", "r492", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r224", "r261", "r275", "r289", "r291", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r490", "r492", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r48", "r49", "r96", "r97", "r225", "r262" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r23", "r155", "r156" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $6,063 and $4,239 as of October 31, 2021 and January 31, 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r190" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Supplementalfinancialstatementinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r326", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r100", "r101", "r102", "r323", "r324", "r325", "r394" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital:" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r292", "r294", "r328", "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r294", "r316", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r29", "r157", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r82", "r244", "r255", "r256", "r423" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r82", "r178", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r374", "r375", "r376", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Payment to acquire remainder of further business" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r141", "r144", "r150", "r163", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r379", "r382", "r403", "r438", "r440", "r463", "r478" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r46", "r93", "r163", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r379", "r382", "r403", "r438", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r296", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r288", "r290", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership interest (as a percent)" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r355" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition gains (costs), net" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r81", "r372" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Maximum amount of contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r367", "r368", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Businesscombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r362" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "totalLabel": "Total consideration paid, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r359", "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total consideration paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r86", "r87", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r30", "r84" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r78", "r84", "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r78", "r412" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r197", "r467", "r483" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r194", "r195", "r196", "r204", "r505" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r100", "r101", "r394" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock:" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 83,586 and 77,168 shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r61", "r470", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r179", "r183", "r365" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software intangible asset" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r90", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognition" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity [Abstract]" } } }, "localname": "ContractualObligationFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year.", "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r65", "r455" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange revenue" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "verboseLabel": "Acquired customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r91", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r238", "r245", "r246", "r248", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r92", "r98", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r253", "r254", "r255", "r256", "r424", "r464", "r465", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/FairvalueNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r249", "r465", "r477" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r221", "r253", "r254", "r422", "r424", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r252", "r422", "r424" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40", "r222" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41", "r92", "r98", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r253", "r254", "r255", "r256", "r424" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/FairvalueNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Five [Member]", "terseLabel": "Prior to October 1, 2024, 40% of Principal" } } }, "localname": "DebtInstrumentRedemptionPeriodFiveMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodFourMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Four [Member]", "terseLabel": "Prior to October 1, 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodFourMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "October 1, 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "October 1, 2026 and thereafter" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "October 1, 2025" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Percentage of principal amount redeemed" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r92", "r98", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r247", "r253", "r254", "r255", "r256", "r264", "r265", "r266", "r267", "r421", "r422", "r424", "r425", "r476" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r234", "r250", "r253", "r254", "r423" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Less: unamortized discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r33", "r234", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r334", "r335" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r83" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r82", "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r82", "r139" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology", "verboseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r62", "r109", "r110", "r111", "r112", "r113", "r118", "r120", "r125", "r126", "r127", "r131", "r132", "r395", "r396", "r471", "r486" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per share:", "verboseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r62", "r109", "r110", "r111", "r112", "r113", "r120", "r125", "r126", "r127", "r131", "r132", "r395", "r396", "r471", "r486" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128", "r129", "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Netincomelosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r330", "r337" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r55", "r56", "r57", "r100", "r101", "r102", "r105", "r114", "r116", "r134", "r167", "r263", "r268", "r323", "r324", "r325", "r345", "r346", "r394", "r413", "r414", "r415", "r416", "r417", "r418", "r495", "r496", "r497", "r521" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r162" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Gain on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r236", "r253", "r254", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r287", "r397", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Fairvalue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r236", "r253", "r254", "r276", "r277", "r282", "r287", "r397", "r445" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r236", "r253", "r254", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r287", "r397", "r446" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r398", "r402" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r398", "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Change in the Fair Value of the Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Contingent consideration recognized at acquisition" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance as of October 31, 2021", "periodStartLabel": "Balance as of January 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r236", "r253", "r254", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r287", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial revenue" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r184" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r179", "r181", "r184", "r186", "r456", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r184", "r460" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Amortizable intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r179", "r183" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r184", "r456" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Fair value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r82", "r257", "r258" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r171", "r172", "r440", "r462" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Intangibleassetsandgoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r174", "r354" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Decrease in goodwill due to measurement period adjustments, net", "verboseLabel": "Goodwill, adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r64", "r93", "r141", "r143", "r146", "r149", "r151", "r163", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r403" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r141", "r143", "r146", "r149", "r151", "r461", "r468", "r473", "r487" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r94", "r338", "r341", "r342", "r347", "r349", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r115", "r116", "r140", "r336", "r348", "r350", "r488" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments (refunds), net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities, and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r121", "r122", "r123", "r127" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r177", "r182" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r138", "r420", "r423", "r472" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r76", "r79", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r434", "r436" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r435" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r435" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r435" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r435" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r435" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r93", "r145", "r163", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r380", "r382", "r383", "r403", "r438", "r439" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r93", "r163", "r403", "r440", "r466", "r481" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r93", "r163", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r380", "r382", "r383", "r403", "r438", "r439", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r19", "r20", "r93", "r163", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r380", "r382", "r383", "r403", "r438", "r439" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r19", "r465", "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r235", "r251", "r253", "r254", "r465", "r479" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less: current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of the notes" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r98", "r207", "r240" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r98", "r207", "r240" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "verboseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r98", "r207", "r240" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "verboseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r98", "r207", "r240" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r98" ], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r208" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Settle of claims" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r80", "r83" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r50", "r52", "r57", "r60", "r83", "r93", "r104", "r109", "r110", "r111", "r112", "r115", "r116", "r124", "r141", "r143", "r146", "r149", "r151", "r163", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r396", "r403", "r469", "r484" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r103", "r104", "r105", "r106", "r107", "r108", "r111", "r117", "r131", "r159", "r160", "r164", "r165", "r166", "r167", "r168", "r169", "r209", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r343", "r344", "r345", "r346", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r437", "r457", "r458", "r459", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r86", "r87", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "auth_ref": [ "r86", "r87", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "terseLabel": "Contingent consideration recognized at acquisition" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r143", "r146", "r149", "r151" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r428" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r427" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r427" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r429", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r426" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r7", "r99", "r135", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r45", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "totalLabel": "Total" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInFourthYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "OtherCommitmentDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "OtherCommitmentDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInSecondYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "OtherCommitmentDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInThirdYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "OtherCommitmentDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Commitment, Fiscal Year Maturity [Abstract]", "terseLabel": "Other Commitment, Fiscal Year Maturity [Abstract]" } } }, "localname": "OtherCommitmentFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherCommitment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year.", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r70" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r74" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r69", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Purchase price for acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r69" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r70" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangible member assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r70", "r374", "r375", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Payments to acquire VEBA assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r296", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r260" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r260" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2021 and January 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r71" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from follow-on equity offering, net of payments for offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r72" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "auth_ref": [ "r77", "r161" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Proceeds from sale of equity securities" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r71", "r318" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r189" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r191", "r440", "r474", "r482" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r189" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r73" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Principal payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r332", "r454", "r508" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r268", "r326", "r440", "r480", "r499", "r504" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r100", "r101", "r102", "r105", "r114", "r116", "r167", "r323", "r324", "r325", "r345", "r346", "r394", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r136", "r137", "r142", "r147", "r148", "r152", "r153", "r154", "r271", "r272", "r455" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "verboseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Remaining performance obligation, percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r433", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from follow on offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock, shares (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Offering price per share (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r41", "r98", "r253", "r255", "r264", "r265", "r266", "r267", "r421", "r422", "r425", "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings (Loss) Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r294", "r315", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share Based Compensation Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r179", "r183", "r456" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r179", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-lived Intangible Assets", "verboseLabel": "Schedule of Acquired Identified Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationTables", "http://healthequity.com/role/IntangibleassetsandgoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other Income (Expense), Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Preliminary Allocation of Consideration" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r296", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r300", "r310", "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "periodStartLabel": "Outstanding, beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant under incentive plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted-average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r302", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Opening balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, aggregate intrinsic value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest, weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r293", "r299" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding stock options, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r44", "r55", "r56", "r57", "r100", "r101", "r102", "r105", "r114", "r116", "r134", "r167", "r263", "r268", "r323", "r324", "r325", "r345", "r346", "r394", "r413", "r414", "r415", "r416", "r417", "r418", "r495", "r496", "r497", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r100", "r101", "r102", "r134", "r455" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r263", "r268", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r268", "r295", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r93", "r158", "r163", "r403", "r440" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r431", "r436" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r419", "r442" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r419", "r442" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r419", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r419", "r442" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Subsequentevents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Acquired trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names & trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r333", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r119", "r127" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r118", "r127" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r511": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r512": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r513": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r514": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r515": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r516": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" } }, "version": "2.1" } ZIP 68 0001428336-21-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-21-000041-xbrl.zip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

0 M9@5W*41"\=H&4?.5[TM(*R'MK4#:TE-*;H:TU[]'^F1X-YME8@*+ =.$8)ER M;HD6R*:DD3&6W5%K/Y9)N="JA=_/>P.3BK]*,? M]IJ#YE23I%=\\/C'?'W_6FWDQ_NSV^U?95FJ>QH#.8Z];8M(= M,&G!,3+NL1:44D2,24"T0BZS(3@*-&A-J(LJL#7 'TT)_==#<:D\N[]B*KST M&%"IPH^OPK.Q(:L8ERX2%' "6@%L$%F5:07G.DHI@]>Q5.'7JL)+CWG<7H7+ MF,>#]'@VYL&Q9@'0%F'*-.(R*&2,U$AIISU/*5*A:G%*Z;%2_?C M2T/\^ H\Z]]+B3VSV",;.2AP2!BXM"9(8IRP]E2YW!]]]0SQ?;-\5MZ3W_2@ M!?UFH7P'(/S]RF]%0]F9\QMW@: %C_Y*(&@)[GP?'A)^FL6BWX=]&%B__[[; M=LV.S0.96IDOL64',>1C9R6_6!X\?9UO"&4-CP0< Q(3P).GX.KGW17MP7$@ M+@2C^-H&K4J]K).[S[!S\B!^\<*4^UFKW=Y%J4N]O8O>SOKWAB7M*-8H1>D1 M%\ H=.0>!:4Y<>#Z89[W0MD#"O25^KIJ^KITM[XTPL^BS'/]>ZB3)+J L,V' MOWT*R"H9D%!MY2A9V^!50^:-<*G/+U>?E^[@E_;WL51VUJTWT0MC!$>" MYD*YP3MDB6/(BBBLY(#'DJUMJ(<4R%VBOK[:;?G;5&)XQ<'$)^XW,^/*'_[[ M[-W-M21JS;Z/K9;MQ.ZPA)P[0<[T"9;\/ ?[&GQU$8/*KKI$/,F$M-$<_'49 M:=0T$$.!)3R$\I=; *NFM4MPT4NM?4JM/9_16AXQYT0)E&B(N>U%0DX:BAP. MD2?OG")^;4/H^<:DL]Q0=;XJ!J74E5M'Q;W0'ME7IWM[]?]#, ME.5TWVHYW:6?9[@9\DN4?X0 REEMZQNN;>;6X1K\+8.<#H#R,9^7QU2A&(/5 MD:JD98HG=LDIY":NKRJ>7']>Z+<"6&'J?<-8$0Q451H24D-0Q M("ZD W?88R2(\%AJC*.0:QL\E\E[Z,97"9XE>);@^4CAQ1(\GS"". '/8*2* M2<"J2*H!/"E!QCN',!8F!J:L(+G)@YPOV%2"9PF>)7BN:"2W=.V?+8 [059L M7")<)Y2$!EKJ#4;.!H>BY#A9%@5-(0=P,5Y"1E;9..>^C7,NZBC/]BF_1[>< MIVNW\KOMYVXJG:*;BCT^;L':%"C3395-[T%"B@[L7P>V$VPO]"OONZ&9)A_Z M;6WSZ_NU?U2X B\)5RN39U[J^(OKO&L.0&#\+9YH*[I!!55J4^/L5V#TE0^G M^5&&S?YAKO;4?Y2QWCBR:C')[[MMN.-9I1=]5J=0L97_?,*@K;@6XO-IV7X^ M+AO[.YVKD[63\JS>#N7ERT3Y![15VA3PN=-:8Q=0_=M91FP/IML%GXOY8<1A M-9"+EB$,$.FXP0$;L;;!U^/(2O-7_&BYVK_"3_R)(S-=K\ZY?%(;\NOG![ KTO,K@^XT!OY/OW+!)RNMW(NQ M7SFQ($S]<6.O_LMKZR79.J5J^?V54M==YG&WAL8;R9]MAV]J*FJ->88K7!X U[<<+K"OM7:36M:[:*"C;O;B$Z M2RRH_&*OOJ0#8"N=$K9S09,N^!5PI%ZW/4>@'I*Q]RH"PHN>:P7#NL]Y-/Y" MFHK^YW_9L\*C>PM!W&VR]WV;[1[MGM;;]:/Z^1>X1AW^?#RLG1_"6&',>9SG M]?9L$+=V]'=K]R@TZTZEVME< M+1I,E/4\!*2%LXBGY)%VUB ;,7%$!CW MLM%OZ;3V0>A7,<]U4IP>(1A#UEP'UE1(8!%396XN24)EREW%"TRA>< M@UU1=)Q+EYK>*)[L-L__/N\_%R*4-Y!])#18S\% $!VXYIH:+Z/&T>)]IM;N MO/NN+W;?-_[7]?ZY<<]-_+=]F3&<<3J*1Q]W1U7NWA7[Z,V?\7*?.L/=U!?' M-\:77[$.I&XXN/XK4S+G8TX'>=+D 00J>74:IO\^[%WN?!U$Y'K1_@"?%0;Y MSK9.[%E_[9]7IQ]F>F;N9A_[VH=+:_E3:QN-(I^A MFRKOLS6:2D>;?OI[R-5#%XW>*N.EWAW$$2:*]:4F_=WF]C=-Z_]>R1E=@J,S MDR+7[8:39JNUV0&#/@!KWH15+.Q\?ZO9]ZUNWM!KP!U_;W7]C^TX^W:J)^_@/7C[XT:]__:-; 6.X=94-=XS4*(SO_<3Z;"%??JI':5O@! M[[&=QF<*1O=TM[U]LK,5VO6<"'=^<+YWY,]W&O54:\#OX3.U(R]J6_"GL;WO M&,$AR(""H[FM+2/(4.H0YCESD60YMC?;6BP6'Y^WZ9I%E9KT?MH>CC#/X!#"H\XNDYN:LS'@+9ZS-YC>M3DV*1GHY\Q)F;7UI%E;JR<=7[MI<&)[HT,. M_X2/8K6G*5>5JO+D6"6RQD G(<@N8Z8!V-\]X9R2B1P9'][=MM MH'ULPCWBG\V?<<[+_-1[.4U)[^=^CN+$[6VR=[0);N;!:>WHQWGMZ$N[_NE+ ML][^<+*WM4WWM@[A<_767B/,G;;=/?J[7=O:Y#M;'\YV&K6S^J==O/=IF^XV M?O]1.]K[L?/I8W.7_MVJT[]3K3FWA68()LDR@U@T&G&M%=*:"J0("XH3Z2!+65F<8HJJ*L5@A&'K=K55[,53^[^MF MY1@<@ 0$MSM'X_QM:DF_L+9/=\ >XW'"3E!BL>-).NU](B%Y;Y+SAJF2 JT< M]LSGJ@M%29")(2=<1#P%AG0@N:IH"-1:29/@@#V&5+5^,/:4G=M63(6)-=8P MBZTCAG-,#>',$VF(+DA%*NG#"JKP+'T(Q!.N!4.M0U)6%7I!V/0ZD52WK@*1R -AB4IP _@S &I$)1Q&;0P7CJB2QJQ@BH\ M2R.((RXY(I"3 E18Q("<40D%;JR*3AKG&:@P)E6V4BK\^J,0X_VD7%(I^L,. MW//@K(Q%7"W#KY0DU-OD0^+1"ZL\448H!:Z-5HR7)&+E$.CK'(E(W/"@,.WG#J6%$!H2Y Q76,2*3%$$)P)B!?!&AQ=J&D56S4AK\^D,1 M@YX-L="4,OXP$P/%%FL#8S ^<,R9=2EB39TS3ED:RVV,U<.=^4P.+[C!,ED$ MG(\@[I)'X,PH9)/SFD<;X56.@59AH5?(=RG##\O0X."B4Y)I:7A>ZV2UXTZF M1 B1R=LR"6(5-7B6.7CJO8CYS!!.F?R;@)S-]$%&XY52.IDB":+*5DJ#EQ1] M6.F"A#?F0%='QW0>$H]X6!.;EX=7)'K*!3BY04A.&=4I:>>=8(0D)Z@L&M!9096IN/5 M,F(9;TW];1*$*Q-\#6@XPSA5B(#G&2,+*&!Q2"Q-(H9ISF:QM4LRIA\^6* M;]]T[JYJ\X)B*F\."IZ PI10\/A0,+=[0UP06'%@,0F@@'&%K(_@W1"O%/?@ MW@B;D\%%5?&'])]\*BAXC&K"UXWMA09O.G&PS%)W^0'*GL0/FI05- VK11+K M\9;=*4LK< LKL" -QS)AHV/("PNNK0L$@8F/2.>S0#(R&0VXMIKBJN%/45SX M3NJS L6'IX>TS/K#);:^<6Q] M9=8NMRL76.86-F!;4>&6QB[N]ND'-8(FF3 M3E;3&!4P;"7S4>\'5YQ8%6R]5>GBQ>4*G[I%^K2K>=$F^6H_XT4-.A=4#LP5 MQ(L&MT_<\/NJJD\_STZ:U?87TN3[J6N;'GTF^X('XZ7A")L KG"T 1EA$B*6 MF:"L)#@G%#%\4U_O+ 9W67T:?,A%4HW"@A.C#"R^%@Q3K9F2EHSKT^OKZM.7 MJ[^4U?]VMA^\#3AS7B441YRH@,# 8I0<=E1Y[K16:QM4K,]C]&3UJY5>[!]' MGRMXM\ZJ=Q:&A[9J*85A*<+@\7Y4+'I');(B)L23%:K6*NJ\7"O.^VX?9GE:(E M0M%C;0 C!85*V56"V:_8 ^!^147'DR8\WNQ#5BOU0K5LJ[(YKDV=%_ZWM:D/ MKOT#;M;-F?B=T?,7MRYJ!(2S7(9ZZK/__1^:$O6O_LSDP=?_+]K6X/ #3.+@ M;+VRTZE\C<>#V,YU;JFI3CU3<9\QTF0>FBO6QU#-_>-.#IO^\,J#%PVL[9T@ MRGFN/0T"_%&3#91UW%K)%!,&X)*;L8$R8P.%#36+(>KPWV?O)BTA/W9[!2)M M7DI)B4V+"_#OXIW&-JWG<6V!;WFRCXWB01*% @6XXD8[9#3F*((SH8.0&!N= M#_"N7]=T=@)7Q\.>/\QM!$%+_,C]L2-Q2B!E(*CV^+C7/87Y'P L5:Z5F78A MEK.\)KB($Y?*<86 G.V\WD?V\!-E D91BCB5 MD.2L.7>:S+SH)DL];2ES%"W*N M,S3U[TYK[[7\5\%B%B$F&\:CHTZ;G3#ILM6,_9+?W%HDS@%#C$G@4TB+DA<> MY2U?I'%4R">E D@$54ZN;7!#%OB]5T$$8"+;KM'\KU=R/X=+&]KL^-8P1!"? M2COF5FG-?CL;-QN.P!P6EFD&A!S\&"ICFSGN!''E%D L!D/; CP:7$+!+RG3 MXAX[3]W)X]-%_Y*9T3XE+=H:]G*7C3OPU.I%XY6\H+U8+)$[>UXW]Z)MSQ@. M1H_U%\Q)M[0,U\# IMAIP-@:N^>UK0^DGBV#CP16 4FL679Z.#*).N2)"SH9 M:9.U:QM,KE^7USY!@3",!><%H?IS.&Q7-J?9/Y"]2AKVX,T>"-!H:8K(23_& M2FX[56$%#Z;_^GW8!Y',S6"Z;=?LV-'W 5-Z<=32I=.M=(OKC/HN]B M\].VAD4/K@N1#7>6]QDT>4BS/8[OWFR//EOC+_FF&G^!3]1N#@IW!+C$^V*% M#V+' YM8N<9?N#;IT'E4.ZN=[[5V\Q[6]VU1:XS!HO%WHZ+? M\"Q8U,ZWS^NYBV?C]];NT8_3,5B< E"T]QJ>P?U.:Y\^G^\UOB0 HM.=S7T= M8XA1RAP)LX@[K)%F-B$B'5-:4BR2F>WU!;\$4FD)CH3S%*C3&+,DM,$I,?AO MMM?7U#H4---/K\0]6GW]^OY7Q\M E!Q.K#@6+D30TA*@0)[PD)B,8H5;@TU- MW=S$/(+F]'N#=UE/>B,.MG/1??YC,]O4W6A[-3L O!VB)^&:5 MZ&BS& ]89R#?'UC>& Y>26(XBS\&):P5&S MKLWRNZOI=2INUUSM^3O!E6,MQUJ.]='&*I^HR>+U#;C5/HIRG6\V3+.?IU_-4 M!)]M J)0SM8M9JL[L*V[D);'[R4,5U@8$EEJO.YVLW/M?EEGN""#(D6.;70^ M&LQYBMZJR&A2W@K,DTEB\1&[J0R*2:![*[K!=J<_Z TSS=PNUX[/SS<:_S1KF]].ZE__^.H_NDSJ6_] MW=IKUUMU>*_^Z8_&T MON7WL77>*QT09I8AKE) -CB)C*,Z.<6$5'AM@Z^+^3WZ_UKB/L[MSC=5OL9. ML]LK]O-&G@Q(IZG\1OXQLYOVT"(XK_WXVZ^>^&6?;;L?J,V?;?NSVSEHQ%X[ M8]MXSZ$9^U_B)'Z\D_[J-3N^>6Q;7V+;-O.NXDZZW*>XFB*0FJ7 H"G5P#P\[Y2(A*2+%)& F81F_L,>HNP4<$SK(.V9&UCO-W_V/6RGO'$ M\!TH8(F$)1(^#1)N=^IP^\9);/V,M2(-IH3!Y<#@^0P,ZIA3J)A'6H4(U(T3 MY**U2),8C(1?&I9*&"QAL(3!9X'!S ;)]T2_9:#?F0&_4*BV"0@@1X'@CB/ M"ADO 0(Y]4Y'%2G7)?J5Z%>BW_.A7ZYQ4>+? ?"4Z%W-9.J(ASX(XB MAXU$D0E/.&9*6%[B7XE_)?X]&_Y][ [+&."2X$_,P)\E0>L0+"(66\29"\A: MHI$G@B0F F6ZI'\E_)7P]V#XRZ>D[P!]FSF-83'ZK6C]OY<"@:>U27W5Q@$\ M]X=]#"#HL'-(4^H1MRP@+;A"(6FLK!76R:)(P^(S]R4&EAA88N#]*6");4O% MMK,9;..>"\PP($NC#-)YKC!Y6=CV1 V11JEH3Z:$61LJ?W;A M;A^MSW52SJZDXY1-93/\1&>3$103<%FX4=IX0:DD,BH<&,ARF9#RDM#J;"XA M)1)#E)(@R3((Q,$SS07N.;*$>ODBQ*-O(@_9[-M)!) M:XPE04E3#F3$4*3A-RA219,0!DM-US9T52W(DBVUN]3NY>0.E$K](*6>32!( M449N<4#6YP2"% 48[:@0<5)Q[4AB&*]M$%45*]4DOM3JEZW5\WOBI5X_2*]G M-\859GD)':)1Y)93!"/'E$2)6<[ 7$=,4JG7I5X_]EYOJ=8/4NNY#5^M-%4. M/&N5NQUAD9 +6B*I(G6>!FM<;BTLJ[0DX:5:EWN8JZG5'(*V(1 MSRUR-',N9[499BTAVNK<,7PI 94IX>1"1*?;Z_/F?UW>F4 MH;ME:O#L/IMU+'B=/"(A!,2E$6J\.RNFF3_/WMOWMS&D:0/?Q4$8R?6CF!QZC[L?15!6[)7$R8YLNCQ3_Z' M42<)"02X."11G_[-K&XA[L0V8.YM=9#9#( )[N<2? <1+*,GCC+ M-)&&V:P]=4J[K2=PF-M&N(Z5.U:^(RMWW'NOW+L6,&,Z91N+(BX&S!WWAH!8 M!CG,LE#4E*1CVGK"I=Z6]#$ITW_/16P^3R8Y+S;^-]SW^5#U\_E8HBY:]K# ]/)2M$PZ&V@, G )IZX*98DS M.1)M;?!@_4?M-=@'VY+I+QK&;QCDZ\JYZ9BZ,O736>[*U!Z0I=?#9XX*Z9PS M1% #Y@&EEGB?+8F*LQ*9LB(',!3XMK:?;"=T//W-\G071KM_5K[4W58PPQ7E MQ'+,=@>( M*!+DLC>%^%0\ ?*(LDB:J3>5F:WH=.V.F3^%F3MO_#WS\J6PFG-?DR\7 O0KN/C+J[VX ZP2W$UR0/S M2A##.+"RD($$;CCAD5L.6K95F"^N^+;2HF/E+J;V$=S\?!@'LS1_>[(_FK[* MTY]'IR"R8^X";_?+WNN5:DP)JJ0C)10PH5F1Q&F320[%BU"D4IA,SBB(:OYE MU>YOH5+ME]EX>I+'/1__;]:?]"N'?B>_0%G:X]4QG G&..%X,E9JHRU-QG,; ME=8^&7TK5-H%4)KN+O?XY]%PTD\5HT;#KC3MLX#1P>72M!)B-B)D$K251$I! MB4U!$6.$,$PG:G,!5>->N]E^-EWCB^?O="R]N3JM:_#ZL?R['EG+B9<2:"$A MND1DE@9^\QR'CVA52E(/,&JSX]]OC'^[89'WQK^7PFELX]^.?S^1?[MQA_?'P>LQ-%YT!K-=D6)3G74CB=>6$ZTT%9YS M$SGO.+CCX$_BX&Y@W_TQ\'K@3 2G5-*)"%\;1U%+G$Q8RJ*>>.XDL2P( M[D0*A8FM)_J+=Y?]&G-R.J[N@F4/P,+KP3*PY@UUH9"H&;"P ",_>%L(5Q:T M 3#_C;H_9WO'Q-\P$W<1LWMCXO6(&8=SLRDD8IV*6!Y.B1=*D<@I-FG-QKG< M,7''Q/? Q%W8[/[8>#UL%E44WA5/C.*,2,X*<3IQDKU@SFBGK+F_L%G'QM\P M&W=>]_OCXDNSSYA(G"I&#,-^K#Q%$C*.(Y;9>N=YL8QV7-QQ\:=Q<1= >PC_ MUGH 3=L20.P6(G1 !Q)3P \\J8&5C*(1*37"R9)6,5?PQ^ZF^AMNR@5I8AJ^$.S_S@8EM'U569 M/4!7BKKI6,K:G]8&%+_,IK-QWNL/^Z>STZZMX^<9T'BX.UW7+T3)5@6:,)X? ML'.4(]8$C^W@M!%2*^K8UA.SS>0G%[5_<^DYWQQ7/YWEY\.NA^.#\N^:8D&# M/-NO+D^AB$'%6421'-+@3<%=H,IAA1#I?&6*ZX"V.O\D[NI=ISY37 F M^LBG)QUK?@1K'JR+S2!"Y%&16!QHO%8G$IRC\++X)+QT'#7>3Q]#T''FWX8S MT1.^QI5=%.M!K=0V( U\*^$YWA\QF60RQI,L(C8HEX78)"RQ5&56=(%_NSJP M+HQU![':V:;WR[![%QDV1NJI=(F8E-&OI -Q2GBBX!B3*)PKAO-^[",;S'U3 MQ&HT3GE,FN_\@#>9C ;]U$,NV7A_\^BB5X>CJ1]K (B6Z,U(%1TP7K/E^QVV%D>\='R0H=@TT MQ]Z!Y0/J5 @><^ZCY3Y:+YC'#M1JF]UY,L2]\-!]:EFW0>IU3:N#P0X&'PH& MN]CFYRL,;.#.)ZZT$(;H; N1,F7B=*"$,9N4%T["(6\],7K;J+NJH!W:=6C7 MH=U-:-<%@A^X=K+!N6@S$\P*HEFRH-MAWV!A#1$J",="D5Z"J6W8-J=W#01W M.-?A7(=S-^'<2MB\@[D'J"UM8(X%ECV7FGA7!%BOCI&@DH,?DL>4I!'98$A] M6W+5P5P'8@=#CW -6WK9A=37H\K5%)E_3GT89/C_U'_[Y'_@QWQA MIWY\W!^N+.S']B_M:N;W)P@[/S"QH^9HA+D P^D/I/G;9^)'COSX'5N4;'^F M>U[?SLQ^-S6.7NZ6AVVWP[ M_76"S2#_[^_G?_V9S@*7>N_#\P_[%7A^&KQZ_>;]_J_/W[\Z??X>P.,4P$; M_=[O_?KBPU^'OY?]IWOJX.DNW7_]Q_G!X8L/![M'VIB46(BD*"^)U!1=7$D1 MJ[(5R<4@ RA%3M&=JUH] (T.X%7SHC\!XL@3. \@DV&> H' &89I+_4G$0^F M![34ZT\F,S^,&>AB,@4R'%92P_!-'DYRJ@W"$48\7B7X0?WLY"3GZ62G=WB2 M;[ZD'^?><#3M]>N,:KA*?]B;PA3($5I_5DP *"E[VS-ENKY^$L3W/] M*F#/A<^,X67/GYT-0%K4D[P!Q)I7\X]<"5( $/#5-9Q246OIM(O2@]0,WAFE MF>66!\F8*FPS3CW?_^5ZH'K>/LOO\"@OZ^/].X\CO.&/\P*9"/_&H&GO<%<= M',+KPU\='+CE) PTD&!&(E(J3@-W2(T\21 C%."2H-#OV5(8>G=5.3Z!MU$M/>OG]67^,K_VT]]:/^Z/9 M!"\/[TQ/QJ/9\0GPN6!5+,!*?)7^^*V*^Q?ZYDQFH5DN"(71*:ZZ=R>UQ3 M M?>(Z>R.C $ITG":6O =L\-(>/44XH)PREH#/H]QQS_VV^ M96>K;TUSN0 /\/O>NR/).95@WA"CBL")XR3M8U9^7DRGJ_B M#+0,$L;9OR$>PRD_^,$[?S[9^N=%%@=N7MN[]<>^\N%*N>>':[ #I/JHZ6OY MPPQK4_!36T\.&T6H]-"-B@1S2>(TZWSR/V'\SR>;-F@C6PC07P(M(B9)I5+) M:L^\+9')5(3.:AT8< 1><87:+"7@208(X=$DIW(NP@:Y=0V ZHL JN\+&"_M MK=E(.(L^HA&4SEO*Z\^VY,VT_KSQ3PQ1]T.TF(VK7MT+,T ?@*#M^O;/HU-8 MT7FO\N($S>+1 F4F%7F6Z 1? )49W_7](0A75)[S]!PO&D<@'GU%L'%N_34- M^+4:NA^/X>U^;JX)*/BV#\HT**8]V%10T <]%'NGPS[H_CP5NX>1SX_FG[ M(*?^'#6S4Y_P"O!(@-"K6](Z>$JM_]J&?9LV5@9Z@<[S%+Z;A_7;%U8*>D4< MS_ Y>X.^#]4Y49]S,@-]#]3PNL_O3N"[N##T;HU"Y<^ZJ.9N57LJD+'P%[I]$R_60TA*N=+]TAMU4OOS"'_9:/@0C:_7EL2[Z2PW;/ MQOU!Z]S^$X3&GZ/Q&R32/(Y]]#OV@21K0*)ZKO(81$;U-[5F+M+%!5,7:&XO M3_QV#Y;W 4ZR(8H3GQ94AV(?8"@GL#70,^:/@?B/\:+-)1<^KSL:H\K(D+3+ MUJHBH\XV)Z6CTX8)FIP-C6^*2D&OMD%_ UC)^6!N+6$RUVK@K(M99J ^V5))%2_!G T/L*&( =_W/!K/EX.KGHM+PM=:!S M]Z#,([[L FD J\8?TFQ\7K/XOF5BH/O'1Y1Z'IQ(A+J*?W4RMXEV]> 6"KTG;^D3%HL,=#0&$DSPJ=9%0(7L[C,.3M M=7_>4LK"6^BV;;OWQQ 9"_&[!^+@M]]^[GV'>@NG/R[?J7]@/WZ_TSL8]O9!:\(P M04_- Z0KEX#- &4([K.4*U48])ME@*1(N?C98#IW;"Q%RLKQ@3BH^S'W3*W< MH.I"N"WX4+,,^@,(TB%N;']E:1,49P;%Y(Q0D@6 MA#?&*6M#=J$X6V@; V%<7A^K_2U730& 8IQ!"SI81I4[B7+K>.V[@Q='5H4< M="HD!&8!1,!$=M1(0DWT+GLOC:3H];RJQG3A^FR498"*QF5^ 2'PK*J=4 ^K M(>0E72/O@UK?>DL!XI%X;P"@V/!:N$)T7P.[5-&L$Z?;*W_ >:=:L_G@T2H@8J$L.ZV]C6)T' M=?>XX7NXP%O@M'K&3?0;,6*U/ID 1TY:>Y@2S/ZJ. MY^'R??3(P$;#!X9]W_L./]0*C)?( S7"U?NYWG"WWO""]-@#:&>Z+M'A$B_D M. !6#E--?#@] YQO95>SUKG@RLAV]9UPMOLV< #D!]VU7L[W)S@9U8S(+DW[J>^"% M!9]L]YX/XT[ONZW%7[:^WZZ@@+@.Z_KYI)\+W!)N7P_FH-I1XR9W8_UCOP#K M#$$-&"P^-D*#^<0/2O7*SN"X@>7&U6Q:\BKJ*B.DNE%\ Q^?OD.3'_>]V79= M;];0"FMHI?$%+'<=I-<(?@SR,1[&ZKZN[=URR\3:EHW[U5U:=-,'S &\FO1:D)KVFY!G1:WYS=KG7V42T-JF2';(!U\BJ^NWT62R M]-^=[Z)_Q@]V%_E=__>[4A^GRI9C6M;+B2RNU!(!)M$L2)Q (Q4+@5/A?2L M>J$[).0GFR(TD,A?$ MJ($=8^P!)1!H 8/&U_6VIAHW&8%5/E4%',FJ1D*JY=!\?*&= P7MSHYG($@Y M;; )[]&?M$YK].4/1^] ]H&4?7Q>]RM5W:I!<-ZH+W4'7N:S:6-6Z;D"?"4K MM0;..CM1L!Z+8F#/,QFML"5IBFTSX54.U&%F$[/444WFOUR1\5C=RA>9:K^F M5AZ4WYI;3RX["(&EWHW&:9*'"VZBWQPW/6-[[XZ8$2G%E(@IBA-91"$N!$I< MYBDJ%8R+[)J"GLVG:W72T5%+HRH2,U@#BT5:P2(/@FG9GJ[FG,Q_Z4[W(4Y7 M.VMX /&ID),DY8(X)S2Q4F05X"QB25M/IN]&EZ#R<@8;F"3]MXV)VYXZF@7C M//>CM#8$F$XU^KMJ)LUMD=;B:@):XR;2NV(U#%==F=]Y1,O3BK +8^3[6WID MED;S]HH;YJ5'VVR:1PWT^]9LK0^Q:AM7X_E?L\%YCXNE@3_I ZCZ\89]6+&< MUW>A?>)+.W$/6_!IGH31<<9/-$ZYUJ?P=/ED+_%XE\Z$NEUHH[:NMG8)ZU_H MU82@ZE9&BWV* 7WX6N--J&9E:;(&)JVIV:2@G,\U_BN<&FV27L#]K644=3TK MC@GTF,&UL *@\8@G?PJ[B &,W"84U!J-G=Z_EU_:3$DMP+6G.5QQDZSX3I;6 M.WRT-4IZW,X]+0!=U:J>K%C1ZQ1Q!0%<<"[4"!SN>KU:^ZG&1X ?W )*RV=^ M7',#RMC/TC^7#KS23[-8'2;HQMNZZ,WPC?V]$N"H)(S1%83=5-T+H#&/IVV2 M0\WJ:)^YY0[4"1H?/VV(Z*(F51V(BZ>?D_WIJ.XNT$?J3T[[D\:A<,D5=?F M%VF60$QSORW&/V)N@Y/9#^K"+IX&6H?+M2T^.;][N\[VCV=KKED@YC9WN[G& M99=%U?HP4CVKUUHASC6^;+\%"B 0^+AY#&"/\Z]P2RMDXO\6,^,'Y0A&N M.4%KV3FK*3W;8Q[4-).:A9G1CSVYA#Y7Y,9]GH.XD$C4VK@+[VC-GL+(2)/-5)W.\P*& M)C\4BR(:$-_N'>/.#7$GUQZX;ESU1&Y73%C;@.T&$-#MN&".*Y/(=GK/IXWA M,\4(SJ1?$YF _W,3KVC"J+-!DXN$M9]-H<2X#4$TN8IXQ9K3=*OUPY?GRV^O MTX<-BVWXY-)U-C]ZDU355(T,5]W1BTRSLG 9S[-;,;=M L]2*:X-0R\RW**? MG/3*8/1N/4?\L?+\+LKS_YOUD<4;C_2ON[O_OAB4QR@3:-HH+3!C;U)EYVC< MYG7B6/4>6+M85+.2T :/=[*6U;::"W<"TJ>FSO6'%2V;>%8C*&K<LNC7)#A2$/^AFI.'@$;5CP$I/]6]]OBH+ZP\:J: .7N$2XR'R1R&A- M\C,"SQRIYKE[R(*+QZL4V#K$E^MO]@YII>8IX)-@24A=.GQKI_>_HW>P2-#/ MEI2*GP!6?]V6.?:'P-"YAE%;W6*1/;F)6M_V\[MVYU:6BBF.;4CF0C8CJ :H M%7LT]8I_.VJ4C#EWPMU'$7:MTD)-1NQ/IHTL;WB\.:/%2LWY[_?G,^.0(5W[_F$(?2%I/I4D;,F<1:&8;5UJE[09/M4X;N!PRM[ MMX+K;(1GU1AR:, T"V_GS&^5A(S57XT7V>ST[K$@Z5:WOXZUKLO(_*@RTHMAB[9HU+\' MPP;]UT !AW#]GP:C^.9+N];.YZZUY^*OTQ'@\._3O;X'WSOZ9Z\Y%I[G4[_>KK_9N]PC_UU^.;]_M-_G>#:]@Z? MO?_K<$_MGS[[\-?AJW=['T[*WN'Q^_W=(QU4,%D&HIWF1'*+ ]NB(-GZZ%B" M\[I:TK6 M2@DO<-GFNKR;;O=X\715]W9<_]XRDA!NZ?:^\MUA2O [Q>'JD5[LL]$][O^>S44V3>9 U7KNB[070HR]E-FTMYEI0LRRYF=O# M_7;!K5 ,EMJ\3N]W8BJ/3S&X'P;],0AJ"+5W[%LHX'WR:5@^L_;7+L>@&#" MJS0M,]![A6TSZB=!=QVWKD'\&N87 V$1]*?AV@A^+8Q&;^:5\M^A3OS]94MQ MON:0A[F .0&/>]'RZ*_PS$[OEW8[IB?CW"SIUED%E\VKI)!" MLR(DD\ES*52VV0>?@2>!*:6UO,5C>TU9_P045_CM2IA^UB0W_]0L\"N))W]F M((>_BR/+C C24Z),P,P5%XAS"L=PRF!S2MR8N/5$WJI:XC.W=NAHX#YHX T] M2CXS5,B)4J(0J;&M@^.>2)65 E$>,JM5$CM7M5U?9#BW78@ #@?G;>R_4<\; M7QR@QQ(O-^#(N U?W:UIT"?"B;B2DI[-U[H@*6P@U(1B9R 8#A;FQB-J(O2Y M">CPE3KBDAMA#">B$E!*E%A>%&%2"CB$1!VE ")R0XK\/RIRW.W /Q$[N@/_ MM ./_,B'H*6,AC"'+.%R_N" MB; 2*- "HG&0B3);S9.3[3GS[ISO\YS??#A*"50-I141!:NK)*;HL* (M4RR MZ$"H*[GU1.B-LN-CH82NJRJ?8"=A_'N0(P^Q.&B] @!#2M?WWV'AOUP!=:#;OMJ?CMTC.L@1X)KWA6 M6A J4R3218W3/3)Q5.=B78I>VZTGYIY@ZS.K0AU9?!19_/'^2 LLJ% 6+"OJ MT5V: .98P-',AL4LA,3.FIQNL+'^<0>]9P$T:&5C#FGKB=Z0_=_@RSW+I4_7FSH >GBZ>?[A"!2K M6"A/0#N\X%]-OA&PWT8ML^[YO_QP MYL?GU_CI%W'RZ0ASPH['F%OT2YZ1\K"UIRZ2U'I7]K#EKX MF]A[<41SM$4 UH-9G(BD.9 &AZ1Q0MJC+.,R>JBO6J&TL?ZZ7U13!I06TOP M,BAOX0'@)8\V:)NH;[L9L>[0[_G0#W:/E/(R&6.)9UX1*="MRH0@(;C(N W! M%PJ'3F\Z]'5C]WE9P<_MQX0!AR=^^N=H-DC/:QK00@=HI7]'+9NIY?E[@ @- MBJ&)&3 AT4"D8B#@A2N(&*#/&^%M,95:Q T0T::7WD:&3'KO\+1ZOA[46M.* M#6JFOUK$?25)P1<2,_J#/%EU-3DG_E>TV* M:^UD@EFKF-" 13'SWCCI]6PR;=LAUDR"LU&MY%CY.WYM-FY4J>UFP,RRP5C- M;:YIJ^X]GJB M A:W7\@37MO$T;#F))^.QGGM$$K[!+7W6Z_FFP)ETG7*W)S">\L4/WU-BM\7 M3NBSWU1"'PZ(>7RY?/O]N>C8%?M_/A>O/AS+5Z?/Q?Z'WT_V_P38__7Y^[]> MO^&O^.\G>W_^:_#J\-7[2Z+C:62O7J?7!T]/^J]>1['_ZS/VZL,;^NKU+Z<@ MNS]Z]._W.R__J7LH>M$K'#6311>H$=$D&[3"$3:R@GC'D?H[6!&KZ> MRY>U@'WUSJ<,.^Z\]=Q([4TRW*:@Z.55CB>QE/)NL]5)8';@Q2F997,E9*[%. MAY]15_AM-#PFM8%L'9[6#CG(:=$3;MY=](.+/W\#SLO MKI[;+/?RN.L#H?]F>]9Z+3?OV4U\X>,;,$!!*R3M&D&]!K/RZ@&X=V689NSM M=9K 9]NHN\5=2I;4YQ"SHU*"G>U-%KR8Z!5%T:?^UI,2/U(]:29&O][C>_RY MW/_SK\&KUR_>[1_^#O?'KC)OV%]/L2O-B_.#7_\U@/N_6Y\8O??AU8=7KX_9 M7Z?_Z>\_W67[O_[G]3Y.D3[\SYN]PY\&?SU]#NOX Y[UI[+WDKZKTZ)?TO?[ MKY^_WWOIZ%__[X3&T_\,_9]N=O#Z/R<'?[Z">^[ROT[W^WN'+]1?KW\YV3N% MO7H*:_[PAN]_2+"NJ/[?AQFD#=;HUNWIM /:G\3[M M/0*1N7DS_NNJD=^?^,1?%/PW/^I=VIY_%*"12_D&GSZB6G3H=AMT>W\!W5X< M@:'M@S6:*%44D<$8XI7@A%FM,9D3+'*PNC6EVT!H5[B@'X8S\*T[N@[IN$.IZ&RFX$L+[Q'-)5\14/P'J2O]]3N1#'H\Z ME+L;RGU80[G@!XIVWK23D?]*E#NSC98J?]\ MG*7UV=@19R3U?AO!W7YI9F&?7VFL\[L]ZT:X_?I * =?G,+FCC9)9ZR+0+R: MZ6QH$B'*3M]Z5$C4OZ1O:2^S9SP2[HHGTA=)K(>7%#N>6L"?H,O6$Z'N1=_: MS/,/JE6MW?)*-]FWR;XT\^)IR%0#'5@>K0>#6EB>-;QBXJJ\K$Z'^ *^3U1( M/A?K_SW]&[_ER>0'8$=04& 96,"%'6MJ(_ZF[ CGC<3 /HXYT#/XE&7Q=8S%*:LHE MJ"A:>B*MS\0S6DC)10D\Z*R1P?6VI)?[S'7^DX=+TZA%YE@>54N+._?)Y]=+ ML$H-HU^(21T&W1L&]2\I&58K&82+) LNB P /YX517()S#*AX3CYUA,GZ#;5 M\FNQF3IWR5>CGW2,_D",OJYLI!BRM@J'B)= I-.*.%T$T4=EQN\_MV/'TA'*W*]#]K![PGE[M*WMQ)N%T#0<"JS5>;^_>'"6CU M!W)_[5AO9%,^9]/+O2]O;G%XL24B+]AY5H.EKYD$NS]0$X0IP;H00M)NZTG- M\KEJ;OUG>MJ+>V]WN)QWWKR\ S<_T?-A#R]7O]+.6/X2?Z0"$CC(>A#*.CZCD M7% 6")9!$XDM[WUQFFC)HLQ!4>UK:L?.53'5E;[WM\V2'.=!,P%^M!8HN*[# M_75#7"Z.R;D+?8KB7 "><%DDR7@,.I:43)"!QEBROSURE0P:6OJE/^SH[L9^ MQ8=O^!'#N>DF@$*4J"&R8, OLHP3WH*D-F?/,W;@NRIC\&,126@FN$B,V1AE MRB9$H[Q/(INB-"_Z]HC4G?CM3_SU[H&T>J-"U<7V\/'SX_-W!X0N^]SJJO=>OZ#YJ M#Y_01O4V74V_/)ENMC0/AG,&[=D-D^3JU+U!1N:N(_D*B K$$N#KNXBJXJW* MQ8,P M.*B>R,QRU2BG%NF5XTF:+V3N0-4);O4N;US0FKPUUU< AK.T0B_^-\ M_]T1LQQL61Y(L1)$E_>16!D]L1KH Y1D3U.NW3DW"*_>0E,Y/A[G8YPX=+96 M]XR$@81R1_1[&/+HT&\34>R__D/M?]CE!X=1[A\^5P>[1Z50PW20A$NLXPM* MD^ R)9%KZZ*,%*R*NX%?[SL$$>PDPNF/]:WZ._OQ^SJ;JOWTNXSZ!F@] "_- MI"N O<;G-H-W5J_Q?/[7^76V>XW.<0F]@! !H%8PK &T8U U_' Z&D]Z9WX\ MK5.TQGDZJD.K>G_FP6 "JM'X>-3[R0_?;/?VJ[8!A+T[F8QB,V=V&U4:(*[) M-.>O99HH[C8.UCH;CV+.:=(KX]%IW9&%NMF.(6G.9#HZSE7CJ\/+PF@\KJ-) M)NT!U7UM%,E= (&,?':5 AK]Y 0UQA-XL=T<]FS2*+3C?.:;06:CV70RA0^@ M5-EXMT:-O<4]OZ+)<Z!WN1QJ= NSU(XX_F_13WX_[>+(G?KJ\WZ01Z&'0/VX' MQ%USP'5@]!C'[?[?K#]NCC"L+Q[5A2O67F:5H:]9SEU6 ^00\WCJ^\.YN&EL ME/[*:*D+, -BJP?* 2YAM-1W&H/#[?3F7GXL1G)T(7=.K7N_*@Q=' 8R%'#PCP0O0 MJVS"L=HJ$A%UXE';)'Q!$6HNSVC]QZT&"[;8U$*)Y$U2U]EH4F,=/U1G 1S/ M[ Q.';CJ+OUT7C>"O084L>+I#9Y;[*)@"%>I"2XV#@0YS'*T-EPDN,, MQ=*DT457Y2 MK+G1\LZ-TW^X6,+-EUW*Q&8:Z[2]RE>GQLP%)6P#".A*OGZZ40T8G35:-&P. MZBMU "O\COKX-GX'#VC:/ZW"$-YJ1J]>%->R^6"]V6F]'-J@H,3V2[L W,99 M=5+@$ACO@3TP/9FL".;O^M^O7Q4/Y6X2UW)L;J2H JM4LLR]"Z* MH=%@+26C?(=O,EZW@18N$8.Z.S%(IV1F2F /3=2^EBRER(RSXG)S@-H:)%'8>ZB4! 6%53+_K)PFVRR06ZM.1"1HDSETP-B5UT ML?@8Q^@ PW=FPS/?3PO+A.<4(^2M5%#5I=9KAL%-I( MI5,H46'Z#!>9%IE#QP/WSP-/]]3!TUTP4O_XL/?ZV;O]W2.P$I1)"H@>Y:3D MSA G#2,2P+&4P+BI"52;Z/]6%+_=.QO,)O6U/SL;]&-5"%LO[JE_DTE5_5HW M+ERK9CLUL>*&/>Z;(592 B]JF6?5LPAT?$G%G*[Q4,L^L[.[4[U@*1JGG0_, M2IJED\GD:$"0!.ZE?#@]\: LFM(V,;+?6Q#Z=MEA/?"[]WKWR$170%7$274) M^0'4!Z_A,(R3L81$/5C36T_D->QP?31LU:FW$NC /R]B&M7>&59D/D48'D40 M,-5Z[6-:T,H=VNLN$'C:>O>KJWWAXH?;KEX.G;;3\T7P=G*_L/[%"+RCXR4= M_W%45*GY?MBK+A.9F""A<$MBR$Z76%(,F/Y(,8KWL=B^HL=4D+]OI/YE-D:] M"(GV,@:'B^$'%"7(&Y6J\0]GLW$\0;ULN=S96>M5G_C&IS8/&\RSF<;-1S#? MJ%_ZL?>F/VS8!ZXT/,[-KT#LX]'@*W+++'$%UP[/.X%?WN:A'T[;L$O_]&P$ M.S7I'P_QN3V>\UD>ST.>U=%5LP%A/9B/-07.:]UIP]6#^;%W,GJ7W^9Q/:Y) M7KG/<1["!='#5CW(C:[;Y([-/]*N#G-+AALC/3N]ESGWMM;_O-4$_##E W L MY4D<]\_F#3O6UO'XPK2;T\76G_&QK?KCLH=JU*">+_H^05*]Z\7F0?TRD+L2 MY5_?A7FP?U-0'S3&)EZ,U%>MLD&NHK4)<*."AP*R*GJK ?\+-_RM?F6R3"KX MU[_W1N-CV+^?*Y:TN0 [NSOUACZ=]H=]8(<::X&'J \ U#N95:OPS$>0M,T> MM'?8/;[P'(T?H?<2H]R]WV!#>\T2+L2SKV"'[QO]N#[K;__\N8>U 6O?K,_8 M'WZ_GN, X(C!_NJ#?G?2CR<7CVF"E5/]R4E./WP\OUPLY)%JO8B*F\],G=_U MOV]R2V_ST\_5GK9L;,U_([/0DH;,E)7*<)NRST7:J /-*KF-2LYU6@U61%Y( M6H.'C#^DV?C=:)PF>?B-:31KSIIWZ*SA.NL0. &-$GXP[DAP@9$"?VV61 KW"J):&EA?:V\K5%L)L(3Z:[)RR*KQ:HL2$GRNRQ%"+ M ]![@U<$"=J?M@IHJT#"*L9GHYHB T(,U=:-,5V,J*ZF%VVW=0SS..!RU?!E M'\&.:+(@FL>?YP^]A4?!AYC\B'_^.TG"FT3A]>(OZI*3]YJQE"53U FC@DJ> M)\U94+03?_A?Y2GD2NG!F#9R$#3EP M+U1**= B) OV"\I7]XV1]II\Y?LOCECQH+N!?$W>:2)YT"18>!FC%\9GP;7' M,-PFZ1K:"H3OFM#9W8A": "O$ 7H\=)Y;IT)-E$AM;)&!+>9*(CN=*X'AKOW MV/JI:,^DT"1:K8A,.I NA9)S$=.HQ-.@+9_Y0RA>64*J !DT#]%?!N-+V6Y M#_(4S(#&JU>/[_NKU+36X5@5M4>IH'PE[LB7L_ :D]7;4 4:8]Z7Q_JQ&/]#I!+\OM.G&2S3Y M_K*'N;U]FYA7->'5NZ#Q6'W&J[>[)DW]H41;=C[P&".34JH 2C_ESJ!1[$ G MRS>*MI/_.[\3A!V47^J&_+Q\Z@[5-J/:;EW/WHA=<*+,DKIR(NC,DFW#)<)<>6B"9-ZXE:F;3!B 1H:PZK M]TM_/)GV?NOG86\?..XW=-O[8[#HT.M_*_*+Y ]7G61 A_<:(\%)H\,.KHPQDZ+36!#87J) Z0ZS)B12P(81) MQE/J@ IW[&7IBN@$BAAM:_D7@;OJ[]X(B'X.G4 ]7XF0^NF:(K<5_T4 ,VM9 MM%,32>#?(0;-J_2?Q\^WY^G/H]6@U#)PD?M5F&,6\F_/?SKX'7@OO<::PD;5 M@*OG,4&\SXP9HA]NU&Z-PJT:&$(DT&33< MPC7QF*]LF*19,-![?42K9U-JZMVS,K)UUL48K,32,)LL8]S("):.LDJQTAWY M Q\YBO_H,C8D\R04RHG4 8"7^D(R3SGA] ^9"A@UFX]\-&Z2TQ%E!@ Z6"'2 M"QB4;&R-^P*'%#@86$5J6RP0B+32):7 ^&+&E^QORM_I*.63*67_W5$LUAO0 MAHCB7&);!D>L]XDD >JCXBFHR+>>T'L"AUJF8&TLA3(9'0\T%Z5+K5^PHICN MR!_XR.G^[E$6AL/1&I(-]JOS$4=Q\$Q,\$I0J:3R]BIYL+UTO:XDV;98D#*: MV4V8!5-7"R@L-<:$*1B#5DLFB"2I9OXA;AR/^^EF0WRGMWMU2Z?&GI[4/AMK MM)&.JL*X?TH.Y:%\I($Z7G*2!@J5J M1,#<<$X"=Y)$GF2.G&;L*@?$:2]/R?S',BYX1:G[HR2'KL#]2HIH!I]$'2/5 M@FB%E79"<&(S ^"*(6JE?+)&H"ZS87#0/RX6I?0G\YJ4938G!J/GR9DU*-TZ M#-O\K!5GZ;S!2_6(PAN^!V;7&,YQ<+YBA^)%YKF*OG5TS(;5G7LQK_7J]GA- MDC32ZR.1TR=RQI+AB7C:2EG#)R2PK>Y+I;NN9^R1W] M;NKP]G3OR)6L7#2@ATN,,+B8B%<@>9UA*@#USA8\, ?XT;@/>P.?O:JRX?)"?ZB^ MN;OQ._;B#TY%&825 7[5C"=!$RT9-:ETHX9RV;<-_-P?I7[\/;<-)";7%'=] MNRR_9EJQO1>@JY1H9@(WLP!B*@6"S M#U*2S9%)JKD"8\A<#S CK':[%F&:?A1O[THJ-D4:>4]H\Q'^1X)J$K5_ (G\)I#;YADGN\ 60W!_LX.DS=G#X!EL\ MY(SU22F"P6,!G5BB8(& N>LDEZ "%:NSNZ'%P\::^!T-"G4Y,.%@MJ^I$V*7%-TDI;U3N;Y#(;S.VJ,)OTL2'H;7+RYB,/KDN% M#Y$+S:U*/AAI*;4.8ZPBVDAE"(EN-.SO1.4 M(>CW]LGVT#I&[+FDS__QLG^ MX,61]5SEF#FA4AELYT")+UX2"F@DF=0\1M#GY+(/V")7'K9OLF)$ NWF_MFT M]]TBM66Z0,P5BFN)I5)E1S&/GV(N]L+A^\='+NL"2KXC)C&@&*83L6@Q6B6, M\-1ICB&X#11#8/O0UP ;WW24O$05CX @&N?@DC!V47-X#H*\[P?-9SK*V(0E MF(ZNM,S*"$%\P#$)CCOB\#RLTRSQR#V/!42HO0)+&B4-Q4W7VG=C:U_5M?:] M4VO?FUKUKK7VU44K)I*/.BE)#;76L9(EIY'YPE1ZQ*U],U8[E$ZJ?BW8>5&J M"C _!%"_=1*T+PW*F R<$XL3.VG O@DT."7\35*U'1/21!:N2\IM"W5:XW5[ MD7NPFI)HN6#'X%1#Y MIV$VGN1YT?/2M&FK'BMP822BCG/;:6L>OYZPSJ6"EF4WH<6C^E+ZR 6U&PIL M_1!C-?ABT8!GU9Q;ZT)4"[4NQ//1>3H\GC0>#!\:M\5M##64KB60?:3C&.Q>U.PA2>-)3UIKY>P64P_S):&+IQX/V5L,X6OSA; 4PW4 MU[.V>?CJRI?W7+U!VSP4]G_0][7O8I7C3:N=1$VC6%&O M$3#':*?7BJJ-=S\=I7XY;SJ6]]')TKJAX#HK;]6>.?T/\P92\SM,+K9,O=$5 ML'W!#X AOMJ>:KE[<];RDS=YR5.7O5]7T^ZRKQ4@387P9N+B@ER; L#647:! M\FK7L7Z]3HT08O9MK9F"=[ H$)TF\YAOKXI_)#0_J078RP**@9],44U<# YI M][6-@V[CWX>CWG$E6&0)/_SMLU,X&Q]NBSF;9I7Z1>'"1/(#-*Y:VPS-[;?HE7W2OKG39'U:Z MO#"=?9[:]_.H(]9+Q/I^[_@H!U!GM9)$:,N( M9,81RP+0+BW>),.S2@:+PAZ$6"\F!&(^:&TW3O, M4:SU>6U5/#P%('JCQ*9<_&PP75&9KTJ]7*AJQ?<'6"_=9G$NTFRVEX #VU^3 M.G%T9.W(-SC'2I9^U9+@,_VJK7E@I6X?LQ3@L[OW#3 M2C:-ZKXJQN-X-)F0Q?.,VE4O[H$>V'LTMG? J4"-CHKS82Y/ MT+MB9MY\\-V\C0ZLH_Y:PZDM>5?PPF]-8;']MN7I8-%C]K+U@J^7XRBO4Y%; M*MFD*C\Z MG#,T03MN$^6.2F\]R(J45(15B:70TVD9XY:0$.95Z% MEHT7M);/U[A1@Q9I(HN:ALBR%>1D=L]E;Y2+4I-[9"WKG:.?B9".#B 9?^^YS(ASS^=OV!!X?/ M^5$&@0*U%PEP;"24A;B M?% D"C!L$S5%^'Q_?:"*!M@4P?LBA,R&62Z#U$7HD)C-:;,:V!WTIQZTQ"K$ MK$74H!5F;RR1Q282J,N$.J=C*K1()F_J_M1J^@_< HIC-RKE/9A@7";C+!7% M"TZ]M5XQECHB>9!*=;IW?&2TXCE[2J+*((0-6!+.LD -24;-1)&1&!,-P4ZU!)15 M1XK1GH&5EKPU7[Y3RQ4P^77$- ^O?("5<9SWF=];A][?+<.W2^;MDGE7DWEO MI->[Y?2FZY)ZYZ&5QYK9*[1V4C)&X6=DP=&L)$BAJ+"KC(DWND>[S-Z;A1&L M;/_X2-!06[>1(K$_JP2)%)15))L40LI4987%H3OJF@3)[U;3OBY7B*R,>>F= MU#S=1>RF9H3@#/@&2CW6)C<3'FZBS!8^Q[G.PKYS:V +#\<,T!+..P6)FP(7 M/!L5N4XAR8[ [H/ HMI_=R2E\5(91U+,E W@_HAX ?GPE"E!1@;X:9T\=5F M,NNYMVVV:YN"VV10+HO<%Z,<4"#B9]LR]U6:7*N.0O0'=&]Z*=PEJI>" M,W M<@4/*0N-SIB2F\Y%(::FQ?@U6C51-Q/7T^44\-WE$QS.!= OHW$;_3M$MKE, MBET$4;3T-39* ;H5);+B6,Z? 'Y=6<+&'(I="D!(62A<\4 $ M8T!@)3#B@M+$60Z[[UDIOMQ0BO!)!057Z)=I-IX#Y1)*@1PW%AI\1>;?6K[V M:CSRYDVI(=\[Y6W_"63^YVC\IM'Y 8BGO:;7-AS7^*S^L5[TDU*L+SS$IASK MC\NJ[OHUM/T:=->OX8I^#8^5TS+72IL'S377^.QLX]Q(^UPU12L68 M&82;=UUZ-F]M[.FM^JR&)_-,V-.'++])K/=?OK M..C:!%7#M/2)Z^R-C(([Z3A-+'GLB^NEO::!QR+X"-K?8(1*XD%!.LO#25W" M[TTIUL_8=^'EB1_GG]"M^^_6-W<(2_AI,(IOOK"V=?!RKFWM#PX.C^5?AV_X M_NN?^GNO7[S?Y\_5J]=_J+T/OPS^>OK7R5^O=]7!G\\^7-*V^!\*-"WX_BN^ M]^OS\_VGS\2KUX,^IE;O_?F?-_NGOYSN/7VC7AWN%VQZM7=\%(PWRFE#X/\R MD5QX8DVA)%A F\B0(-9[R)R4L825R(A.5Q"<1 ;^,*YC=Q/,E\MN U%]*V5YQN%1M M8G*"?CP/^NAI53VQU=$5S+*8#-!(T/^>-!TVA\WG5@K[Z\RE1=AA=);'*TYV MO.(XG\#7FD$\\#KWO@/4G'Q_V<+!>;&UY#:G11E:N^ZYZCH&<">P;P-_-LD_ MS'_Y$<,K W_^0W]8]Z%^Z<>+4A(5/;!ZIWTP=EM=MHJ.YNVE#@CF7%5@IF/X M+\WOW+Z]4]_ZYS1=?J\JD^[*M^D.N_*]ZR[+^(YT^J,N>_U[PLINL5_38A6] MW8+^62FWH5Y@$&2C_V]+;*WQ4-44SW" ,_!Q#S%H7HGT ^VQ"E7S.RTNXNYP M$7[V'B_SXXKI.$9P6N?!AOWN!QCM3?HB;7 1%/K>*7SN9'+1IX(-(A8ZP?K# M=SNXV,%]^,OM-O &6KSF4;$<[LL_Z7=5"(YF<(DT^?X6M/'X#P\5QSL\R)6D M_)4],_T&G[D[YYMDH8]OCL>CV3"1=ETQYES*CQ^%SI\;LBZI_74/T&I#17R, MG6!F>9T$[N?):>_1/O]_/= 3?U%RW_RH=XB!R^ SBT%%I4/-+-7)4Y,"%4I9 M[5CK6;!7# 0D8MW/T#H.77Z[/W>Z]T/KPY?G.]Q>.]P#];SU\G^KQAX_*5_\/1?;^;?@7O-_N)_Z%>' MN^=[O_[>?P7/M?=T_V3_Z?,/\'PG>Q]^&OQU^HR^^O.5VOOSN81G*'M]^OZW MPV?3O9?T_?[KY^_W7AP9E:F461!G$FOGC 7T4HB([B(>O15;3\0V-?I2Y++Q MUSX,J^!;=V29Z[3MCU_,NDSKL.^;Q#Y;(N>)JZ*XED$F'Z07UENIA(,W&J\J MG6,?[;#O$6+?AS7LP\;S\(\D*F/_R(#3\X*U1'A>M-D;18R[%NEA8&JE^B M*;1Z'^_TOL>+?6(-^YRA!B=@$:MT!$O79NQJ(4D16DL:!2O:;#U1VT9\'=AW M9P=EJ?\\?C=DG5+4E/;Y\9N,[9&O]$;SNSWO1B#^^N!)<8=3M&,I6,^O@J-6 MP;_.9Z>DU?'!7'(= MT>@=VTBC8PS8FQ,1$90?&R(DIB7,@A,5"N:03M MBW^RW;F9TQ]4PUJ[Y94QH6^3866DDFO'1OFY]]$-)Y4!MU M8G#8RND("S*,">] D\R=;^3Q\_.Z;\38%&RDG/! _;K*<3I8DCR -0N1/@A MT#[0YI/M@XZ?'QD_:^6]4S3;8HRT4MFDJ7'&8 6GILQW]O[CY^=U>Q]0E]*@ M @G<";#WE21>@I 61DAIE'<<*Z3DMF67JW._'#]_;-K1H[?J#W,\&<(-CILR MUY3?YL'H[,),G;M@T8;'_IM@4U$T:;0"/-!?[>V?Z/GY_7 M;7_@2&Y84.C!TJ"L)$4:ZA4*4K/(W:*VF9:=@S]-V-HGSE/+(JB'$Z< MD Y]\AYX6]*2M,J=\?_X&7K=^"]9"2HD)=Q(#P(Z4N*Q45^V8>M4_80&\R'==>4UUD_V*@4"5)G<&V?5(JR8(KO%A: ME+&B2$4[X_^Q8]'+2\9_UJ@PE@S&/]@)DJI(;&"":(J>9F^I]0P#"XY_,A9U M@85'QL\E"@MV?Q3146E\"EEQ;J,O1B6C6>R,_\?/SY<"_Z4(:S0G(<(/Z9,A M+CM)/.4)J^<,6!(86%#NDVV%CI\?&S^[3$VTW)D@9>3<,1HMC;& @4BSH)WQ M__CY>=WX]R$(XSCV+P@<:&?\/WZ&7C?^K2S9^)!(-MP0J14&VK@G)7*OM9=% M.?3FL6W#'E-JWM\V]']0YR?EAO)[W[&KNR%]FPY(8[%]OY=@""H9F+$Q:@,H MI*S-14KU68S^#@LHN2<^IB<$C9KFW3.^?.$^SMF_EAF7C?V M:309;#Y!J!&,2)D+\1Y>2D=9%-Z@P=\Q\]^5F3F5447#F15.%IF"]%:;+(*W M2H*I\&#F?L>T=V':2VT.@F+<&T=DP$[Q5!;B/ >F#51(88H6F)XCY">;\QW# M/C*&-=1(#2+7Z@RL2YDO+G'G3$I%Q^#99S'G.^G[L8Q\*8Q?C!(F92) 8R+2 MFT"<99*P#(>KD[!6A\9-Z+$JQ1FJ)'/&>;1V!>76"J,7*G27LO*(877=BQ5"L9X6380RH$E]YR<]$%YUCN;\1BBZMNNUMBY^ M&E?S[J0?3WIGX]';?FJY C_9GTQF'CZ\&.H\7^%T5-]/_3$PS&C<=&6>9G_: M.\VG(8_KW.:54<_XA;/9&+ANDGNS,WP)R_3'Q^-\# N#3[?P?)6 GZ#0G5SJ MSB:"SEQ*A4.K(@M<"RN\\%(PYB(]>K[)8GJ^_\NE">>;!YF/QP@2V(KJI_/E M1_[MS_%/N[@3P/CPM >EOCO9G4U/1F.<=GX[-4!_G6K 1P] WW_]YL.1\BS2 M4$!JFVB)E!:$>-24H*+&8\*J1[KUA.]<'C#6 _X=P"\-J304@7061Z>GHV%# MH#LWX=J7&)O^'$@=)!,^Q/8*3U]DPX8WAY6@*K]M?#YDY3Q^V_+H@C^ONFC/ MSP#%?54R!N+SF,9SBQG>%-L@< .,]^O-T+&39JB'/4_63! MF?-/-Z_8-L*/:EXT0]GAIL-9,WP=%*GCDPH)<,/![/]G[\V;VT:2].&O@O#. MO...(-BX#WO7$6K;W>OYM>1N6]U>^Q]' 2A(L$"" Y"2Y4__9F95X> AD1(E MD1(V=GLM$BS4D7=E/HDZ>>4@E@,OO+R&^\6N;)O[3_]S*3@_NH+SH\OFD3;G M'\@#9;GD_7.6Y6BKP;G\1BKA#U[B4; 37J2OV00U'&GA][,I2.,Q[DKS2"T3 M=.N)"05XA_75]CWN.#;7PX@G&(?F>N38'KAFB>B-'=S*L@<_V9CX@W;5#^?@*KC]'6:X5E)9@$N M9%K.*^#*Q3@/_>AT;4 MW;M2B(HI?I5,T>O%92QP>/S6.;SXZGF^[<;,T1VL"G!2(P5V2!,]X($=&$:0 M1*;U[)4_7*Q-4II1T=T%+[G&U.:3JB S=:6>N%9MWIL[L(87(XWL]35]QTG; M0O1]CE?B4Y[,=IG-G2Q$B"BB([Y^>9$ETU,,C X-$1R5>87RS?+K(7TU%^X2 MW]G^T'97?VT,S97?736L:0Q]Q[K1L%=_9P=./]E^LG]O,,HN9.4O*&E1U=NRI*NE"GN-;=RAVN7EJWR>C<&.*F8P1%(-,*+,X:#0 MTN+?P:O+*O08LIBKT%@Y6EW=O ;U[,?1"^M?^63_'94_OUIV]K=8^TKF>31[ M^ %=+$WNGJ(E^D/04[^3Z^[D)_J#)SKM'H/YL!.^8EO[7;W]KJ)CA1[IC.7T M-PH]^@?(2B$3,&12;4T./OZ]/E 7)+2-&6QO-JZRF/XZ9_F,;Z)2-V]'>LTF M+5/$,,B](HBT; T*5JO 73>,=AM M/OQIQ4'D!8G!1!31,*]+F;EQ%%%&2UJG>R1O !Y]=LVW9'3XV]'9YT^'/XZ^ MO?OQ^=N?/XY^@[E]^]/X?'QH?/[Q]OOA\=_YY^/8FL^N.;(^7WS&3)P?A];A MMZ/LZ T\?WPZ.GKSX?3PQX=OA\=OOQ]]^OOTZ,<7[(.\ $>:6BR-S$B/C!B+ MHWU7C\S8UVW+3(S8-3R*P9L#S]\6U/DF@N=!V\!OJG7N0]+6*VU%/N=WYWYS M%*](SON#E\3I6Q$TUL(%WF+,=>X^_B^,>[<"L1CSKMY**_ /- #)[/Z]N."E M^%G[3[A'L)XWAQ;L@?7EMW?&__WX\ZL?6YRY>"?B(5"RR9G. MN)WJ2>C[L1,Y:>)&()F&UBK4-GWU-=K^$.=?DTE/G+M&G&=?>9S&9FJFNIO8 MH>Y8=J('L<_T,+9#VW4"RTM-;-X]M!]+9=VMR;MO*?,;+WJ?[/L[ M$V]W8..KR,*!B"ET)& OXC83Y:.?&!CUB&Z8JOF_CC,2]'5B=: +L2OTAF)88@ M>Q&RC@B9K[X) ]M,C,33P\2+=<>)N![8@:N;B16ZS$Y"P_:?O7*'QD)5Q!KQ MWMZ^Z>V;+75MV[W@Y3L5N/\;8_9]$'.+0LJ=1WA,'-_T6*PG!C<0UY'KD>VG MNF\[4>IS+PPL],;\+39LO'-#9TO=WP0NW-!W=^X61UGZR5-H^O9\L[N8K<-# M4*#I757->/)F5HHBA*P05U/I5>)FTBDQ:QRVR.;8%!$OF^B5#1;J*S M,')U/PT,,_%,ST.H:"LP%@32PE7Y35C^H?O'W&&?RCV^^K@E7]_;'/LW(#M+HW-7(3V-/CR- MGGWU>>Q9)C?UU$#0(VX$.O;,UBW0?DX<6*GK@NGM.$-WL8[O%ALYEFT%:1I$<>3:IIE&KN6MJ&/O,U#W1\0?O5X,E#A1R$,O MT!'H37?FC]^?WSC\_@J;ZUWQ__"7MRE'UY\^L9S,> ?3+>@^?Z_OC I3Q2 M,V8L#CW=B2,P(0-FZ $X$'J<,)?QQ/=C/[B#*,J.$6>?1[J#Q'GVU4J9ZP)A MZ&&88DNKV-5#RTIT,PFC($FXYQG\[O)(;YI*\>C")\O6M4_F])W)H3[A1; 8;"N)7BI:,7ZY&1 )E'&"^);.X&]K-7MCVT;MW88X>;7=[.7-XM M7K\S_*H^,W//>'T^,],S'#L-;*#LV$)<=,O5 \N)=,/U6. GGNMYSK-7SM#: M9F9F;S$\'HMA]Z-O?0KEG4F3^11*QBTS]8)8-ZT$7&7#3?0@M#C\R6+3CU,G M8@E($W]@V+O4)WM+69([=K/P-Z^F$L0=V^,25ORTT,[AXVW>-'2[7?0W#?F7VT:M;B8"% MNF+7L9D=F0A(D.H.,P.=V4&H<\;CP(@-GG!_>]&KWKYX=/;%?GET+8%3PWOV MT:T[DS;ST2W7")TDM%S=\DPP.+S T(. !;K+_,0+6!HXL;FMZ-86+8Y;8KM> MW6QY9\58BU?N+J]VP]ZN?2CLX05G'PK;LIQ<1(-U3#^.?9OKW#! 3AIV"O:9 M$>J&QUW/-1S?2AT*A1FW;K6\57:\7S2IS9K8[_\+MJ9N'H7MO/&B]TE%['S@ M;K7GWD?H;J$(YB-TCF-&J15'.DMM3W>2R-'#P&5Z8B3,2MR0.T;\[)5M#/TM M(P>N9;,^'5F_\U;FK@;^^@C??8N0^0A?8L2^F8(9&5DA Y\[-?0($U(]UW1< M*W6MB%-^VET@!_;V36_?/$3@<#L"JQL8-'N/=XM2:CXRR%D:![%EZU9@.]A^ MV=8CT^5ZPEPGX8D9NA88.HXW"+Q[<7FW%C;\F9K+OEH4KEV[M_(%7 M0.J4WR::1B*CBN:)Y?Q7#)EE;_H_-RNCVKR_<%W$[GTS:-$,VL(\ #OQ0CN- M]"B*#=TQ@EB/$C 66!R8'&&F_=3/!X^D%#5]Z]O;[ZKI# MQ[I9B^D': +<3_8N)^L^<'OE\%%T5P;A([3B'_BOV[32?#H[=E#OV,%3:$)] MH3JTRN:LV@EX'E,M85.NI2PK-6H=>JLVK'MP[ (=X6X9Y''LU*>UZ&6-G7PB M^]53UAU2UBXT,;[_*-7*/L8]@-S-3C++Y\NC-P?? M/W_Z^^S+FZ-O1S_^M/'YS]\.?[Q_\\Y]_^8OX_#;7Q>'Q_\^6PCM?7MG'+[Y M]?3+IP]GA]:A??0FR8Z.\^SPQR',\PK+4QXG&$CK5A/;Z 81<;KF[% MD1,(S^*4MM,'"]@S.3&*X1)V$, MMI@Y]/U]$:/WW^?R_IF>&.%I-+K!F&B.Q%8BI2ZCLY#;B5!DJ8FHK7YYM#KA<-^"X>E%D/L>\RR>!3[/'(L*PYY M;+B^RYD?&9['_3VQ&-+L.T_T'[PL>F-A,WFP4*G(O"2([5A/G0!=(L_20S=R M=<-W33>Q M]T01[\?_\56*;ULI<(>RT15IL+MQ0+NVPN7",V>C-B+;$Q'TEA M: M/]IPB3C#QOCIC9RUI=62'IFQ'P-9AUQWG#C2P>2Q]3!T AU$E>_:H6]&EO?L ME6,&"Y)J(>'[)H+BH1OZ/"*.?]2AD"[3]Z&0+4N%AQD-XN)9J>XDEJU'">>Z'7EFQ"/#BHSPV2O37,1FZLV!W>+X1QWJZ,V!.Y4*\R$- MW_5]4.JFSGP?S '3M/4@#%/=16$LZ;P5NZ,+9ZW' P(X)F*\''G=T.TDC/[2\"*R<9Z\LU[V% M'=-?V>RH';,_80W)]S,07KT1LV61,!_3"%UFQY9CZP9X,KJ31H$>FHX'GDX< M)HQQ( \'C!AK&#[FUE"/2#(\WIA&;P[^7WUL"N\_RCCFKTUL#=283YD$:,A!!YILYMT]*=*(WUR(IM MW?:L,+9MP[:"9$LAC1W(T;@*&'9)N6*YOITX0ZDG(P'=*3%=G,3A0 M?F+&3A [4>C$SUY9 ]B.6W(&F'ENHPUY+3L?JW(#.P9R\/34MR+="7U3CP)NZCZ8K=QP>6HAI(7G#;TM XRM M:R'NLDCM+;];67Z^943@ S$G\6TGM7D8NY'#H\2SX1LG2'?0\NN-NTV$S7QP M+(B;KOY) M:V4Q\ *8#_?9^$S>_[)6+2],M+T[0#,BOHJ03?@&TR$M\"F;"'G@&VFF)HOB_,M=U@3' MRV:QX_BV&21.X 0@G3T>@+-M?/6?O:(&6AACQCZ>*"__^V?V:MFI+38)DP3I MP6P7NY_-L8 0H"#_3:PD]QS+*JXY@O-DZCGFI#M3/WQT4:_,^;68F7 :#)M#0KJZGVGQDK@5/PW-(, MM92&'5;Q;L :T&.H-=GX4K1[@S5LYA8Y*?/3E+F!PV,G-7ED)X@78EDVQSOD M9.X:$0QHHZW-WQW]NAOX$*LBXWNJT&_>*.[XK^]'?WZUPM1A/K-U[EF^[B!N M:,"#0+?MU+-^NQC;UB;7LH?V_!FU5GKVDU;-HF\\GFK30F,: MB([,19]6L%*^9ZPCA#+7C%I/,<#),.T06 MT%ZS,B^T*AO-N?2;AS(C_BE:+*H7< L_K%!$U6+ M)RF82=RR',OAH<'H2.J3M6[.JA::1ZZGF,&VEHLS@%CK.&SB*[@0;)X1]# MK7V0&O^._^;8,[%$Y8_"/1-4!PKF/ />;-@L0RZ8PH,G<, YK^@R^>*4X\G2 M3Q88$WZ!+ZK2C">"218>8=2F$4\=>(;("D=%GPIU5%H6H]7:9BR#6%V4?#/G7)*VLTC8WZ2),__E;+.4#*N$*J!U-9S!1 M:UK6K:=&S-\.+@XOOG+/]P.>8HO1--(=E\=ZY!N1#M:D9WN^9Q@^6'"+BN.? M*$(W(PDO<< ]!(KPTL1AP"A!X =1P/S82%+?L'J2V &2>/_GUP3.Q;$#4W=# M&TC"#D(]\&)#]R)L5^\9CB@],)811<<&R/DYSU&.M(T,%I]F\+D41&19:'&> MI4+::+,)2J/)I"Q ^6K196U,U,(2_AAETRFO%7-4P&'B'TD&TG-:E(U%O^BT M-WX/'>VUWI3K/MO860JVUBK:6JM5]%$!!HMI##6U[+OM[UQ;"6_ 2\D+M,>J M'>G6;![5+/.7^^6W0^/HVUOK:/3E]/#'GQ=?CM^Y1]\.S2^C/XTOW_Y]=OCM MS/X\^O=HGF6.CO,S>(]U""SS9?3VQ]&;7W)XUCK\\??HRYL/H\/1GY?OCY/L M\^@+L$R,4A0XPDT]L $\YL2ZDR2^'L2IK7N6 TK0'*!A!8S$ MC3@V(M>$DPC2R#5 4;H)F(@!"%YV)]V=UR&HJ^(@ORXTJ;L_,M?:7+T8H%L: MG+AVD^^-60Z%YX(JZ(\BS^)+\=^GS#A'!U]]-TEL"P';K=!&K#%@'#,T@8^" MQ'5YXH %LL (ZPIB;VMR>+VH3L,Q M&G0<9Q-0QO"#40$JFB4X/;"4BEFE)HF. SG):NC../!."N+GE^)5TER,^/2" M\[$:8\(P0@^OHCT3'GEK'\DO'VH'<5S,QN264$(M.>5B3R]A_F!YN^A M]K[Y3HY7\C3'@ E,G<%/IXR.B]PI#&F 49/@RJIB!M9G-8 I9?#C]JCS(RV+ MK5(I^P/_+R&NNI] M?-&-&[=X3UZ\Z'B/^\)UU.5N1FMZH6_1#%J/_7 _+._E?4=S7W;VP72&+J[[ M=[)]38F2^)]9@;M-#%H11\04ZQ(G)_SN#+<-;Z@$$U5M+LIX];(_AYN?@R7/ M0;# 0"LDXS,AXZXYGH&0J7/LSS,:1#@=(-GP",?JKY?88+T_L9N?F"U/;)DL MO#+07%R,.Y)P[MIKSG3<55/B-:M.D82T&/_!_S/+0"S7Q@08J16("XR#2SD# M6U/'>.EW^!A)\J39KLDL I,32)6=LRRG'4W@'Y?:6&@/^"_]1*@/>'597J): M$!^B"HE73PM=]N_9J!L[!Q-E5D?TJ].BG.H8= <;&8O$I ./@<]F]L.57+-3 M!X0;A'YWM;C3%,*0(D69-D*RJ(-9.#^KR^)0^%"\& M4PIM2AAO7$S;8W:E%YA,[7HCD82ABH[$Q>+B98=XPZ9W'484)K[K>482^DZ8 MILQP#&Z8+&&VQ=UX5>:E.^\T_5Z,3XZ!3M[P:+I?=Q+W[T<=?S;>'[^SCG[\ M:1Z^>6<>G7SU+!Y$F*(#_BKX5)$9ZRQ.F>[:?AS9 >84/A#22ULQI9)+&9"6(#;A41"[4C:>,]@(H=Y .&(0M$0I MBH)2B R,2V=Y!6RN5=G)&)U'] _C4PQSDV@ $G6!MY-D%<58U-\33ND:XM'S E,HA$\Z M("($LHAJ-Q7?"80H DY(OQ@DFA28A89<$>%.X9VUV&30VGR,#PER7KJKS?"7 M9*16E;"2+C*<,$8,2\Q]E(O8@I$R-7>ITO# M=C29^LRDYS'GC;2OVW'^T]-91?P,-BUV-<1XFCSLULA#[?UXH?J[F^%%>9V8 M!##&5!MP:.!W"FEMFS1W!>XY^'%CO MCV/[Z/B==E118:<6]!UK%A4]2QP44R<&L:YJ;4T/W=+'S M>Q.CDW<\R?OQ!Q[/2LSO_(556?572VR\0TD"7Q=CU*LT[R=]!_3G5Q8DC-O< MT:,P=8'"?:!U,[;TT$ELS[6\)(Z2->Z 'LJB:,+G5#] %B2>+1>7,L(44\IB M ]V>-/G!$\K.TVJ]LCHFO[ 78DYUM0&54L">Y&Q2\1?J'R]!XT]R=ODB&],: MZ4T2^,S"S;D FB/J TL,)'FU@ BVK;7>>WW; M\L6^5JX)&Z$1VUGM+>&'UJKIO.[X89#[+/?[A>4B[XJ"@',YTPN@0UO;B$=8 M\;G&HO>LW'/.'4ABPXA9;*>^D3J^$08^&#Y80NW;3A@%3*:JF]<5SB_+>?D$ MWMJ"&51U[:"J:S75OL)ZW?X>N'C^IM:3+.@\L;_\]O8"WI.___3./GSSY_?/ MGV#L-['UY=.7;S!/]_.W$^?HTX?1?$'G^S?)V>?C U@3%H""187%G;".HQ]? M\B^CPQ^'QWGV_LV)^>4WL+@6@:;AE"TWM%P]LCRF.\RW](A;AF[R&"C <5([ M9%OK]G<#0\&<- Y%"Q)D[U%$#U-Q!P@1 VSFCLNSVC5NN<4M629]YA57+?4% M"]JUQ43*0A%(CHL1.,NG\"L,@V=C^)MKS_.BNL+[>42MDU8#B]^)3,2 /_SK MCH7C;RP;_PXG^&XTH-'26I"D(3/A7 ME+JASB(>&HX7>;9E(7+F,H'Y("W5;FK[784SLN."M.OC7P%H!@.WN MR YJB@T4!0N]U#==Q,NU',,.0N:&#CB- 88*+#=9%U;O'J(#O0JXN0I8TF(; MF^7:,7-UVT?P9,OP$6("F"1Q3(_%01R'\;-7WL!84A)Z,YMY.PRW'32HI7G# M/1J41(,*KD"#6K_*-@2AT6-(/7(,J8 MQ\:7XSS_\NG?WPX_AL:7_SLUXM'?8_8IG+W_]@[F!F/\]LX\_/'N$MX)[W[K M?OGVUCA\<_#]Z =JQK_SSZ/#[__WX[/Y_A@T'6C1HV\G\-W)U\CBH1=$GIY8 M''O"FZ$>^$ZJ,R=)C=@*;,==*-*.$P];Q'(_Y*83^DZ4>KYEQUX2,H?SV)G/ M2VCV7^/G@FOF-<=:,11R,S$--UGK]R5MF,-F:1((JLHKY(E,COT'"]"4%/][\<# MBOZ)ZK[7;W[16 +6059-Y3V)!%/"0EM,'FUE-.>7J\%L1GP)F WCH<%")TZ9 MF3I18H0F,](DB9CI&VYLQLMAO5H8-DA? O[[?0H3/Z275,=-'EU/8==3V%\_ MWA^??77CR(@"+]!=WP+_) H3G;' TA,0GRZ+G!1D*%!88"SU4)!L1-1X$SFS ME?.?%RKT=W4@1&!R,$Y:N87BN_6((GS:1 'O>/?53CS?C!)+YQ[('H:,_-G^HD;[S"O4H?/F^5+O_]]I>#@48Y M\U5<9A%6(/*\N/AI8ZV9I%;H!JYG6H,EEM,CR7!0 1R+N+*1G1A#L MHI!* !AD\J9&0(!<8NG(;#S%]#,^FN3%)>= KV,P!.,,/X1?%;&(]6G/J23= M>(DD3O\T7_Y$.>A8ED+5^& %I#/93T\[Y2RG:I!L% &CB1FS!@=.>RZK]3]R MP0NN83Z/?WH>_H1E^^I#,$0T,..K:?63R'G'=0*;X$96 J 4%L._PZKP7C$G M<+*23XM!&QEU/LM>U9[$,' QPH7BWE-5BH)?!(-$("^.&)@CLU%3WB$@76"4 M!^5F90C8_??@VL%"R'V-934$.Z8R=@JUB>I[O MWY%MN'!6(;+Q=5P,.QK/!$%VX!#@Z1E"B%#N*Q(.K@#H7?X[ M<:\D/#O;$&*"JIC>\%C(#KM=Q41 /B@54'@(@"$JZ:+:Q=,5#A]^H909NEWHIY2U7 M*^TO>JR%P"+*Z7BR)]6.[>/QU/'\+PE* 0N\EDM.CI+XE?:183%=I1TT7E51 M@NSZ??C[\/6PEMGB:?EP+;P5S)0X)\KK0(&8$%#3PD],_R797I.BG*8%D#S^ MOCUY015+IRQ=0O02-Y*:,>RC$UDLYJ%C.VF(V'TPD3CP#3M-32$U3=2YZA]] MY&"+LO)/\.5.+D!.FH?'?_XX//[KJVN&CA_ ?H.43'3'YZG. N;K-K-3GK@\ M#>P0@0RNJ7R;4Z:D:3N>_T8ED['IN9QQ*_ \)THQ/=J-+#]T4+^&1B1O0>>) M(^C=OGN@F6\G7PU@61<.26>#3YX1Q2X8RZF+;I^]@FCF?#^I M$DYY+JS86T2,;D@Y]I8#1@_<)N'!B>3HS;NOGLU\*TH-/;31"'.M0(],'WPI M(V)N'*7<8^!+!?[J>-%0^PV4SE@"@W6P%U!EM0IL6U1$T#\S."K">,ADRZI! M5_N1U=%1T_BSBZ(\(Y*6;G9+B \7HW9RTATPJ^^S<;"MB _# ?= 'A(ODQ$"<8" MK&XRX8SJRGE>\0L,7PDA#;/^4\AGT"X?."HQ#"G\BA+>-/0_)53*M4M'V,X" MZ[7D5VT5'KO"F>$,L]V1:E3 TO(/E'[_B,F1(DQQ$)/6-T/;IEU4]PK/\3GI MHWXZQ\3?MA]1)"^5BU7L)8!9TTKD,V8L=Q M3#J]%$TA1'S&(V! )M%L2EN;9Z-,F" #]78V%GC24SZ0+U??1#S')A3S'X/] MMO"13 =9_!Q(:OY#A>*T\#G91_.?(JC7>&&,$;N<_PA,K85Y 8U_6S)FQ?G9 MPF>GR^8J()#F/[T ]V?A,_RY^@P)I(*MSEFIV(/8LB@%6IE@4K$T81#*@[R\ MFF'P.%MT(*\.Q/$J[FD?<>M93!+FI> -8&X%2X.OAFF_W^[W=OP!330.,D?)3%P[\5OZFG).XU*N04B\-D>>,J^ZS48N] 'F&6D"Q!B MN@T4;Q[@HZT?EOP$8\<%WD4(I+B!@K$J)BCZT9.%U9$2FQ%4:Z-?:!BAM@A! MC$2I>+9]!42802@GA@MVAK( LCLR+>IW ,%#VBTP/9$C'3OVJU M-I NCBHQBQ#CJ.*L*N !L57-OM%TFL"E"C^U3ZY- H/6;LI&8 2LUA"5K%_# M,Y2(;#&;H,DBG@?+ ENP#,2=7$J-O$3H&EZ2J%AIQ>?E;.?>H+VS;74K39GF M2-J8:#5 4\NM;;"%@0%GBK6O4'$XE=;U&=D#@ZXQT-HY8%386?2S\8JM**6" M;6MX>06BE+P 9N/894&J3W4C)S+TKK ")$VID6YL#ORZ:JI%*2X8,Q!SM&$T ME)@-'PLP\FL$H;!4VMH24P &\D@I^FDT1.U**^0^P\6I3E;1O MW^ B&1R,Q[BUB_;A_ZMO8]JM2X4.F,<<&:QA;HKYXRN5Q,)'@-,)[9*,8;)+ MWKZN\\)&19'F)5XU1$.'3_ NNX%6A+/.&>SM M!?9H2)"*SO! VC",2/231 1EKE)Y1.JRIX.D0R2&K(QG(^QK0;?JZ)QW)DBK M$X\OWD)=Z3:M&2_PFCS\^[_76B^M^_TY9O'QB_VXA?LD$+I%PB)*?M(JP$_C MXAPU,'*6N+ BL*]:8^E\C$(TJ7,6A?#@(/XN>%GK>J*C$9*A,!=BDJ9D,@A3 M3=V 8ABX$JU!/DE3FA0V38.N@1ME24.BO&]>\Z]Y8V.5=?+\&48,G_W4$MFK M[1)X^O6;7_#I@B0><9C,#<&+12%^Z*XWY]\S0C)3"^K80]?E?U3UY>2O,+NV M+:ON+#_4'TLO"*]$Y3TG)I.V?>WWHS$([$K[99: ":UUR]3(+U)O>_W^EP\' MS;B@QD>SJ:2"KG%(V+QX<:XT;BM7E=?"$/1D!90"AC80A+SG;-$"R<46(>!E M!HB+&HB6T%K%S23^.D;C':52_2HP1(1)\Z,YI8Z>;TZD_2G*/6PH(R[3)]TZ M?%8* L/;-_CA $\.@1M) (Z*J5C=E.=P4@D^PMMV*]K+C4$/2F5,40&"?H3) MH-8[5T"T;?,SH:ZI\!.$ML5AL@5[>8%C]JGW0%R(_@FD(I%YB VS2MTYP(ZT M;?8ZG*@>L)ASB*B$PL#L0HG2*1@VHU5O[I.Q3/'$VOY\1EF5>TVT M:;GF*OB--[04Y#Q=-R M$U?[93BO8TJTD6VLT/I/F]6*=31U3;M-K;1[K$-N( I@0ADE MT F"%#4G2T9GTN$$:E8-TG ,(F/U M*]6Y9[!L+K7"BLKB#%= :AQD3$4),$+XR%A#0F)\#$\UOV?88@7O\/ TI;*J M75HY-)O+JEGZ3MK#'/T?^=H2G&>9Q80#2OSZ,\XG2_;L2$[B#SG!/9%WG[AH M6@;R'DZ:_"_4A:>L;B%#4A[%!$H"U9(./3CGGQ1(QR8U"3@DY)58AFD@*YO^ M/Z^6$S5*,5@E'1&CL)!QE#=HCF>ED"HRCRW'V%HU%1E,JD %!NG8+!6:#4G] M;'39S;;[]PP4H>#S=R '$G%_0*^1T MGY-]*9@%]Q:& 2[B) ,;PW" GV/>IX:7A\GTE,(HU66%=T2PF#'%8VK(:&E6 MZ"N)[ E=YUK&%=>Y_),2S#KK M&)0@/H3$4ZZ/>*)UFRENGB[W1%6][UY 8#.,:MK:6TR6&9^B;4M:A2YTV83% M\GE:+=X0"N5&;4-A_V!MI]) (==*7 ;C"50JIB?V=-!RG>:L@UI25X(P:E^T M=3TAW @@CJJ@QA4EPR8R;KIK.XYXCEXA8>PR.)%(KJ+$IV$E-.Y-8>)?H<,(F7.(5 M[ EJVZ38$S($=4^NLNIWTIC$\G:[Y%QUG7VA=G @,[+A[8U)6XH+(K(@:$BU MW6KH$7!^'2_G&); IL*PS\JP)E>Q5-@]&&+0E3N*_Q[!8DZ5[ZA>4D]DZ6L: M6TPD9C)!."+KLLY17F1K?2+<)WKC MD*UV>EE1*H&*[,34$IF$M(C:GV#NF1)YT ?U7J^K42MR+UA?_*:]@' MY\+U(M7-Q>[!$DC>G18@[\?:P>P$N%#6^Y@A>1Y-9N>2"_5ZN0/P6.*A2 1Y MMG039'R8"'\N%]\:&G4!+KENP*8@B)MA0#+$9Z=%GI"#*RP%FI!P7["7:524 MPA\DVIM[@3FTK/H-9"I*EP?[GE'0*\>^9VG=]VR\,,? ](9A':-1?5'AG\"] M2:?+FO)/E^["H/4Q[1@V_ASA9<$%K ];"E^,14,O$?1ME0+VDKRNEQ)YT-9(*NR]$$14ZU3Z226!U680 M7?"!22(#"W7DJVDQ+:8EZ%Q&D:Z,3+4F(H,F"0:8\+99%&&)H1;"0AKB\2W. M&!$UT%J-ZO9O%[R^A6BF*R->J*!RKH)AI"[(CEWB0J@X58;!.RX+%*42.&<@ MA$;L6X%> &Y1\R+6CL-@;QQL6$\)DC.Z9L)7 NG 0 ?9E&N_P6HGHL>4.D[2 MK6J&-.]95>=#@N<]'VZ)V5C&0$"-%ZKQ+]U:C<&D*8670\O$S:)"2,SBD!>^ MW;O^>B/@'SK=2"L-CW%F5/)U<)UHEGUOKMN:) L5M6D%>P[:O;I:"Z#54LFR M2+IH%2TLL +_/E%,4,6@_ 5QMJ\B6V3,K$_R4-37"UH\Z MQ0E51!=9A:DS%H(LZ92>AZFL2T$0M1MOSPYZF $/&0RVK=0TQ]U;? MK=\J "W4@%=>371R,B[:.7)M^=DR'Q>V2"O.9?*#Z!DGMA9?*IS7B%I$=N09 M&L]CGLO6J-_A*U$RDZFTI65[31#:4L'Q$'BA%4$MJKRU* M:T%TR\PH8?6K1I[C8JPW7H^(=C]&9';"RRX 2\Q@!&K2K*!%(#@C$G MWB22^JZ_+CVE6@#*K\-^HJ),'P$A3,-IFZ!=>ALM;K<@P=;"5F[S@POP]=RK M^::\#SWKM2'R#LE.J4\X*G)Y$5VTXW)U.(XNCC ##?_ $'^=ICR;8JH864 J M(Y2\(TIO1GWU%L8 /?6Z*"<#+?DY^IF)5L;"-9O?P&<".(A@7]0-]USQ-/6= M$7(5:= UAM9"FU%RAJB@8X)D]@_+&!J+#Q5U+YLZT@'_(!'0ZGP(AJE0QK(% M8JO9(AKU$DA%[L?\>E8TVD7]?8O^NMZ2U=RLL^I0S+C&*U@TH6>9R/N31 %S M*/*J(WW!"]!!X_#Z$8P9#^JH/DQDA/!08.J)D)[R!YJ,JI)/9R7R@M($E%!U M&959HJ-;,,E9S)7;II)QZ[2EAV:Z]43%KUD*&WI\FI6)]@L;G\UA2RSKF+3K M0J2-L[E T5=@>M0ST]2N2>HD0ZK2-\0A"!#RWWUA/879R?/7=!EL(+;N*(["^HH&=L M"C!G#NW-X<4$_E0/-W67<%,;5$8Z&U=&HEBX5P?RJ+)I1Z*].$N(EI>> M'KY.O#S075SGDK(%/-":N;AO@Q.7B:X8&&TE LB5=W.,EA5'#[6W6"]2YP&H M+&/HX,RN\CE'!D4+5N"*UM,GMUNLKKR7ER-%E.RE:B&W<%N5X4/9SS>42 MI$0]J.YK6WGD"L%C/L&PDOO/6X57]9;+^(+(&[R1$\Q_)Y58H:6]4],>(FQ9,?T:*V.W_K('+3N<+-QJY2ISA%1J:J8#?(? MO-HG@=4N%E/)(LJ34D.HG:0K/AU3Q^5;%N9,.2OB C[/+^G"NB-WZ^975%!% M/UV2K=]"%5.BDR1S-1'X9 M#K+ND$6L2:>! P$2+F\,?L3-9X469N0J$Z)P# MP1":3!MX9,POX/>36:[ U01<%-))!G8BAVTX&2J.:ZFS<+_JU%,AMHA;'U!;VA1<^MQL=I!/=-G:F["GLSS M9ZIB4 "(M+!*9,H79M+B7^+.C^[WI7]$D7-VV0(CPR*P#//I1:X OFJZMT+V M6*#VJ#/ 1*F<[0D^Q+&8+$D3AEY&BNU0:[(;=\Y15&XTZ2D(U*!2$#NYB_,9 M?>K>MB6MV_E<$FN"D)<(XF"@47)W4]I]*1R@2F$"M3=:"H03Q6Q#[75+7L,S MDI$IYPPL]YF(*@QJEG]Z%$L%.$U>TLXLX]K:IOI\1D7" M=U.R&E OPIJ,*$6)2)/,NP4Z19*HDS.+A<+QJ[. 5?JD""^@(]RNMUU1V7]? MR9'2$]^]),D-2?<7-+ZZAYP6Q10$RWBZ,VM:U]F\D%F8#!8D*E&6+XRBD%,* M\9)IH4ATF:P50KH-.%!C#5!L;()&HY*9XN*]2?P@TY!,67(TX[*HJI9QW,K\ MF!13JN%>K.H7AC@;@:NX+M; :B0!34()W)I>5^%2/<'+=:N_7.\OU^]=$)"'"P88I2YFDO&A+MJ,.O=57'!X0S(@0P97_,%5QW;YZ%WFAK%E$+WWI< M5O5($X@*/ 2L1QMH1,%,P@:!B89J303L:WB:.K&T#5NTU#I2F.-+"W]D+)-BH &-ZP"6F+YR:J".HU=I0HL3+7E@;7,Q/RRKN3B8U&F(*J#$(*A M4%=417OJ5]5P+2#]+-K*[1P'L>&Z*+FM:6%OK\Y!N-9I$%S5H)HU, MF; ^ =-17#HAS#*%A_$;$0 4O#;+\JE,0*#BAV8[*!2,C*?NJI#O:AEUT:E$ M_-=5S#C03@2RPPP9(YUA1%(E4%,UGE" DIVP]DC(#%&JGL]DI) +\&JA#Q## M2ZNYMX7&CY/$2Y:BI/4)P'-5XZ<*A<0MZ.(9MV.'HLR5($%J.)"FXR#%>=.2 MU7%L(H]<@ A@8%%DMJ0%:$7<7D(,49@I=1DKL-$YBR^5GUS#9/R+GAY.W4H'F4M;+$(L2_.5JG1-KBH=(^OJ%.BK1N)+@ZT<:U\ MX!9LY<).53-RU%LA:)4+Q-15M1Q%4&;'',C$YNGRUJ&#A-G4>-6)]>UX@T!/ MQ%*?@K8PY3RJ-@P1IL%1/9EE"C"L-+1DIY07L1YNVHK8"6[0]D):>M;;R MF=J\%GX?):70H.OBUP@YT6 ++T+F#$2:9)O%Q7V.DEAM)",9_9"1@B95K4;; MP3SH0A=!=C4 EM=:>F:C K:3,J'%C MTX)P-5N[IZ0T+@ -)HK!2"&MQ+%"M[E*9)_.1FQ.N MY-V;(:5KSI%,)#QN:U/V5@:\HRPOV"AJ2+ SJ[B2R0F6 \LD(ZP JMW(@2KO M)?HF>V,1+0A_(NURO'J88J]'RLAL #:+/!?]*)"X,2D4"?"- !C"3AO*;A\T MF1KTLC;R$'45J?%#11E7@=T":CPD45PG$KQ "D7\E.7I7 "\@1]B]35A.T^, M="KEE\Z4:FNH>X/TOZK:D\/+G:5SH10VB6BV>D5D6:ALMQ/TQ*B. M'65,DT(KTFO$[6X;PUM4$ 9+@7&BP-@86K#)% MF!^MJ@V,S:1"_RN&5BFTKIQMBPD)#P+S+-YJ:W@B;H MK9'"06K\7G0E=?"&SP6>VMP,^/@\*XNQD#/2>08A.RNI#W:3/C'".'+=\*1. M$$,%AC?28Q'SQ4NZNNZ^A4A\3BT.Z'B*7+7S4*E6RL*$26&F1 U)W78*1.;2 M:"!H/N$BTY?/U60T2R/MTN#CM8FZHS9%R+[IZ@V#+-M:(>M7\Q@>KTBB$!) M'&9SSZ_VJ^0$\T!P,]_A-6C>8B+W*3"6!,O.T>JMO3QMU<%)0@,-<*+RG5NC M-!D'%7":V IUZ469#^#-H7"[YA7RZG@!26VH80,%":H@RVK1;JW?!2Y/.KUN M_N+&MGN"BZ!M,DJ$1:K4FJT-[,8:N!R1,'K-\>^)C@%3ANR$N0T36!_"IX$M M!K/I@OK8-5@B2P]KWCJ)^$*B1R,LNL(AGDV5^-9^%?I,^\#1\N-U#44[RVYE M8N% 1E]%63E\5 -$+..VE A4H>HU7"1!F9MBAA9Z@D1]6UA#U6X+L4IR(AZ' M8(AN,&Y/"*8VI"2_HC82%>\5'R,BF8 $35K(9 <--EF[U]XQ/O [/O"K_+I. MDU<91REVLA'IX(D@J*MTVT#!GR@P,]7D2SZIL#+F,K*5%&Q5W[4RGE;*E-TY MKYOD\GTQG8.I]X M1(ZI*+''E6(P0#\;%Q=CH>/R=BUXAV MDX1*5.C6^4A3A=8(_,?RN1808PQ(%C.1S3POQMIWT=>(RD: #[H@B//B>4X+ MD%&*+^0*,U'<72_<4%)R)SI]\6E1B'@_672-OCSGS0XT'5A ^J&)W,T4IXU) MBK$$MI?A6C0V1<_.A9"E3!*5#CGZ5/^99?&9*&>;S^:N6X"J&U\UO>1R#/03 M[Y!]:( J&7%0>O-G0BO,N-EH%BV>UY,FY"FZTB:')W,3UFW*$I1<*(M M+*EB-B7!CT9)W4R4(DXR(-0\HL(IF)4]1B L$=9KPC.%C.4LP_=NL76#>RW\ M7#"5GQ&+U!-\)CO-(JO4GE[3^+%&O*XWCOA)[EYKQY9.1*0/4BR2UJLDCXA: M@4R7-UIBL4MI151V+.Q!-UD;KQ:PY_LI$"(\4E<]"&9B8[3&"(L27!E1VRIY M

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�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

FHNOW9Z.Z>BW7+0G73TH3PC\Q9AZF#+3,646L]7N0,MVRI MT[2F60_WW+B)UF6BW+@1U\/2^B M/SJ0"W?:W()DFG-F*W >)\PMTYW/EMO7#!R>U21;O:NRK'9+G>508 M(,HUH#F-02Y2&HL8\IQ3']HXDS WKOAJ9;2RSNI\,\^8Y3F0;NQP$SPC4\)! MM^A='R;^ Z^NV1UVNM69E&E'65TS\FQNU=4/ABQ*J(8NW#WOOVVVQ;^5_/O: MW+$9:E3,#;BQ1"JSTW=[#4UA;HJ=H&6ZDG? EHHB5W8[7Y M+>3(5'FQ2N&8/M[4*BRBQKRHM"\J#5Q$!Q/MUZ R%#6W-T8UG71EN]G;O*5H=51ZP(#7R^@ZNJ]!,!O;CRWA:FEI MMK,'/0//<.W$(OSDULOBII_7VFGVQ2FMW5?X'Y?]?5WV?MRQ.E$D1@F2,): M8,;-/I9IP&@2 Z'R1*@T8=#--[UP[[G10:E>9/5S/R1Y"5?_0=0-((S\?!_M M']#Y]B40[B= -P RT:F.PQ?#ZW3FBL4=)RXOKYCL%.6*JNV3D6L?&;CE%M^4 M?%ZI>WV:TKD[5BQ)".-$<042@7. TIR8C3-3@&&-4HH99A)Y;9=[1$N P(ZE@(@$$ZA2@++6[I1B#G##,L,>V-HAK^Z65@>##N8\40N$TP2#-M2$*F6>&,A@!F<#F1A@G0OV_ MU7U;<]PXDN[[_@J\G AWA#"'%Y YF$CY%NOX[A;/K:F)_;T0P6N,G=+5=ZJ MDFW-KS\ +U6L&PM@$11[(W9:EDAFY@?R0R*1R/3J:WA.T-3\AT9/NRM3U:+J MW=#L++9N[# $8H'9H1]8WO1P"8E!Z>&LL%'IX9+)A_1P\7K_ &MSQ.\_OMP> MEI*O0V&(*)-FB:$BF.0TDEK0+$JH:\CUHK2I$<7V!*3M$O6M MZ4ODN!_CAN_E&.V@J 4FBSW CMI(](CD7@;0/;8[*) C17NO!=0K%.P,4$=P M^/(S1@L7.YO3#B"[W^3/MN:!RKPM$R&03@27 M%%**8X@2^U.&..21X$3%/,\BY^Z3OL*GQL6-_N!N ?9[OM^ RHJJ$4%CA[=+ MUVN$+M-W2-P#L_DT(7<'[D:--$WV-;<\:O9\Q M\"FL7U?+]7HF<1XG$1?$4"5R&F>&]LQW/C6T?U?( M[F\S0R!2Q[:,7,HP1"G+(<.IA#%129;33#*6NQPF\A/KQ3)CG3 *T7=LT#9O M$V(7W[YB0; -TH)*43=FZ4*SFZ('PB@P'_O#XTP&#@"<\.O62OSM8?G]?YN[*Y?._%#R M0LD)7<\Q<,7]FV!V]5]=\/BS+O?GO4M&Y3S0AE,H\HS(EM ML:AP @FA HH$4Y%QF<89\LL <1,\O7R0ZIA(GV;@CE"[K0$'A&^T$N*EHN!5 MH_(OH%B "L[=&?*AVX/[X31T67$7T6/7%_> XT2A<9^[^V:A?5>+)_59V>KE MYJ&M@D-W?%X\-%6(ZDY],XR,%R($@YQQVP,/QY EL8))GJ5Q$@M&A%=53$_Y M4W-2MGKO5:M;;C5O]WOUS5OS&Q@W(@L(=V!&JS6_ 3O(VP7/[EJ0?[H,>8_T MMU[ #9P5YZ?#R,ERO0 ZSJ'K]YB7:13ZAUH;'\@&\GY^4\+\>+^TOVJUGJNZ M7\X4CG(B$P)CE#"(M)20)F8YQV+-,,USP5*_8T8C*3XUOJWTKK8&:LW!9@F^ MVRVV5\;!>9&FHLYO@1M'3W%L Y/[D(U'6Z_(N]8K8G^]UY7T!E0P3*<=J>_ M3:I!J;/R$ZCF$6Y(AFYBZBW??^OHH$WWJDEB?[,T,S%K&G??+S^K8F%Y]M-J M*922Z_<&["]LKM8S0F2$,6=V'RDVDYO2D.1I!%DN$$M5%J4YWL,:=9Q" MAU(/^ROMS &-/3=-":C[)6AL HU1P%H%2K/&'"7WW;!11VND3;)11LUK VTP ME#OVU:Z7,=IVVV!PM'?AAGNH_TS9>S*W:1Z;Y];!\C*0=_^5+>II_E?SB,WZ MPZ+2_CTK5G^P^9.:)313)(XTS%!D1:>])B.LF9\W;UF?-VY9JQ0V"O44>V06"!V M*\H*"W-9/9O< (L'^&/J[X^[?S#I]V@D?V+B[Y.7)_)BX]GAN8ROTVB>SHO! MW?:,7DZ)(5KO/=\*L7IB\]O-&[9:/9M?5AR6\40I+"-("$F,!Q3ED&DN82P( MS1+,,TZG!X0OL)!STY7L&M<:A M&O)=0"1@;[YSDE^P3=\%,+H[]EVZN1_IE#D39_,W#<^MM5JME)REA.9)FDL# M>FI67DBFD!$MH$KS/#)+LI01IYBFK^"I44_CX6R6@%5':\&JW)N550Q3/ZU* M#X?7+:W\J,EY.-S8*03(@0FJ5+F=Y7VSG^8-6FH/1UJ^0 W*6\["1Z4N7T@. MV[2=Z/E@]JK'S_C.L$QSA*889(9_DLUI"D3MII[ M@B.!(Y1$LZHKYY<-6VW&25MPU-[G^SZT(6 NJS'8IBUQ-B]3EFR^PM-:V@RQ M*F]AY+0%UU:%T/6K\&[AF(\\V1>A ML2#<:_"NU/HO]Q:,D[L28%S_0JDK>]DIC?V@!N"@3+FV6CWN%R4;7"J!CDMP;.,1ERF.H4B,4LW9"N\ M4UM3-9-9PA,N$Q4[)5RZB9O:JJW2&%0J@U+GFXJ!UFV2<3])YX!X]P0Q/(Z! M>?U:"+U.V[DCT^O@GQUU]H]&[NB^MCDLQ1S%B+(::4 11 M*@V-Q$+!)*-Y1),X2YE7*9;38J9&'Q_WZBWW:-%\!DW7&/.U& 4/*K=++-O^ M@6+^5#KU;RI=FW).7;V_>@2:NV 9.+)\4M3(H>0NI% [/[YEX*PQYDQ3L,N3#>OVDY%OC M[)5'58NE+'>IRPR:6<)0@I@D,$Y% A$J ^>IA F/58*D8HQY]6>X*'%J1%$E MOQ5&X^I8O :B6DZOK26>5'$1;D?2&!+$T/1A=065LJ#2=ILR6"I\4^47#D@E MKN@,2RH7I8Y++ZX@'!&-\XT]%R3S<@25/!VBM6<$%VLU2UDD(LTIY!)CB&B2 M0QJS#.),Q)F*N=!Y//NN5GSIO$1Q$NSSY;3%A_N RBJ/%=O46R^BO46C*KT] M%S!N@^"XH!D0%Q]'RR._N M*W)4^.4-)'YF ZG>)K(^VL$&TK8LB,T3M(6XG]C2)5A6D6:";X0MPOYMI@_6>E-#Q:4JX2D<0ISRAE$,;5=[Z6$,OW++@OO[]?UD3P'?)Q&&8Z%A(HQ M!!')"*0ZH1#AE%%%113QU&]I%@#Z<=9FXX/O-NL' #3P3'WH!< N=0B]-+M(Y\AN'A2]/=E671#R8/YKCQ!^M:L M.[>'1S\OY_/WRY5]ZHS$$4ZPTE#GF)NU&U608(X@5@QE. 8W_VH/MF[Z#[%JX33G]5C<-BUCK]WKN/\\2&/'2V_,N_J--??+[D.SI> M#G[8-V$:N?J!;/QKY/2''>#!$-!E7@ M::<72KWZZIQ%X:K..L=/';VWSEG#3G77.7]QS_B7UDILBN_J0QE8N&<_/QMF MJ8I*/)F%5=T[P]#13.J44Q%K&'-F%AU888%_OM*0:,PGCC M-6P@QEW\N+$8;UB.PC'^3_"O*OK)D-_JS4K)8G/[L%*EE_6;*OL%D)P8/R6W M"QQI.(JGF4T@-!S%)%,BH6F*<]?RG^?%3(V/2DU!I2K8ZNI>:+$#T&[^&0ZF MP%QS&B'P9Z6H8^CD E3NQ2.'@6RD*H^>+Y=7U<7+0'241^RX>;0ZAI<-:!<< M=+C:CPW7J\WLS?)I84CF&UMMGG\WXWC[LUC/.$VHUL3,/ HIB!)$(,WB!"I. M$*&)BGCNM&([)V!J#-C6$5@EP9]63<PW!#B!><\;%^?/]Y+Q70Z3 MN;?E+)E_'3I*9Q\^RH=]R;3FD[YXW:1:;+5R*VX?#/O89J0?%IM5L5@7HBX= M*BC.D>9041Y!E.<8DI@HB#G*=*:I=&Q+\N*63(V>.IIPW0#6V "*QHBJTOJ+ M5SKJ_R8%WLT9\_V8_KZ-6R.OO8S"+2Y@"\Q0U;0G,[C3V(JYVIJ_QJ;+4(,V M4CLP#X7\XQ/_9 _JG\O5?Z\_+,3?ZL5AG""*:,2A9,*60& I9,S,KRD3L8AT MJE/IY)"?>?[4)KRMBC^O#X%W>40Q)6 !&;XK786BK_UB#F< L4]V' E M."-%&7Q!\@HS=$#0$5\X===H@84.E=L1A:[+_(GK%F51]$4MBN7J]^5&K=\^ M*8,*K5\YE1*9DX3#G&L)D<0"DC2A,"9"LDRD:>;6D?>BI*F1&?I;%OTO4&D+ M2G6!--ZY5=C](^[&]C+'#8988+:S8)U#JP?W=)O5\]EXFZO">I[V#\81W?]% MZ\H9Q89";34PSBG1*>)CCG7_A7$K]+)Y\L8KR[X:_50+,KC M;\*H6ZYWRQ_43G&_0,EUXQ;A-)?:./.*I!%$419#GF$,8ZXQICB12BO?PJ>V+'G3J@QU4^T/K,LM@^I' MW[T"GV%P#.\' C=T1)Y5Y>?J"M:_;[O/U[6LZ^I21=UIJ-)_P+AY#]2M[ M*#!N=+H'-$G MROK\$8VVY.LB<-H]]8ZN!=C]=X'?T!(<%-7C.1[L OU'8O+2@ M4KD^C[4]]3R@3^<.T;">FX/<US-&4\(2G4&N;X33.1>S? M0^!0RM1(J.F.P4IE>[0-.(+1C5:N!BH=/Z2E5!@CJ&E6^B8:&(63JYYLXR9T:,=R)S=)&)>(;NR.(?!T0-ZQ=79#!$0SNA/!-J\J% MC80W2M\T!YB-W@,FH?3$:F!7Q$WVR,Z(%R#'[HC?[?VXZ7VQ*#;&O?ENPT,; M\R85-FVP),%?5\OU>A9%6&JD!$QE(HUO(ACD<:QAAI$FB#.+ Z^U'413T4B@!H\J-Q;L-6O;L^$&W"_!:P6L'3>@M 184X"U M)?PPN&<#CC <(^4)AAL6KV3"*P'M2#/L^^31$A"O-+V=FGCMHWKW!5>VIO;\ MPT*JG_]'/<^T)(E,;&Y%FAI_5F &F=V>S'"J-(I5FL=._NQ9"5.;+-[5K:LK M+4&I)C!Z>K?[/@"R>V(8!)[ M.^-3)\NWJ>MOZ9Q]\$3Q^[5?=J@$^VYSUQX M;=/-#A>U;.1WKWYN7AN=_WN6(HYHG&/(& MH_.$)9P)2M/GUX_AQ\>MX!$8- #3P8G\#X3KZA;M@)K M!2C-"-*]U1O$0)U=W?5XH:ZOWD"=[PCK_ZA^L]G'Y4(N%Q]L=17.%O]]I[59 MT$M;3N[CA]=WG^L]"B:I3%-A)JP\SNLN9BA#,*6$B$A2I7*OCK%.4J?&@Y72 M8*LUJ-6NJBF^*C7W3)YS0]^-] ;'-##-.<$98'?("Z=!FR_;/ZBQ-/*^._O?HJOMA"%K?PTXY$FE$D-HSS39M4L.>2QBF&&&,LE3E#$ MG)IRG!,P-=9I= 2-DF6!,?ZW<>9W_)LO^IO&;Y7>UL 7UU5JLBG+WN!5\NS>PKK\NY_+]J$V8%X; LH8J/L^0I"!OKS7\]+#%YC@CK)G M&@M!R\2;O=V(K97 F EJ.T'5:MPVM6M,!9\G,,#NNT@O/= C;3&]W(![;4&% M'(V._:D@8D?;O H)6GMG*Z@FQ1:KU MVT=Q2@Q$'.8911#%B8(T(AS&"8LPR133V&D3Z:R$J1&<5;+MFKA_OZ%/7,< M[.GHJE3#VZ=5L7BH4OVK$@[E'^O"OW6%7R5G!%,>:TXAQS*#B&$%&%'^@1,\6GTNZ)XC/^H..Z7AP'YKU?: MO;%O;>O.5" ,N*'>&^5A]]/]U1AW.[TW3$>[Z?V?U(\V#UK(-I5OWA;S)_/; M2N[=TV:]8669OEF4BCR/A(9)C%.(.&.0IY1#RBE5A, M_0G2&W_",QHQ[O1P716GK?@-JBX2:GGL@-.C/YZC#J MM-03H,,YJ>]C>O3O5"N]7#TR8]VNJ&0YZ_UC46S6]7)2I)BGR!8@PH1#)+,$ M,BJI8429(J1R0X%.I1Z=)4YMTFDI#5:[NJQEG33P9/7V:%OI!/GEX,;@0 8F MKS:&K=JVI<:@5+E/#U G,#W:@0X-ZEB=00< UZ]=J ]079U#G9XS7A-1'[/V M^HEZW3A4ILQOQ<+NR979=4:J_?5N]QQ)'E$D"8Q%$D&$L( \01F,8VU[Q N= MN#=@]A<_-0JO=;5%$4IEC;\Z9"I+YTA<)O.P^ 9F]K-9"3>@0;TQ 30V#)-? MTHGZM=DC0Z'_TKDA_4=A@*0/%Q"]4SHZ'_K""1LN!E].QW!Z2K_XTX>%6:FK M>_9S5RYP=W0JLOU.4BX@+H--6;&V$9JRE^\%D]LF(A;73BO1'+YK80PBS32'/#%Y!CGAG/4S'# M(C&&.DME+FF2Y,0Y [N'_*D1BWG=$G=/IP_@EQW,P# &IYW:<;E; *L_+/.< MK 7[!56V=H [>RS66E*65PF+OKNC&7@41O(T@XV&E[]Y!98=#F>?IX[F<5YA M%H[;*4904I>7P7D M&!MN%S29PK:;&UB.FV^.#_-WL-\OY_/EC[N%;>.V>2[/1YNG-[WJHY2G>VRF=2+F[N0.A=Q(WNP5"'KYJRZP=#BFG;>/YH&Z M&-%V-9VN[UV4YF'3^*[F$;<_B_4LX4)19%B2$$VMRT@@1XA!I&FJ,_,')KSB MEZ>$3(TKRR78IK4$,Q*,3V(T]>R&=!)1-[_O6IP"LV0?B/K4C#F+P= E8HX% MC5T1YJRI)PK G+_6O]Y+W>MDMS1]MY!OV4;-.-%"4N,J415CB!*"(8_B"*:$ M*!*E4642V77Z_MN8SV\8UV?OZMV!3?C9-Q4 PR MB7FF4X5AI"0R?@ AD!&D8))H9'Z=QYSWK-795Z6ID]EFN3[J M1ON^!3M[#YF;RS'N0 0FJ9/GCG9'DYK31S?;01FIJN>UT 8J\ME;K1>J^7DM MC.=+@%[]Y"%ZQ-E0V/K+MY5B\F[Q!UL55I0M\1?/4A(3@O(4TCBU"25$018) M!F.:XIRF,8YC+_IU%3PUDFV4L]F&"O#E:K7\86,,ZU+Y:YK&=8#O1J0A( U, MET>Y;J76H%+;1@VW<'\>Q,OK"U7 KG$=PE^P;=QE2+K[QCG%19@'KM5; M5?WWP^+N6]G$8_'PT?[[LPWXW^E_K*O:R3-!-:(H5E#K+(>(: 892R,8I4HR MHF5,"?8XI=Y#!:=/;?SCZ5N=P=PJ#596:[C4\&FMO!KC]AF5RR'[$""/EE97 M:@Q>-;K_8N@-[/ N];\!I07P3D-C0U7>/1S>/EDMP7 ?+:-E M[?='KD=!D1')RJ=Z*\KQ^WEU2!X'*VC/U M0OX/M;9I*0OY[NDQCC;HC0TYP+$>,K5Y;^ZDR'["%! T 8+,L M?[TM#&5!N*D3!P?D\9$';M@Y82SEQYU?1AZ2H[EJ;/G]YKTW*R6+35--M4PJ MP9*R2.,88J0SB$220HJDA'DB&#)35*11[#-#'8N8VEQ2:=BJRMLC/^<$D&ZD M?QT\H??G_9#Q)L[SQ@]*<2?$C$I&Y\T\I(V.*_M]X!UMZ'YC_[5T;;T!I M RB-*!L8@3\K.SS9PW>4W*@E(/:!>6=XV+VIJ2=X@_*6KPZCDEI/@ X9K^]C M^M'A[VIC0P>?5LOOA53R]?,_UE;NA\5WXUP5BX=Z0[Y0ZQF1>9PK2B#&L6%" MBYR-##?7H;9F^#\$1N4VSS$CTIK M_K <,EJ/)_2N%G-NK^4-^U888MCMA2B5B4PS2'%N%G78;ING2$,FA/'L)!8D M\JT=XRAZ:A[=F[(W8ED??+G=0JSVQ\O0T;Q@W#K?9G@\S^YZ#(<;IX4!^06V MRXOV=FVM>I -%7_$ABY2XRI^[)(UGK"<*&#C^X1^G'8KQ-/CT]QFS;Q5WU9* M%&7@S/P\5V4$;2%O'Y>K3?&O\O>&9(T>F^=/YAWVLR@D*DIAS!,IF"2<1+I'.XNA])MH%E'+/"!;]ODQX6"#Z,:3HX[) M."S:'H>V33=@:U4Y6[7MN@&-9>:G>5EFA( M#PE\\.?WH_?73^MBH=;K-\M';@NE&%&?E5@^+(I_&1]9&@&%+O-*JPA V19I M5>Z#?-SY9>9O3X]*UN>:JBOO-E_5:L8SIAGAYK5(8MO#*).0)E$&)2G_H#11 M7E5IPJH[-=>X5 J(^DR>3\[H2,/K-AU,9] "3Q*-H:!EJ:WLU=@*VL;6L5/0 MF%O.#2V#06WQ#6@.93;!UM+LX2:/<89GT"DEL,JC3C3CP'\X_8PD=="@\':% MLPO8M.(IDI'(3#0R2BE$,L&0IB*%N8P%03G#4>Q41;._"E.;/,HXIBY3)>U+ MUPZN;'7W#*CT&)>K@L4#H?VR0>-=H&5G19!82W\0QX@C=ZDQA7BR TR.<667 M)XV<%%M5%-J='*M8^OXK6^QE-WU85/W\#JJZ_;JR/>_-2N4]*U9_L/F3FB&N M(ZIX!H7UYI%.-.0QE5!RC5.I:(RT5T[29"R;&HO7.90VH_9I+8%YM:K,VK$2 M:P=_<]PFA,GH.Z%Y9H#4W+IH6PN>:C$!-@:@H\3=;VGX3K!OD;I/?X$ &GIC:&.YK#&J5!ZP.V@ND0=G;3?*HS.H%QB'K^=W< M\UB#X<#EO)#57H;Y23SO2EBI*!8HDQ)F<2(@0K&M.F9P5SF+$D5P*A*OV$V7 ML*GQSZ=5L1#%M[GM JV!:&ON>=ZA"V$WWAD*M\!TLZ?F#:@4!7_6_PU2X\L% MF6$/2'0)'/>HA(/I1X)8R/L70CBNL0"DP/+>6V6V<#UBT^ M:_JP58N/Q8Q;L_BLF4<5B\]?V>\+K]=5Z_MEO>G4;%6I]:^KY7IMOO=$IXA@ MB!&GYGLG$O+(MGE G$*PMVVMZ 4M_A.,,5F4$9Y*+0 M4?G$%8)#=G&^K^>RI*Y:YK21S0+RM$R MR?L!?==,"W6G]T^R_\9^VI[9KYO:NF^8>>W,[V<11R)+10:1^5^("(HAPVD$ M;;<(E<78_,DK8]-'^.2XKJJVH&NU;VJZ\UUE>:#ONOX*@VGPE=E"E47<]HM8 MV-/CI>Y@JSQHM!]RX>:/VZR+OW]=SHWX==6D<"'?%O,G*V/; M6E4F1-*<0LIS9BA1,LAIKB#%TOB!7&8H=^[0_1(&3(U6&PP@JY,)%MN^H575 MN.VY=M% 19J8YU, P9X-3>._R^[5!A'7_+%7I]N3O\KO!2!YX5S?63OMGUD MRV3*#PNP10'8I,L*!YNC4ET'VE#8YMH5&*"-1M.&]M8V-:H0\:[!^F)ODGN5 MZ:F_42.5JOX+O%E>I:]?_B%JC%>%^2=#;E;Q?5(^^;4?M"9.%U4@M MA%G7EGUU9EA&.-<,PX0SL\;$%$&6X0QJQ*2D$=:2YWZ-1T^)F9K;8[4$>VK6 M?:F\.X^>!-5QZ7@U5*$7B?XH]6@^V@7"P.U'3XH:N0%IE[G'+4@[KY[ ,6.V M_EJ?@/[.YG9W8*85)RE1'$8I0Q E40Z)DA1FC*8YT1R;A=N+'3,^4G=JQ%1& MEFWR7EE33.T4?<&SQL=C[,9OTQFYP#P9ZJQQ\RZ\Y1XV.5 M_[I'C<_"'_2H\7FI_MVQWQG)F^=;*O[,M(].J6W?'8T?IE7S:MW3';X>J>R6:KI5!*KM\;Y;XP MVR.V.LKS18FG54D\[[__7LPR*7*S-!4P$AF!B,8*TDQ:=Y,R)'E&A?;R+]W$ M3HT>&JVK>@)KH[<-V:OJ3.%ZJ[IG]IG;"+AY?\/C&IA&]B']4D-:']/<:7T# MWO\!?_\P8$J:%U##)J:YB1XW/'92XV_Q(SM;PQ9KG]7FUG&, 8TUX%5MSR_E^%3W-(-4&G5C=W)"=;/NC6_ )M?^.KU@[^O> ':WQ.[_ M6/]^BG ;R<+G$U+($)[!"1RZ>?':%QW_^_&J*1-NC]H?+:+^^$ MH6-#^_1]H^TX=ZK=WA+NOG (1[/5XX@)P65.",P4YQ#%'$.&$PPSD@FA8II% M:=3?@YQNRZDC?^2*OE)GP>WCY$VR4U1/M*[TQP+W?3HK[ 4]J,N=G"Y>[Q\R MKY>TSW'"[XO-7,W2-->,1F9%F6,"$48$O^"]->.9\COIE]"X'PZ_!)/"7[@N'5^C[G-V] MY'#QLMS'W.C'9P M^^PU/98D3=[&YG9W&MA68RAD><1HN;A?OE:?6"'_4['5W4+-HDADVL:S8QTC MB"B+(26QA%@PD:4YT@FGSLL57^E3^\#-2Y-Z^.C>8#LL;4)"&'K9L]4=M)0' M>]K?V.39UPI8"VZ M0$8(T)B[K%F"HG]6.NIXP7"Y6>:,H3S#E66X/M5.(!$X@R:F ,D(QCEF614AXE?+= M>_S4*'ZK7;_<$C&Y?\77@!/Z2*UR:!C[TZ;_N@7_0),:-^U>?-//RR.ZZ\XNNVQW** MC26,MT_JP^+^:[$JYWSSH2LD*6.0RL2F(YJ)FF9:PY3E$8DDY5AYA5X[I4WM MFSM*#>ZS1KBTVJY,#^*TNE85Y4W#VO!(AQ3EB(&\RA.C-- M.#3_Y@9V1F-)E!")5RZCKP)3HY?/2I2^A%Q^LT=VV=86\&W/F#+/I+IX_EPF M!'5>O5ANP+/:/M>WT9+GH+IQ6LBA"DQS1G6PTQWL*S].$>"^Z W<7GJC^R'^NG8K.>H422'+4?$!<0M,4P>GEY]; M!2<^#@Z<>VA[0 !'"F1? Z17Q-H1FH[X]*4GC!:-=C2E'7MVO:6G;VIT9NNO M=ZM/;+6I_]&*<7\P;]'BH3@Z^1?/HE@F(LLE1)F9 E&<6!\5"9@D'&>R6<1ZJ3<_;'&:ZNCVMV+#YF6.]/8/4GU7\V79)KQ*7-^K MTUK[KFOPC3W;^.2-_K7S=@GULK1T]7O1ZHKDZ=#V?1,<'=L1QC>T@UMI M;>&V1H#FWRTS;L#.D,,3W0.ZN5=B.:R[VU>9<=W>*R$[RJFE9G:B8,&VW' B4TC9:-FXP)(3E,!8YR](\8R3UVBYT$3HU&C[*<=RI M?5.W3!PD/_3,$+AQXM# !N:_03"],HNT&Z2 &:5G!+]@=FDW%-V9IA?N]2.G M]6HS^VS[+][^+-8S+662$LEAC"B"B.04$D%3J&F.6,QY*JD3^^P]=6KT8K>- MB_6F$&P.?FL5TO_3*NM(*/NP=3-&;S "4T)/')Q)X*3=75^YN:'UA9M_'7[= M^T\=XO5U_J!<8LS[ 0,DT@HG:QAC6!G"04,D48)C*2 MA,>SA7I@&R7O/BUI]5H>"9SN@JQ?IY[V$+@Y WT1';D?CVTITN@W M?/^=$\8':;G3EO,B779.&'JNL MQ(8ATD1#PG@$249%I&2J>DC*Y"7RK)"BU],PQ/ FDVW=^-3RAI_0# M9 (T!NZ$8-@$Q).2QLU#[#+V*!VQ\V+_PV!OEM_5:EN<'.M,IS*.;5$D"A&3 M">2:,T@0SBF/ELNE0/?V(/ZF_O1KWVLNC_FJQ (_ %7Q@]9 MU_RLM;V.>NT_:;1S7B<-:!_R.GU!Z!->9>;7+,MS$N=*08EP#!'2 EKW'$J. M.<$RB?(TT!FO4O[4OE_W?,*^@'=_WB/ &)P$>ITRZLY#' 3Y4*>]O$=@VN>] M!LH(O1+'P1>K>&@S#PE% I"DM-C[>I!Z[%YH;*H&N]"R)'7?2YF7^X^G.\ MJQ^S_+I;*MF3/,ELX.Y,"YVJA;^5]/Z^KPCM)JM;(<:MMKW;.?:CW+$>&]+(,,AY3:!PFPHF.I,IILPUV>8D=7-\>>VF!*:)1$FS8SVWVH>VW MO#7#(VTZ_'A?7M]/8PQ?LA--RUS0LM?F,)86MT_S[&R^ 3NK;\#VM:C[,9:6 M3^E%< \W3.J%&"DX,947PRN>,=I =40_PNLP6JQD-#C;D97QA/9;+=GBTW?: MM@I8U[N[7$=_J+E\_[20ZUD<12)/,85:, 91:I8(!.4(4AHE7**( M24T]DN0<1/9P\,=(EJMT+9/?S(LN2IWA5Z,TT%9KL.3SXJ%V!IS#K2XC<-E? M'P+0D7/E[I>@TA54R@*K+2C5'0XY=P=W0 1'!ZO[1M(TL/4"KY^KGJE7[WK=QE M6SS3G1#232B0Y4L/_!+V!K+MC9.VA& MV1@#,JC7'$3141WOD% ?^NY!907/R/NQG.6IBID2&'(M"$0"2/94C,@V7A^6$_\1R\ MCC$(F8&WPW"X_#OSS*EFW^W,O2+WKO6000Y'W9NGE =S(RIL7DP"!:4*HLRL M-AAA*<022:)8Q%+ME)I]0<[42/_H&)!5U.M\\R5@W5SV > *3/"]D+KVS-0A M#B%/36UEO>2YJ4.#+YR<.KJ\;[V5\C2P#;Z*KXOE?/GP_+EX^+II-C6(S!47 M&8.1DAPB&2%(F*$)',6*9%3G:83\BMU68;#9:NQ;4:4;9$IYCI6D MD*&,0A3E%/($$9@Q1E*4<(6H5SG< 2$>)6I3UPYJCJ8'1-J-D@?$+S U[][- MG:J@TC7 _ITC+@,7J>F6.7)]&B< CDO3N-W6=R?_\=N3^4[?F:_H6ZM3KXZU M2G B(>4V(Y"2%'(1:X.Q(#(C#&GM=>S]C)RIL4FC)E"-GKX;^Z?A=-W>OQJD MX,OU&I^MBD%V^CMA&'B__[2LD7?].PT^WOOOOCQ$\;QR39)KSIA&",;E"7F; M",!%+J BC$1",AKE5S10/B5R:OS@5.2MQRK0 7Q7[V-(2(,[(%>C.7#!O&"+ M1@>Q$RJ6U[64]+BS9ZA)?%7R::[N=,>)KZI]'<]B*1'ED-$XA2A)S-I'4@DC MFD4,BPS'B1&C$UFMO$I.ZCC#W[!KH/BF/D*@C4H8-9PZ'L'^+R!FS8 MJ)>[^'$#8=ZP',7&_)_@O\GZYOE:V$X^5-",LXRK3&=0QP1"9 ME1?D"<-0HP@EFFGC=3D=H^P6,SG"JC5M,FNJIE^K6EOWS;T.8"_OG X#5_@( M>H54I66S$_=Y2*C<-SR'@6RDG;9_[[O_U_4$L#!!0 ( (J B5/KD/$M68D ,M9 M!@ 4 :'%Y+3(P,C$Q,#,Q7W!R92YX;6SLO5EW7#F2)OC>OR(F^W60@7VI M4]5]%%HB=48A:21E9?>\^,%B(+W2Z:[R12'5KQ_#=3IW.GVY\ MJYE26@J0H MART?#&8&@]F__L_O%Y-?OL%\,9Y-_^TO[*_T+[_ -,[2>'KV;W_Y^Y0?OESO#S_Y1\)%O_\)<]G M%[_\8S;_Y_B;)^1_=/_HY>SKC_GX['SY"Z>/K/?RE_ M!+^ 7Y"YZ:+[]M_^?0WRG=D\VND_(@P3@3[Z_=%^LO_^&^__+(6QWPV@4^0 M?RG__?NGMU=+GH.?+,_A/U?CY8^_QMG%K^47?GTY0SA\]&>%W.Z?+W]\A7_[ MRV)\\75R];/S.63\G/_\08I:&5VO^=^O_^VOU\M_G<,"$=.Q^PY_GCP7$OY[-OOV*'_QK$4?YHI-+ M)Y-[RZUE;REW_O8O?R-7[_Z.7X0B>?C2=K\ZV)(^M#5LX6Z)5A>XW^]#X_[WR<_S$R8]/\'4V1SD$ MY\%&M)G*!#2<*!$'AA&O05LE8X:@>U'^G85WP@%O'P?'R+,12'R$^7B67D_3 M*SR)1\$H8[/A)!GIB+1*(>TY$)U5I%ERZ[CO!1"WEMT)#J)].!PNRT; \&7N MIXMQ$?PEH'F*4006B5<"A&P?$D=)=&!4 MO)XNT9-Z,Y[ ^]5%@/DH,>]CS"@"CG*0D5(\\20*(YF0> XR1WL4&NZNN!,* M5+LH.$J"36C_$YR-BQ"FR_?^ GT>;C.+H(FC.J+/@S8M=.A-)C$'0DI^G,/P MT*H[H4"WCH(C)-D$$MYB1#]'$]8)_C/*'U[.5M/E_,?+68*1]IH&9SF)T:+[ MXSDZ/=8JHJRB+&KGF.D#&%N)V DGIG6<]"?G)F#SQ7]_FU!\XSQ>)RLN+2'/ M5.40\/2#4/QEAE]9:TE63$AND@OL.$]SZ_([0<6V#I4^9-L$2%ZDA"I87/[G MW7@*;,0,4&,M$&Z#(3( (Z%\*ZC0UB<\1D4?SL8#2^\$#M'B^N%=T-%PUG-/@3:$B8ZI^G# M_.-\]FT\C241XVT"(TGR!EUMC?&6]6"($0[ &^UCR/T!X\[JNZ&CX5QG;Z)M M"2(?9XNEG_P_XZ^=4VU9 IN-(X922:05 45C)6'"9L&,L0YZ=#5NK;T;/!K. M??8DUH'!4:S>BSGXCFZAI$TA.^*IER6+CW9/( >*2>Y-#IH)=A0<;JZV&P : MSG0>++J!55XNSR^20Q'E M&(]2_]T5=U-_PWG-HT0XL/J_S'TI3_K\XR+,)B,;%'(L+>(V,R(%!>)U#,@" M#\YHEP(51^G^UG*[*;[A1.7APFMDT[_^'L_]] RZ3+PRV>:,?DER5J,/JQFQ MFGET9'VF $QH>YSR'UIU-PPTG($\6I1-A ,O5_,BKO7=;($TZF"U&!D+H(QR M)'*!D%96$8L$$,Z#E0&$H**/Y/3#J^\&C>;SCSV(M@F(O)WBIZ$XQM_@E5_Z M2[9&4:@0*!YNP!5&O@XH\25K1I-15 NG])'E?MM6WZU^JOE$9 ^B;0(BY8)_ M_M(OX6PV_S'B5#N9%24B<84RX9QX*PSQ+/K@2D;-W2V!/;1*XFK1W0#1? [R M<$$V@8//%WXR^6VU&$]AL1@%SG).R1-C=$F?0B8A186ZC"IB:!1E+Q=8MQ;= M#0?-9QL/%V03.'A] ?,S//)^G\_^7)Z_G%U\]=,?(W210T3V$<0JH5ESF@0O M,G'2F$!]5-H>EU_8LOANN&@^S7B\8)O Q^=SF$PVU/,LE2FAL@7G4"(92##( MAW:E$,AD;DT?MQ,WU]P-#0WG'(\48Q,@0,(O2H'/+/[S\SG*;?%AM2Q/?$ID M/9):>J&XQ,@I<")+G9CWU!'D341JN/?QN!3TTS3L!I*&LY,]B[D-T*#DYG[R M=IK@^_\%/T:>2:>5\<2C2T2DC(XX+C@*"(7"G#5)'I>[>'#9W:#1<.;R>&$. M?5^U#I7>C!?13_XW^/GFT8&# ,@$@MEG])E=0HFHI$A@PF4PR3EWG)/QV,J[ M8:+AI&8O(FWD'< M#10-9SG[$&A3F%@_45HSD2!H\)(1)LL=74)Y. .64&DTXY 53\<53#VZ]&ZX M:#C%V8]0!T;&"^0@=5Q,_-DH)"92*#D6#6CF/ 02'$]$9;CP>M/ZO_YZ3WCO\ >'O]E'1VBZ@!1GT\5L,DZE-4/PD])U8'$. ML%S#O M"F(QQ%(4@\#22:-?22-Q2@D2-:+%4<:SWG:;E/TB=$BX7'2]O6"R7&Q^THF< M4';9M>&_[T/=H09DL\:+Q0*%>\6KI*R4=G&B&<;BN)T$"=)0(@*/@8<.;2QO'"-*M2*;> M!R5\SK"M_N98Y-PA9U@ ':/?!Z%RC+ ;0,Q+OSA_,4WE/Z_1\'_S$V1F\6+Y MTL_G/\;3LW_WDQ6,@$:E:5 DRH1,1>&(35D22<&$0&W@BE=!T$[DM8"HHV P MJZV3!H#V(L;RV'+Q"2(@2V$"[V&YN9=6)E$I;+'Q\QKEWBX5L.WJ\ET$ ; M.:+4@([H(,:DD!<4!0G,49*YLTXS8ZG=]B[V<+QLHZJ%XZD7/[HWT3=@9SX@ M)[[49+X#OX!/I;/FA_SW!73B&CF>E5(A$I&-)1*\)AZT)SFKJ#.3 >BVM/ 1 M1]0VLEHXK7H!4G_";P!);U$'T[,Q>FEK">%F>/T]3E;E=OWWV2S].9Y,1@(8 MU6,2 MC0CHR&D\\4/P) H=/&1*P]:^4X=#:"^8]%X,4P$F!XGT8"A\@WF8]1]-O9]- MX\:#DSQPL)[H4BONSO$*]'P%'RT&0C-I8L\5Y[8\@#%:63+"P7"U;$D MNU(X;"Q5_5*KBJ(:L$(W^+J;R+ &O+085M#%:F:QL')*T88_#2K#J5R$-( SWR7SU("/>&Q.= MLT2+"$0&5U)=3).,?D)65%#JZN2K'R5IV!QC/4/5@P(:0-*[V?3L"\PO7D&X MNA#F7KKL<[F_\0Y9$+@/D@A$":.#U(I+4^>D>X"883.)E=!SK- ;P,WMA/M& M3C^N3VPDGI!B<\A$942I1"#VMY-J,^0;MAD9"V#=)S(VTI(7:=6KV0# MB4=E323)J\),4L0+H4F2>%([JXSD=8K,MI+5C*]]DJS D6IIX,R[>6S?R-_+ MJ(.3$ E+UJ*!=7B&1\ 057K'I0?(\FAB UKF5?9*T9NQ5S\CJ5R0(ZH%E+SDW )'2 ML6J\O.A>TTW3R]FT^'LPC845QH5P4E$\B$N?@6@I"2"!L)@9%30!A3H>]Q:B MFG&*ZN4&^E)) R?8%@D9QE/*@A/E-.XW4483.V2GS(SS7#'AE8F#O!0?@P!NZE0X/4#, MT$TA^M'SO7=)QPF]B7N4&TT:UQSXZ)!GGPE+Y5V>\)%8EP-)6G()X)14=6!S MEY*A:RZK8.8H<3=@:%ZDU)6=^LE'/\;0\J7_.D;O:X3D4F&S(Z7G )%4*^(4 M&F2OE,M*:<$JW;T]0M"PGE$E\/0A_ 8P] F6?CR%]-K/I^C,+5[$N+I8=457 MKR"/XW@Y4DE)2X/ @$/;\E@*#_2 CI[+PAG%$M-V6T>TP^'T-&W#^D65D-6S M2AH V7U!C01&!2I03:@J+2R\%L13#&^!6F&CE\9K>2(G>]A$4240'2GR!N+_ MIZ*.$?IP663A";,<-P$U:&F-R$1+!3)FKRW4L4M/4=9,YO$D50+'*ZHC("*RBI.>BM MQY.\6"W/9_/Q?T$:Q2BB0#D1&[E 5Z*,/HL@B$XNA"R]")5J%;;3-716XZ10 M.THIC4+L[6*Q0DY\I"(Q=(.CXZX("3G)Z+/FS+B+B04EZF3+'J=IZ+3& - Z M0!F-PNKF8"7@6D8TMD2'A"&W06\@4' D170"!)/1V3I9CB<(&SKE,0# #E5+ M RB[<4_QZ)$OG6:<6TIX*AO'T=R]M2X;AS$P.GE7QXKM0-RPQ375T=:W>MI" MW+V37P4P,E).F.::R*0XGOQ,$S!*>(@Q*%,G%-U"U+"]A4Z)L*/4T2*R+@]^ M1X7TNHP*4BFB>&P@@6='@A \1)^RXG62N8\0M!.B>I_8-1RB#E!#BVBZ>U72HQ4:LBUF> MK9\FX=\BU_C/<.%S_ ?C;S#N:O\G,]QI4[]*XR7<*28Y_,K@< +JW2CT))2> M+AS6#R^N\'\%=F]#]I8KHI5G1'J.F S.DR1CS)RE%'6=.X9'"#K^JOWR [^4 M7/1(H#^064[$6I&*=Y"($U:2Y*)TTE"N6.4KE(Z.82\&^M#]_?OU@^4\X+FY MF"]+!_>TBDN,4V#^;1SAQ??Q8H3>HM3>,1*C3.N9OVCL,S':XJ%?&F['G5Y$ MXP(W,(+?W<7'8Q0TLJ!PDL\D3*.6+,F=.G'6.4!"!X@$<7*[3X64+4<-<']<#3U_R;P!*+W') M<9DX\PK"N$S72Y=\I)"$R(F2R)PD4F6,5"%'@H8YZ.RLI%#G^>AC% US,5P/ M1+U(O@$$73EY&-S"6_QR,8K9.&4UFE--D0,>R]1KSW%+6&EB<) KS8JZ3TLC ME2N'.\ ]B;D!H'R";S!=P?6T (H[1\90ZAS*NR!N&4& <_3[C$\VEVK[.M>X M=REI)$HZ4+/WWCD<(>9V8/(&Y52>0A<6_C%>GK]<+9:S"YA?31TJ\R+P?^F+ M_SX";I.FWA.*!)5#5Q-7AEO)K)GAR2CNZ^1C#B!V6+ =AXZ'H59-50V@\>5L ML?R0+QF]$AKZ>,FBZ29,F$ D*U_SV>+!88?>8P284:#TADC2:;+1;(FUDM&%)3!#\'96.F,NT'$ ML):F?Z0<*M\&WO%=]6I\_?UKN22\/M%MRGBBNTPT= V+?23!B4R\BL(I;H&' M.I'[HR0U4M/=SP'5C^ ;,"Z?83(ISMDT_>'G_X0;+(TX**.#5X0[@YPPBX&J M"9QH:P.35I4BNTHYY\=H&O:0ZDGI]Y+0O6B@ 2Q]0G4@ >==.NL;3&;=\.H- M,]0P#Q(/7,4%)5)'2IPVEE"KC;0N+E["*,IQU; MR RHE9AD,1(A1^:9P=.ZU'8:JU%DBI,<(0'+D*6L8XEVIW'8MTEU MC%(E#36 O7OR&AEC7)"ZM++.GLC2:S8$&X@.PELH&RC4N=>_1\JP[X[J(.DX M>;>4#EA79;Z;+18CST!#"1^\+A/XA'%H:G4BV0K.'0?+:@VOOT],(V]O>TX! M'"CL%O!22E;>SZ:SVZQ/6N)G"6?&YOO0[P>=108VD5<%&W&\NJ%"> MG)?6LB$19I-*P2NJ31TT;:=KX-12?7#UJ)8&;-3CC(!WR:5HB,)C'4-6A>ZD M1$%Q;4 :F3&0J.-"'0>M>LFE^M#J1QD-N%C7SN&F0&8\72%3'ZY>[?T&>3:' MJ^%%L'C]'>6'.L1@=OZC\RC*X))26C/K;@HV-GVD'0W!H*/)4BD\!9I)D#D3 M;CTK/3>T5G6J""HRU4@_BWZ#;B= M@9, 7790R)25$% IH_$(08UTN^@3?\<)O863&98W8FRAC4V26@(*Q2!%BL0Q M_,.;8*R/3CE3IQO/+3(:Z6'1#TX.%W #EN7ES2?O:S:0GP^YU)DJ#0%*NP6= M(CH+-!5GE&4B)#54,)-"K?*?I#3E_ ;L#*;D0";OE*_^<4XEBOT M\62%T>R56QNTYQ+0K9DKKW'#[XOE7XBL=DSG4V7 =*!,VEUX-UQ%D/)**38#/^A;-W*P,?*K49@O;=;&3K MKP:?A>8;,+5;972C&]OZ'%%,B9R=)3YKW/8>K8B'*% 3P!P8)VN]1]R+S&%. M^>>!N-FIU-\NMB_E=[_AH+@Z'6GV)'08 MM^-GPG)T" M8=)K:H1!$UVI8=PVLAI!U 'Z?@PZ1PN_ 23=X>&RK14>WRI0*4DT94(J0QD% M!H$X$?!X%RXC6W7R1P^1TPARCE?WW9S1T;)O $ WW--- SR3!+?)D" 2+:YA M)IZ[0+)2/'.&V\S5*SCU?MX%_@#9-T 6!X9[G[)C,>PV,ND")<2 M12,Y)\$KC%^,==R6@2ZNCM792M; N>O>0=2?#AH U-V9[IMVKB@1D[E$@<0R MB*H$IM%2_ .HY5E[6:E.Y&%ZABW9[!]"/4B] >P\D$!/P:7,@R_@%>P_N_;Z?V@]--L,GDS MF__IYVF$YE.&:")QP4J45LG^6I6)=D$$D;ERL%@ M)'V%^7B6<,_,E_WA:3V<[-5JCH?XQVZ!;KKBIDBB/)V_*,7#G29'0O#D"I3 M&DOK&9#HPW$(MK^T)TH9U_%O!X?Y::@!V+])_K!;+[E[LR^R1 MF+G;8.'N!OM4;LX6XR5<-AY=2^(3Q-G9M/N43BBC0)7+@7IB$B)+2LJ)5;@7 M(W4,0S/&4H&\*(PWLF=MO29SCRH/1Q$N6\)P!2YP2@5 , M&+.Q(G)=QRSO_UBG6H>(4Z+Q<.D?#)UO, ^S>A%.X#PD1PUZ*M:6@A;HTE,D M0>"6LPBATN/^ R.<:F]3!XYP]M'#D1'.ZVD:L. G^L5YGLS^K#M)]H%53E/> M\Q1[_5?UO,05WY05KXHV5-*"\3()6_I0Z"#?^=K,S9IF/LES\]N,/_Q^S^40 M2V?H.N??'D0V K(#L'!_IE\5Q;2-N6O&WOL+N+P;=,A&R)X2GQ*>]Q$D<4 % M84)8+Y50NM( @3T)'19[U0"S.S"/UEX#X%S7P&MF M>H>)L-?"!P(I%1>W-!%FP1/&P>=D6=*RCK%JO(SD&/?L2#$W )3WL"R!T,?Y M[-L8@^S??JS?@5WU$GX1E^-OX^7XYFQ&I1T(#).8DJFT(S#$Y10)MRQ0+_&G MJE+WP;UI;20..! =]U.I-575!AAO)(N5%,XSC^YIHAB.2XD;LTRUM@F$,Y*% MI.MT$]P_55\-0K5UOC5;OX\"&D#/K8NO,)W&+IRVQO:4)2P4M* OZG M2-,2:S@GF2JEO>=1J3K9CAK<#'ONGAC+@\.A@2WQ"G#E..Y4C%]/H-/U--T< MBC,"[E3,#$7+/2.2 A#K!1"1J3=@*W\P__DW=B'\62\_,%&0?*8J &"4D+91^V(M:B%Z&S6.L1D M=)TTU(D8'+9&L+GMTB*L&C@0-J-/2A75[;DDI>FB"981XZ4B4DE!@O2:1.MY MD(8KZ4.5_?$H2<.6*S:'Z'Y4=ZSA[RG/L%[XQMP0]++POR_QAV-TLUA*99PW MD$"3P%W%&/$*_]!628V10A2>2T)'@\-GV/F(&2HT\YW%^I:>WS=#S*>!."1:FHG MBGM @L5=N=[*77',* 6FHT"(9,:[3F/(7%:1>)LM YHU9W5ZVNQ&7VM/KD^$ MPJ-5-:A360JRMHCN7?G^4VD,_"'C^=)Q-XI6Q0!E0(*CY3&O3<3*1#%JXQ&T MIY;97@ =EU%P(J ]]X0K M15&4VI7>BI%HP:W0FD'TU69<[DQE:Z^=3V3W>E);JP[@?'6')X\\1;3CGJLR M&D:5=[61$:.-$C9G:NJ-6WV2NM:>.)_. 3Q&30/7G3]E[Z_RI"5MM9H738QL ML(897>JAG4'Y&4-"3.C?:@6Q3"]RZNZ[PD..W@>6;NWY\\F/WV/5T:2AZYS7 M31[JBD.4H0<%*#164O+2Z4Q<:,G<=B)KLWE"2LIMX%1PX]P M]G;Z#1:/"-)1PZ+,'M$5+9%:>?1+(B"'#C)3 4#4Z?"T/ZV-/!-Z5_/U1E^J M:L"&?O0_-EVGUL_I-E?VL.A&,!?V-P_M1F X)&THT;E<<6I(Q IJ258F1IHX M]ZS.<;X/E4V^_>@-,;,3J:^=1,^&Q3>SJZ?"(\MRE,IRI-^6X;I)$.]2)LR; MQ%@"H+$N$&\0T^3[C-IX.U09[<'J:N>@"-&W6/[X./'3Y8MI*AVKOI9?&2D> MRU@Z3I@H/;!4=L0'J9%5H;@W7@M6ISWR[C0.F]0>VNCUH[J&L7GW?7MYY0>* M4R",X<:3PCB,U PCD?HL /^G3)TLXI.D#9O%'AJ)1RFJ(0#.9Q$@+=Z@@#_[ M"7S(Z_Y]GR&NYIWXWGQ[/QYA$"=2\!AI91^)I Q%%U4DT23G/3CK*HU3W(V^ M8;/9IX9B_RIK(#S978@CR)XQQPW"):*!U\D2=$4LH48[;8SCGM8YI7>G<=C< M]XD!64EU[29PKAXL/2!('S"Z*MU.661 I,GH(VU-/%,X*9C4<8RH+C@#D_>T6!U I*R MP2B+&DY"<7=C-@)TY,R(2M'(D[0UF9VI!;J>5=6 =?MXM8D*]1N>NA?!(Z># M##9;H@VH,@LD$1M]N5WR448G7:QTI[>%J";S,-7@UI-RVHQ[KS?0C6&Y(^JE M2E8%DB6G1$:)?'D EH -1*<=G5NXIXDKDZ7E$-^&B[RP^]3\ED$(8P$1R1HDQXILP1'AB-&!E) M7REAO#N-PU8$GAB+E5370(ZNL%7^OR3!O_D)=,_[4&+CB%:WJXJ8IML_N/&; MZQEJ]\LFXV254"JOO\>N0\4GM."OW M'X9U@5N"]UX*;&84]7$L!Y-2HI!)4"P2R;,C3I9+TF#P/TYF'>I,F:R/V6J^ M!O0X7/**-ZNKKUTDG0#_9S#9[.\VS^<5:A1LG+U$OO+&9:&4%QJ0( M(A>120=!@J84N:YC3W,E3X?7GW[85T5%$2 M$B]=-"5N%Y\MX=R$) %:.K8NSN$##SOH8:R[SW .ESR30#GJJ_4A@, RU@V MFLB88WER8TB0$8CQ&8P.(*FM4\]PGY:!'YR?=?'5%%,.XC[ M,/^(P<7E-UV-[F)<5'6W3G?S1H:-;%12%^Z$@VY"M23.&$84-Q%_HI@.E5Z* M'DCQP&4U=0#T,$SK:K,!U%Z^^NY:BJ;Q0[=.ZV_8HR__OC/JXL+/_\QR^'R+;^?IL7X;#K.X^CQ M\Z\8_SJ;C&,I6;C%T&)\\77R5-_,_=?X]9J=NXQ>+G4+5%58@^]+]+0@_>7( M\0OS,S^]G#-4)DK@6LE?SF3[>(.WJQE$?G(5=E^#V8C(4@!%M),>G3KMB5>& M%A]/,>=$O#&VNM]1#7V0?_0(BV.(*).<)K,%.LSXVY^O]7^]IS]>ZO\+JORW M25?/Z:06%K'_W^&Y W =P.FP\?_J]<6_"1LO( M^FG.C(\G/#L^#GN&/,QJ4V<)9SF#2Y$$G0%]9B.)4SH0F:0UU%IMH4[2L8FS MY-;"G;9^7.].Q:(#@X%G% %]1H^BL/$AWSDA?MSE*@0-DN8RUR^6%JU0(@NEB7$N8"3#0JI4X;D; M?(7B^Z4ZR1[%?6^@D6R2H+G2(W1=?(4^U(Z;-YU>+Q6U6P#R'T/?][8B_/9%+^, M:_D]O#,I>MG"%89\Z?7OA">6N4R,YRYK$[4.=>SKOI0.F^ ='KE5-=L -G4D<-C$\ M/%;KZ/*G20*\@J4?3TZ2 ]@L-4P*X$%&F\H 4#20SM)$#"\HUU01GTH[5:L9 M=2XJQ^HG8K+8EW)H!C/.I*">>G M:1OZ.4@O(+@+K7XU,G"IU9O99#+[\\-TW6#V [KGN G/_H"+ /-1L?DL)DZ4 M2+@# 06&OK4B,F 4Z'%'NGSW9(+(D[P;J#YUO#WYX>X X0GFS/B79 M@*7IGA;=W2R@:>!:=EVZ2HAU.Y0_(N$?*V\Z4L@^&T5CI0ZLOJ@;,#Z'FNYW5V_0$S4TYY1)LK14)Y1!(*(Y(4-U5-ZBZ'DFSWI'X.%::@MM MY2)XG+H!Z[/I^DDOI ^WMA(M[32L#P1#=_2>-,=XW2M)%(2<',('N*@-P:?) M?)Z1<.^X[%F?#8#U>N1(Q^#MF2,Z>QZ%2&CF2ULUX8!8I@RABCNF-7A!ZURE M;Z/J>?J7_4"Q-VT-'&7?IQXYZSQP2V-*** B$V1""4UL\IQ0CK9>9)69-EA\?M\MEB,C$!GP09##'H-Z"WX2*S4 M%AU4G;.6ACM:YS[T*]>Q&V;D?7 $L/V_1SN M*.Y+ZJV^FG@/*+#28'>"AOTKKM4E-FX1O=.3B(<_IY?W#CN0V--CAM=^/D7X M+#;)C*M*;VF#C"$9$E29Y^@,(\Z;1(Q+60!/5+HZ[Q,>H^C8 _'NY]YX"L0E M!6K+4Z "96DP,+',$9R'J"MU''B4I&$3O;U@XNYIU8_XGY5-Z>YL#GEL MM>W3ZMF7A\BM;65R<#2AUT&D+PWBH@ \3V(BG(<8@E6956J^7,O*?([GD%8E M(7=WA=*P(+Z8IE?CR:H,@BS2OMX$QK@0@D=!Z%QZ: A#'&>),.DAEOUE4Z57 M(8<1W*B%V@=/]_*H)U#=L[)?A[\6W?IQ]2Q8S5>?CT*.JJQ%T(!1E,#C*_)2 M^R\LX5(P)J,#Z>KTJ:MEPE"TZP$4[U"T+[ZA1#N\SVX,6SZ?37"#+R[WPY4H M@"6=LE1$<%MFB*%KX+W(1 /#L]Q*ZF.=]_$'D]RH&=L'4P^,^#R!^AK(M-YB M=,15 (OFG1B;-/JF@%XJ0"B-_Q.CWK&HZMQ3WB)CZ J-DZA^&^#VTD,3B=)_ MP/CLO,@"/]2?P>WBD@^KY6+IIV7"Y]H)V @LY)2D,:6DI'@;UI7)/BH101UW MW'B??!U_[2!RARW;J&+FZJNM 1.W%Y,CRK-S DK]:4Y$IJ2(TU83C,LUU3%( MSNK<+.U%YK F\@2P.0:H>^EP?X"Z-4"GT,_XU5U9NV[MDT"'1#EQK-RB<>.( ME1@Y)E=-AZHD$-YD'*>G:VTGB9:8R2F%0:F= 0B-4^$"^8 MY"JBSU-I%N9/:"L/0\Q19G(?]37A97:#XR^G1JZ]\8ZQ%\OE?!Q6R[6?ODDV M0;J\@WLQGY>+OO6HBP TI6 \\=%9(DV6Q(: (O9,BZ3 @ZQC/(^G?5C_\Z0X M/K&BVS6\ER'F/2F/CM 9[J%>$/I$/O_&N"(G,C!!E(V%+6?0O0J6E-?NS$H+Z'N=))7["('# MEA97\4IKJ*:) _]!QD;&A*BSM&6,,RL71J5E$"MI-^.MLPDLK^-V/DA.6]GO M7E2_"[SVTD(#!^Q=)BX%-.(A9A-1,":$1*33E'@#0"C/:/*348&GDX#IDJ"V MLHRG@-,AFF@ 4"^FRW$JI(^_P6>(JWDW!/3U]SA9)4AO4+3HNGY=;1J"WC/\ M%Z7H<*2Y"]9G1;@O7.A3>BE>>)*\GFH6-NN\O%X'#>*]KBH;[%D3G,\Y$9U+ M2W0!Z-5G[HD0.E%%:;"5SI/]Z.SK9<2-U:ZGR%V7]?BL@TE9DR"\(-+*\JI7 M9N(4XX8IJJ2LTXEG-_K::!U6 5F//7/H45W/R&P=7$/Z^&?5,F$5ZT?WA!OE M*E)-(U&Z'&$HDH(*1[21$8GQCLJ?P9!=%RQ^@C@[FX[_"]+;A/H0,01A@BP>!XL4MQ!N51=2)@KWJZ.[=3LYQB0M M;R((BS[@'J*9!,TIT='8Y%3R&/-7-H:[4?JL3O1]T/:X):R@P@:.[,=ZD+N8 M4]#6$R:\(1BJ.1*HYR1;S1(K5Y>V3EOE8X8$U)LX414%.\X%V$&09*0A"(:R< M^Y/E@H[@8]CBY.I6>>712,4O=#J'($20,6YG<.QQ/J9 &3O'=6=U<(?X8"2\TS^BD"^E+ M#2VSQ%N!?HOP*3(1C*T\UG,/8H>M]6O 6!ZFM@:0^<:/YYTY_P-\J?SL(#YMQ(OOIU^7>$9 '$VCEBX5;Z?K MFLBWTTT1Y"@C\\J )%XK*%N6$2N8P9,C9\TRX[A_J^#Y9"P.V]^YVBYH$R(- M[)W?9[/TYW@R&8&*5MO,"70UQ3PDXEP"HD1.3&6: M1Q>3<4#-NEN1KR#A+P M,ZH]_#B'R?@"OYG_>#'I\(8_G.5;)TNO10K[+%BK?N%@I@/7:/J4@R2#"5@9,;#07@2;&+E+M6':!P&AG4: MT_T>R@P_&Q;8S4OFEW_YH?E.9Y(@H8*9*.U-P8RK33LIBY?#9=S-+,UC@/#3[8U[CXOZP3RY=Q/K[*Z M3'AP H_I7$;52FHB<5XPPI+2CAGTY5C=-PDG8;/A0I)6-DZ_4&E@'UW1K95T M-!M!?'(,PQ.OB6>.DJ0X,P"6\U0'XGNA;YBZD6/0=Y" &P+&Q]4\GOL%7,^7 M?)'^8[58KON3,L2W![-R5KF M],UR3/F!QQ#B2,[^\_-V6]LJK2R:^^.\W_G+$0"K+P)+H0DDJ1?3N MP (QW%.KH^,VUNGA6Y^W84>>/XN=T@,HCMTH7VH]./@XGWU#P<^F?O)VVI6T MEY^^G2*+?G+M<';3WKY.8 G7KN=&+.M)<"@7^="?#>UB.P-J(YY\DUFM/) 97)'!# MB4I:1&8UYU"WKJ]DS]POB-K;CNM7GW MBJ#7LOC=EZM5%'\@P\.4Q(<(#C1$PH5PI1.T)"'+C(&KHCXR_*MTLOBLI9)X M69ZZ\)+F4HR6RC9.;(9,%%H-P T9K:K=^O0G+(G?!VU'E\3OH\(&$I=;NKG^ M]N,/_Q^S^FI"C)[5F0JW!Y'/K'1^ M+[3Y)P@;MLCSE&#K4T--U'E\ MF?L$%W[^SP4ZT]TW15(;=J1SQDJG")-0IC*6X0%2,SP0 #B#G*'26,RM9 U; M&GE*N/6GG0:LVV./_FC,-!CP1)@HB03 2(V93)S+GBDE;K/TT#W'W4MZ3#W'WD62;EN;Z MXH>&')G@DFA6^E!9@9M&,X]<@33*&B%HW=9[!S_$K>8L#7V:'::3?.,-(VN\@QVJ").B)ST,0;)PD#&P+(&'BE!ZJ[4-?P M,]/CP=:C8EKM[T7\H\UAR]2ZO:PGUPMYRV["X'Z+#]" MT+!1S_#(ZT-/#<#M.DFV>19=-I2_JNJ&U]^_PG0!=[BTW =EHR?96-Q4B:$' M9&UI<>Z=RQ; W'O&U7?=Z#[T#IN('!ZL)]#RLW<_-T>)1\=LT+=W49$ M:%+K FYE*'<;BA/+\%LIJ'1>LB"A3IW@KA3^#)[L/EA\W$3WJ,D&'(Q'N?GM MQQ?\B'7MKXQ@1>($1$E.0^F%ZZ(E4FKJO=(RJ3JE7CL0UTI]?Y^HV#6(.E!% M+:.N,+096*X@,6M]R>)U#?H<":+,UE4 R1MN_%U/ONV/A@NZTRBH#Y0'H@0MO0!88HX81(1- E&6KN: 8GHS_EZ^VG!BK**!:DZ$L::$A9I8 MH5%,X,M 49ZSJ--MXG&:ALT*U8953[IH %4O9Q=?5_AQ5Q*Z9(,%--T8UQ/C M2NTEP]C?=49>2Z\%C8FZ.O70CQ T;.*F-I[ZT$(#8'I43.^N"E%<4M)ZA:&0 MXPHYDIJ@4RI(3@Z]AQ'CZF(U*9W&7@$2 M$=<#@O'K"6S:/US,YLO+G-&CS(]R&1S&K2/)>GH9)X&.1'EM8U8JT%SG=KTO M#AIUZ?H![2!J'K[7XY/2+H05C:A^ZJCU;Y9.]]%O??SNVUGM:F[-J.C2E1G8@U MP78B@2.VJ;)<:_1"4Z4!RDW>GGV$>:?$:80/83(^ZR@H M%^FQV.@R+_SL0_Z,/UUD7/WJE9'QUCOK\6A(Y7V&\X&$TDW;.NDSYRPJ5B<4 MZH?^G^&>;A\"IEH4G MS"IA%+/L!D.@T,#&^%FZ#P"(13&)9)PIBW&*580QXTBD(.T MB6F9*XW"N$G%,[?,!R+A7L.H ]72 *1V$N&(9@ZEH2K*A#$B9>+$>N!$^,!C MY%R$4.>Z:B?RGKE%[ >$_2NRB=YE.[&%/XQ%Y6TZ8/5"YS\6V;I,R_H/Q++$1E8 >4-7#=C7GY< M"64S'6:4K%?>.46DB1@:B"B)$T&3H'+2#)2+IE*GW;WH'';4;2.0KJC:)KR/ MWU&ZBW>SQ0(6'U"AKJCJO=AXDYV>X#=T' M97?/L>-UU$ @\'D5)H7\]5/XD9")9S""Q%1R499:$BS-R(Q37GO!,-2O@K#; M=/P,#3:.@=816FFGP.[JL!D%0;T)8(DR#NEW&&AXH1B!;$QV6M.@ZX2/5R3\ M#$TPC@'48;IX]J5T7<>/<;>)8&V?IW *-V_KNJ=U^78705/NGXO.V( !IE&V MZUSEB*>.EDGRP1BO>(AU^HXUX?Z]G7Z#]2C9]0EPLVG-R#*9M164A)02QMX4 M2'ES3#Q/GN?R "O7:7>^C:J?P1G/05]O&FL M?0_-F[WN[]U-FX-47)G%R#M#-0^XI:Q/9<13B;J\(=QZFHS2/O,ZY<2[T_@S M.)['(+.2-H^-3[.]E]P?XT6$R<1/8;9:C$S4NGC=Z*[[[OEJ+.^C!)'< MY6"=9)3>-9D/3:W98\EA[W:'0UU-S31Q^;6=N5'4UN72+CLD@3(#'HG-I;+( MY\!88@SE6<=KWDK7L/>RPQO!'K7V[$/RF[_XTB_.WTQF?][L!%\_.-^1@M.& MZ8>(I:F '3]729$ST65HG61E. #7C&CJE7+4LQQ_XO=Q&Y5=W0F\B,OQM\X7 M?X?>#\"5G)@PX&3"?>Y*2VYM97G4RD@2(J'H; JQSKW6SB3^#*'\/FB\5T!3 M19<-1%:W+ZP^^A^=S$8^2A<-AH;9BVY0DB%.H1L.UBD>152:U^FN_C ]P\*O MDO*W7AT>I(D&\-1-X/Z0_[Y8C\;Z$/",FI:)6:^_QW,_/8,WL_EM3J_JT$;H MY0#WQA =2^T9CYP$KPU1@CJ40FE'5R>_>P31PV:93H/,4^FTU9;IU^/>?#=; MT$_3V6R6_AQ/)@?XI-L^K1?__(5?[_\<#R,[TYAO)[A= U$)3F-)A,1 M2S\0<)QXYR)A" BT9Z5QAZM3B+D/F4<7I.ZRV/5@ 6%" J<5R9(%(GW*) C* MB4X84VKK$]-U'.7]Z!SV&*Z'LWO5J/6T]PQMW,%SR)[^S-KVKN*LL?W0*#F3 MTC'$8)2"R$03"8$;E!=SX))FWM>ITCNIU;MNWOCXL-3%G9DJG#KT8*DCS$+I M@YJ*/'9V@$-R*9Y?&=7SH\.WG4 M>W'W_X_YC- M7T[04G0=C(S))FL\!D0JX7\9V&MI D(M,.Z%SU;6J?+=@\A6)MKTBY.=I]E0#]9'8%$2H4MAB7! /$A=,E242IV,\77>,^Q)Z+"XK :8 MW8%YM/8: .?G65[^Z;L)&9LO7\$WF,RZ/K9=D=/ED(,R/));W,X>62%29SQG MK!=$9VN3\4H;5FF$Z*XD-@O(XX%R]_"NHK4!X5B*H+H:.USR;Y]?W!/@FAD9 M&8T5WUI MIHEZQDM+6YX=QO/I;#([^]'=0&X88LESRQ4E/A23*\H;"NLXR0)C,D G.>F[ MF9>^&BIN)6S8 MM3PJU/#35@U[[,?8(BF@W]>)ZCXZHR8=*6MSDL$FM!$"HB M==;F*&V=/EYW*1FV2/:4D#I*!PU@:(NLWEUUR$F0;7(VDPQHA64,%IW%@(>^ MLQ%E%#Q+=>XZ=J&NE;E?0Z5!#E-3V]!;CYKB'"P' X11C^:8,4F"DABHHTW& M74IMYG5> #Q%6;,!Y8%8V!UL^RNF;:#=F!MUD#:B$$8XT&!X'#(_! M>1*RY5$*X*'2X+G]:6TV**T.QCZ4UTZ+D2V,EK%1*E@AD+,R3J'<4P.0D+PD M8(6,VG'F=9T[P^UT-1NK5D??ODII];73EKOT'J9W[?/IM4L#3C*A:[^;VAQ4 M>2B,T4)4I1L2=)-2#.%*&AT90XOU$U257CO)O]\L7:2 1K*3,ES%5 MH91#2T>\,AC:H+R8S]0E72?8;%SO)Z? ,X!0A_X'O+-."_/OYR/Y^DW M/_WGWSKOX[/_-IZ>E4ADMIHN%Q\Q"LFSR7AV@]'+ORLE@ D$A9B*IP_VF MO2:41@T!K(SR;D3YT!WE442T!:E#$# ;0AT-F*R- ;\1U:CR& 3C6\\$BJUC M)3E#A+,Z9Y^]U)4:P]\EI94$;'^'W''2;@ N-],A'_)=;W(D6.:&<4\TE24B M-F7$C0&2$N4>0]D@39U[HNUTM>%^'ZCTN\==?QH8]'*[6-K-F^XWL_E=&S[2 M05O+D >ERW,U[3SQE@9B57 Z2<-]N-NV[*%C;K\KY M^2'_[?.+]5&Z^#+WT\6:CE& (%4JO2H4_B$%L\0EM ,F*9:9!Z;E+G#8NLBP M*"JS>-C*PQ:[] >>RC)OP(>Y2H==\O1J-5_/^1G/THA[*YPWY6UT MZ0,*%HBETA+CI>5.*A9XGSB8MPU.2Y7!'%6 M.IB=P32.#WHRONW3>KG6V)G2$:#94RBIX+!5D! 6,2" M]T QKI;EP1E-"+4Z5;3[D'G\H,$=%KM^6>P3DUJ83'SIQ8E[+1%KJ"9H;+J_F;*S^YGJKX!I?PD_\-?OZ'7Y8F[3\V M.;@[K17*G$-JM"?.E2O*I,HXY3)=62C.A2R%LCLY:4C)#=G@=W?EQ/XC1S9D%&= %\*7L M%*-8#&]TZ8^5M/:<9<-%G9J1D[J:9=C%RWN'WBA;86-0@)$68 @?N2]/530Q M^$.#CDF6H4YQP\/T/">SN0]N[DT<.UX;#214'KS2SSEYYC,:(E9<;'.O?/SZ9:9B\][U8MLX_0AZZ66_3,NS%=873[$AQ-P>8&T^ C

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end